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Chapter 1
Motivation and outline
1.1 Motivation of the present work
Parkinson’s disease (PD) is the second most spread neurodegenerative disease,
after Alzheimer’s, affecting 1-2 % of world population above the age of 65 [1, 2].
There are two forms of the disease. The so-called ’sporadic form’ is caused by
environmental conditions and, probably, the genetic constitution of the individuals
[3]. The ’familial form’ (∼ 10 % of all the PD cases) is instead related only to the
genetic predisposition of certain families (mutations on proteins involved in PD).
In this thesis, we have used molecular simulation tools to investigated proteins
involved in the familial PD, in a joint collaborative effort with the neurobiology
group headed by Prof. S. Gustincich at SISSA. Several are the proteins which
have been found to play a key role for the derangement of this form (Tab. 2.1).
Among them, α-synuclein (AS)- the first protein discovered to be related with
PD, a decade ago [4] - is one of the most actively investigated. It is the main
component, in the form of fibrils, of the so-called Lewy Bodies (LB). LB’ are
plaques found in post-mortem brains which constitute the hallmark of PD. Its role
in PD is further confirmed by the fact that AS mutations are found in patients
suffering from the disease.
Several are the proposed functions of AS, from regulation of dopamine release and
transport [5], to lipid metabolism [6], from vesicle-mediated transport [7], to traffic-
king within the endoplasmic reticulum/Golgi network [8], regulation of dopamine
metabolism [9, 10, 11] and chaperone activity [12, 13]. A striking feature of AS is
that the fact that the protein is totally unstructured in aqueous solution: NMR
investigations have provided several thousands structures compatible with the ex-
perimental data [14, 15] (Fig. 4.1). AS may form fibrils spontaneously after a
couple of days in vitro from its aqueous solution; thus, any mean which would
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interfere with the such process might impact on the derangement of the disease.
In this respect, the recent discovery that non-covalent binding of ligands such as
dopamine and its derivative inhibits AS fibrillation [16, 17] is exciting - it gives the
opportunity for future design of ligands interfering with the fibrillation process-
and intriguing at the same time: how can binding occur in such an unstructured
protein? This issue even more general, as many as 400 proteins have been shown
experimentally to be either completely or partially disordered [18, 19, 20](See ar-
ticle review of Peter Wright on the subject [21]), many of them implicated in
neurodegenerative diseases [22, 23, 24]. Therefore, ligand binding to unstructured
protein may impact largely on drug development [25, 26].
Surprisingly, however, neither theoretical investigations on the AS subject nor
theoretical studies involving the interactions between ligands and unstructured
proteins have been done before the starting of this thesis.
Here we have attempted to gain insights on the structural determinants of dopamine
binding. Clearly, this is not a trivial task, as the established and standard prin-
ciples which apply to docking and design of ligands targeting proteins with a
defined 3D fold are challenged here. We have hence used a rather elaborated
protocol which involves cluster analysis, docking and molecular dynamics simula-
tions. Based on our calculations, we have been able to provide structural models
of the AS/dopamine adducts, fully consistent with experimental data reported in
the literature [16, 17] and with experiments performed within this joint project by
Prof. Gustincich at SISSA and Prof. Lashuel at EPFL, Lausanne. In addition,
the computational studies have been used to design new ligands which might be
able to inhibit AS fibrillation.
A second, experimentally well-characterized protein in familial PD is the DJ-1
protein [27, 28]. Several DJ-1’s mutations emerge in patients suffering from the
disease, and they may affect some of the several functions proposed for the protein,
including a redox-regulated chaperone activity [29], a regulator of transcription
activity [30], and protection the cell against oxidative stress conditions -a possible
cause of PD [31, 32]. A major issue relates the PD-linked DJ-1 mutants to the
protein’s oligomeric state. Whilst the WT is a dimer, mutations may alter the
state and render the protein monomeric or multimeric. This of course might play
a role for the disease [27]. Here we have applied bioinformatics and molecular
simulation tools to investigate the relationships between PD-linked mutants and
the protein structure. The computational methodology was validated by predicting
mutations which destabilizes the dimeric form [33] and verifying the prediction
from experiments performed in Prof. Gustincich’s lab.
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1.2 Outline of the thesis
Chapter 2 introduces Parkinson’s Disease and the proteins studied in this thesis.
The next, (Chapter 3) presents the computational tools used in this work: The
bionformatics Section focuses on cluster analysis, molecular docking approaches,
molecular screening and computational alanine scanning. The molecular simula-
tion section outlines some of the key principles of molecular dynamics simulation
and force field development.
Chapter 4 features a computational study of AS-dopamine interactions. This study
can be helpful in understanding the fibrillation process and might be used to design
new ligands with similar characteristics and interactions as those of dopamine.
The following results of my work are presented in Chapter 5, where new com-
pounds with similar structural or electrostatic properties of dopamine are identi-
fied. These compounds might share some of the binding features of dopamine and
its derivatives towards AS.
Chapter 6 focuses on the computational approach for the study of the DJ-1 protein.
The structural properties of the DJ-1 WT protein in the reduced and oxidized state
along with that of two PD-linked mutants (M26I and L166P) and one physiological
variant (R98Q) are studied in order to gain insights into the mechanism involved
in the disease. These studies allow us to design later a new mutant of the DJ-1
protein which affects the oligomeric state.
Most of the work presented has been validated against experimental data, most of
which performed in a joint collaboration within SISSA.
The conclusions are summarized in Chapter 7.

Chapter 2
Introduction
2.1 Parkinson’s Disease
2.1.1 Clinical and neuropathological features
Parkinson’s disease (PD) is the second most spread neurodegenerative disease (af-
ter Alzheimer’s). It is a disease for which there is currently no cure.
The average age of onset is 60 years, and the prevalence rises significantly from
0.3% in the entire population to about 1% in people over 60 years old and up
to 5% in over 85 years old [1, 2]. However, about 5 to 10 % of people with PD
have ”early-onset” disease that begins before the age of 50 [34, 35, 36]. PD is
a progressive neurodegenerative movement disorder: cardinal symptoms of the
diseases include bradykinesia, resting tremor, rigidity, and postural instability,
along with, at times, autonomic, cognitive, and psychiatric disturbances. These
symptoms result from loss of dopaminergic (DA) neurons in the substantia nigra
pars compacta (SNc). Approximately 60-80% of DA are lost before the appearance
of the first motor signs of PD. This causes a dysregulation in the motor circuits
resulting in the clinical manifestations (symptoms) of PD [37].
The examination of brains from PD patients shows the depigmentation of the
substantia nigra (SN). This is caused by the selective and progressive loss of DA
and the presence the Lewy bodies (LBs) within the surviving neurons of the SN
and other regions of the brain. The LBs - the hallmark of PD - are eosinophilic
intracytoplasmic proteinaceous inclusions present in surviving neurons [38]. They
enriched in fibrils of the α-synuclein protein and other (often ubiquinated) proteins
(Fig. 2.1).
There are two forms of the disease, the sporadic and the familial forms. Patients
with familial PD are distinguished from the ones that suffer from sporadic PD
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Figure 2.1: Substantia nigra from patients with Parkinson’s disease immunostained
for α-synuclein. a) Two pigmented nerve cells, each containing AS in the Lewy body
(thin arrows) and Lewy neurites (thick arrows). b) A pigmented nerve cell with two α-
synuclein-positive Lewy bodies. c) α-synuclein positive, extracellular Lewy body (Taken
from [39]).
because of an early start, greater consanguinity rate and greater frequency of a
similar disease in their parents.
The sporadic form of the disease has been suggested to spread from the interac-
tion of humans with chemicals in the environment. There is a higher incidence of
PD in developed countries. This may be due to the larger exposure to environmen-
tal toxins. Consistent with this proposal, a drug contaminant called MPTP, which
bears a strong chemical similarity to many pesticides and other environmental
chemicals, is able to induce PD [40].
The familial cases are about the 10% of the total number of cases and are based
on the genetic component of the disease [41, 42, 43, 44]. The genes so far shown
to be involved are 10 (Tab. 2.1). In four of these (AS, parkin, DJ-1 and pink1
genes), mutations have been identified that definitively and unambiguously cause
familial forms of PD, whilst in the other 6 no mutations have been reported and
they are involved in the sporadic form of PD. Age of onset tends to be younger in
familial PD compared with sporadic PD, particularly in the autosomal recessive
PD.
2.1.2 Known factors playing a role for PD
Misfolding and aggregation of proteins (i), mitochondrial dysfunction (ii), and
oxidative stress (iii), play a key role for the progression of both forms of the
disease.
(i) As in many other neurodegenerative diseases such as Alzheimer’s and prion dis-
eases, PD is characterized by neuronal loss and the formation of protein aggregates
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Locus Gene Protein function Phenotype
PARK1
SNCA
Synaptic ? PD/DLBD. Onset from age 30 to 60,
PARK4 (AD) Lipid binding ? rapid course. Fulminat LB [4, 45].
PARK2 (AR) Parkin E3 ligase
Parkinsonism. Onset from teenage to 40s,
slow course. No LB, except one case [46].
PARK3 (AD) Unknown
PD, dementia. Onset age 50 to 60s.
LB, tangles and plaques [47].
PARK5 (AD?) UCHL1
Ubiquitin Typical PD. Onset at about 50
hydrolase/ligase Unknown pathology [48].
PARK6 (AR) PINK1 Protein kinase
Parkinsonism. Onset age 30 to 50s.
Unknown pathology [49].
PARK7 (AR) DJ-1
Oxidative stress Parkinsonism. Onset from age 20 to 40s,
response ? slow course. Unknown pathology [50].
PARK8 (AD) LRRK2
Parkinsonism. Onset from age 40 to 60s.
Variable pathology [51].
PARK10 (unclear) Unknown
Typical PD. Onset at about 60,
Unknown pathology [42].
PARK11 (unclear) Unknown
Typical PD. Onset at about 60,
Unknown pathology [52].
Table 2.1: Monogenic forms of Parkinson’s disease. The inheritance is shown in
parentheses (AD, autosomal dominant and AR, autosomal recessive). PD: Parkinson’s
disease. DLBD: diffuse Lewy body disease. The SNCA is the gene name for alpha-
synuclein (Taken from [53]).
that are typically fibrillar. Cell death could arise from such protein aggregates
[54, 55], or by ordered prefibrillar, oligomer, or protofibrils [56]. In the latter case,
the fibrils could be neuroprotective [56]. Nevertheless, in any case, the molecular
mechanism of fibrillation is currently largely unknown.
(ii) PD post mortem brains feature a reduction of mitochondrial complex I activity
of the mitochondrial respiratory chain [40]. Further evidence in support of the
role of mithochondrial dysfunction in PD came from the discovery of some of the
familial PD genes. The discovery of PINK1, HtrA serine peptidase 2 (Omi/HtrA2)
and DJ-1 mutations confirmed that mitochondrial dysfunction is a pathway to
parkinsonism. In particular, the subcellular distribution of the DJ-1 protein is
primarily cytoplasmic with a smaller pool of mitochondrial and nuclear associated
protein [57]. Furthermore, the DJ-1 mutations disrupt the protein activity by
either destabilizing the protein or affecting its subcellular localization. All DJ-1
PD-linked mutations show reduced nuclear localization in favor of mitochondrial
localization [50, 58]. Nevertheless, it is not clear whether the toxicity associated
with increased mitochondrial localization is due to a mitochondrial gain of function
or to a loss of access to binding partners in different cellular compartments [58].
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(iii) Several factors involved in PD points toward the role of the oxidative stress
into the progression of the disease: A. the inhibition of complex I increases the
production of reactive oxygen species (ROS) [59]; B. DA neurons may be a particu-
larly fertile environment for the generation of ROS, as the metabolism of dopamine
(DOP) produces hydrogen peroxide and superoxyde radicals (see appendix A.1);
and C. the DJ-1 protein may protect the cells against oxidative stress-induced
death [31, 32] and its ablation sensitizes cells to oxidative stress [60].
2.2 Alpha-synuclein and DJ-1 proteins in fa-
milial cases of PD
2.2.1 Alpha-Synuclein and its inhibitor of fibrillization
dopamine
AS is the major component of the Lewy bodies and Lewy neurites in familiar or
sporadic PD [39], suggesting that the aggregation and fibrillation of this protein
play a central role in the development and/or progression of the disease. There-
fore, the role of AS in neurodegenerative disorders has become evident, and drug
discovery efforts have been focusing on targets related to AS misfolding and fibri-
llization. AS is also found in the LB variant of Alzheimer’s Disease, dementia with
LB, multiple system atrophy and related diseases, which indeed are collectively
known as α-synucleinopathies [61].
AS is an abundant, natively unfolded neuronal protein. It is highly soluble and
its localization is both cytosolic and nuclear. It is enriched at the synaptic ter-
minals, where it is associated with synaptic vesicles. It is an intrinsically un-
structured protein but has significant conformational plasticity (depending on the
environment AS can remain unstructured, can form monomeric and oligomeric
species, or can form amyloidogenic filaments [62], it exists in solution as an unstruc-
tured monomer. Inside the cell, the monomer is in equilibrium with membrane-
associated forms with higher helical content. Oligomers and other intermediates
are kinetically stabilized by dopamine (DA). However, these are transient species
that further aggregate to form mature fibrils. The formation of Lewy bodies is
presumed to be a consequence of fibrillization. Events such as the attachment of
ubiquitin are thought to be secondary to the initial aggregation and deposition
processes [53] (see Fig. 2.2).
α-synuclein is a member of a family of three synaptic proteins that share consi-
derable sequence homology and include α-synuclein, β-synuclein and γ-synuclein.
Synucleins have in common a highly conserved β-helical lipid-binding motif with
similarity to the class-A2 lipid-binding domains of the exchangeable apolipopro-
teins. The α- and β-synuclein proteins are found primarily in brain tissue, where
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Figure 2.2: The pathogenic cascade of AS aggregation. The unstructured monomer is
shown as a linear structure. In the helix (bounded to the membrane) blue and red circles
indicate charged residues, gray circles are nonpolar and hydrophobic amino acids. The
green arrows indicate the pathogenic formation of aggregated species. Taken from [53].
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they are localized mainly in presynaptic terminals. The γ-synuclein protein is
found primarily in the peripheral nervous system and in the retina; moreover its
expression in breast tumors is a marker for tumor progression. Although nor-
mal cellular functions have not been determined for any of the synuclein proteins,
there is evidence that the expression of β-synuclein may regulate the levels or the
metabolism of α-synuclein, since β-synuclein inhibits α-synuclein aggregation in
transgenic mice [63]. Furthermore, more recent studies indicate that increased
expression of β-synuclein can decrease the levels of α-synuclein by mechanisms
that do not appear to affect α-synuclein mRNA levels [64], but it is likely that the
functions of β-synuclein extend beyond regulating the expression of α-synuclein.
The AS sequence consist of 140 amino acids, lacks both cysteine and tryptophan
residues and can be divided into three different regions (Fig 2.3) [65, 66]:
(i) The positively charged N-terminal region (amino acids 1-60), comprising a seven
imperfect 11 amino acids repeats containing the consensus sequence KTKEGV.
(ii) The non-amyloid-β-component (NAC) (amino acids 61-95) [67, 53, 68].
(iii) The negatively charged C-terminal region 96-140, which contains several sites
for post-translational modifications and metal binding (Fig. 2.3)[69, 70].
Figure 2.3: Motifs in the α-synuclein protein sequence. The natively unfolded
α-synuclein protein is shown in a linear form. Shaded areas represent the imperfect
KTKEGV repeats. Human mutations are shown in red and map to the repeat region.
The phosphorylation sites are shown in green. Taken from [53].
The NAC region has been found in amyloid plaques associated with Alzheimer’s
disease, and several reports suggest that this region represents the critical deter-
minant for the fibrillation process of AS [71] and it has been proposed that this
region of the protein could promote the formation of β-amyloid in vivo [72, 73].
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Several indications point to this region as the highly amyloidogenic part of the
molecule. The acidic C-terminal tail of the protein contains several sites of phos-
phorylation. The C-terminus also contains the alternatively spliced exon V and
a calpain I cleavage site. The acidic tail tends to decrease protein aggregation,
whereas a hydrophobic region near the imperfect repeats promotes aggregation.
The AS’s gene for familial PD was initially mapped to chromosome 4q21–q23 [74].
The mutations involved in the development of PD are: (i) the A53T missense
mutation [4], (ii) the A30P mutation [75] and (iii) the E46K mutation [76]. In
addition, the genomic triplication of a region spanning the AS gene were also found
to be related with PD [45]. Patients with gene duplications are also found, but they
have a less severe phenotype and a later age of onset than those with triplications,
which implicates that variability of AS protein levels can predispose individuals
to disease [77]. Nevertheless, familial PD caused by AS missense mutations is
extremely rare.
Structure: Structural information, derived from NMR studies, is available for
the monomer structure and has been increasingly used to study and model AS ag-
gregation and interaction with other proteins [78]. In aqueous solution, AS exists
as an ensemble of disordered conformations. NMR studies based on paramagnetic
relaxation enhancement (PRE) effects generated an ensemble of ∼4,000 structures
characterized by transient C-terminal - N-terminal interactions [15, 14]. Upon
binding to SDS micelles and negatively charged synthetic vesicles [66], AS adopts
partially an helical conformation: two helices (amino acids 1-38 and 44-94) are
formed in the non-polar environment, and the remainder of the protein is disor-
dered, as shown by NMR spectroscopy [66] (Fig. 2.4). The monomer is prone
to aggregation into amyloid-like structures, particularly at high concentrations or
upon exposure to various chemical and physical factors (e.g. shaking). AS fibrilla-
tion proceeds through a series of β-sheet rich aggregation intermediates, including
early spherical protofibrils, pore-like, chain-like aggregates, which disappear once
amyloid fibrils are formed [79, 80].
Figure 2.4: Structure of the micelle bound human alpha-synuclein (PDB code 1XQ8
[66]).
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Fibrillation: During the in vitro fibrillization process of AS, early spherical
protofibrils of AS are followed by chainlike and porelike protofibrils and finally
with a rapid conversion into fibrils. Both A53T and A30P PD-associated mutations
promote AS aggregation [79], but in the case of A53T, the fibril formation is very
rapid, while in the case of A30P the formation of spherical protofibrils is promoted
[81] with slow conversion into fibrils [79, 82]. This observation prompted the first
proposal that the protofibril, rather than the fibril, may be pathogenic in PD
[83, 84].
It is know that AS is able to bind membranes, this could be related with the un-
determined physiological function of the protein [11, 8]. In addition, the affinity
of AS for membranes is increased in the form of protofibrils and is decreased in
the form of fibrils [80]. Furthermore, the protofibrillar form is capable of perme-
abilizing synthetic vesicles by a porelike mechanism [85, 86]. These amyloid pore
structures are much more prevalent in the PD-linked mutant protofibril fractions.
All fibrils, independent of the original structure of the given amyloidogenic protein,
have a common cross-β structure consisting of β-sheets in which the β-strands
are perpendicular to the axis of the fibril (Fig. 2.5). In order to attain this
structure, the proteins have to undergo significant conformational rearrangements
to allow the needed topological changes. This suggests a simple kinetic model of
fibrillation involving conversion of monomeric AS into the critical, partially folded
intermediate, which leads, depending on the conditions, to the formation of soluble
oligomers, insoluble amorphous aggregates, or insoluble fibrils.
Acceleration: The rate of the fibrillization is accelerated by di- and trivalent
metal ions. The most effective cations in vitro include aluminum(III), copper(II),
iron(III), and lead(II). The mechanism for this presumably involves the metal ions
binding to negatively charged carboxylates, thus masking the electrostatic repul-
sion and facilitating collapse to the partially folded conformation.
Inhibition: A variety of flavonoids and polyphenols can instead inhibit the fibril
formation of AS and in some cases also disaggregate existing fibrils [88]. These
compounds bind to monomeric AS and lead to formation of stable AS oligomers.
Another interesting class of compounds able to inhibit fibrillization of AS is that
of dopamine and related catecholamines. Although several factors including post-
translational modifications, oxidative stress and interaction with toxins and metals
have been demonstrated to influence AS aggregation and toxicity [69, 70, 89, 90,
91], the exact molecular mechanisms underlying AS aggregation and toxicity in
vivo and the links between aggregation and neurodegeneration remains poorly
understood.
Dopamine as AS inhibitor of fibrillation: A role for dopamine (DOP) in
mediating α-synuclein toxicity is a plausible hypothesis to account for the relatively
selective degeneration of DA neurons in PD. Indeed, (i) the toxic effects of AS
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Figure 2.5: The α-synuclein fibrillization process (adapted from [87]).
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appear to be selective for DA [92], (ii) AS can interact with and enhance the
activity of the dopamine transporter [93] and (iii) overexpression of mutant α-
synuclein can also downregulate the vesicular monoamine transporter 2 [11].
Several evidences also point to an important role of AS in regulation of the DOP
metabolism at multiple levels: (i) the AS interaction with tyrosine hydroxylase
(TH) inhibits the synthesis of DOP [94] (see Appendix A.1), (ii) AS is involved
in vesicles formation and recycling through interaction with PLD2 [95] and binds
fatty acids in vesicles with different affinities among the pathological mutants [10],
(iii) VMAT2 expression is decreased by AS A53T over-expression [96] and (iv) AS
binds to DAT and regulates its trafficking [93, 9].
Furthermore, in vitro catechol derivatives [97, 98], including dopamine [16, 99, 100],
have been shown to inhibit AS fibrillogenesis causing accumulation of oligomeric
species in vitro [16, 98]. These studies suggest that oxidation of dopamine may
play a key role in modulating AS aggregation and toxicity and may be linked
to the selective vulnerability of dopaminergic neurons in PD [101]. Dopamine
forms covalent [98, 99] and/or non-covalent [16, 17] DOP-AS complexes. The non-
covalent complexes were shown to involve interactions between dopamine and the
C-terminal residues 125YEMPS129 in the C-terminal region of the AS sequence
[16].
Further information on this topic is presented in the Thesis Appendix A.2.
2.2.2 DJ-1 and its PD-linked mutants
DJ-1 is a highly conserved, ubiquitously expressed protein (Fig. 2.6) [102]. The
human protein has 189 amino acids and belongs to the DJ-1/ThiJ/PfpI superfam-
ily (Fig. 2.6).
DJ-1 is involved in multiple cellular processes including sperm maturation, ferti-
lization in rodents and oncogenesis in humans. It is present in the nucleus, cy-
toplasm, mitochondria and extracellular space of mammalian cells [103, 104, 105,
106]. In vitro studies showed that the ectopic expression of DJ-1 protects cells from
cell death induced by various toxic stimuli including oxidative stress [58, 107]. DJ-
1 is indeed an indicator of oxidative stress state in vivo since it is converted into
pI variants in response to small amounts of reactive oxygen species. Interestingly,
some pI isoforms are accumulated in PD post mortem brains [108, 109].
It is abundantly expressed in most mammalian tissues, including the brain, where
it is localized to both neurons and glia [108, 111]. DJ-1 does not appear to be
localized to LBs in sporadic PD and other synucleinopathies but it does colocalize
with tau-positive inclusions in a number of neurodegenerative tauopathies and with
AS-positive glial inclusions in multiple system atrophy [112, 113], which suggests
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Figure 2.6: Domain architecture and familial mutations of DJ-1. The position of
amino acid missense mutations (single letter code) associated with familial forms of PD
are indicated (Taken from [110]).
that DJ-1 may also play a diverse role in seemingly distinct neurodegenerative
diseases.
Several familiar cases prove that DJ-1 loss in humans causes PD: (i) a frame shift
and a splice mutation were found in a young-onset PD patient [114]; (ii) a Dutch
family showed a large homozygous genomic deletion that removed 4 Kb of promoter
sequences and the first five exons of the gene [115]; (iii) additional PD cases have
been described with truncating, splice-site mutations and deletions.
Structure: X-ray crystallography (Fig. 2.7) showed that WT DJ-1 in the re-
duced state (that is, in a state in which Cys and/or Met residues are not oxidized
[116]) is a homodimer. Each subunit assumes an α/β sandwich fold, similar to the
flavodoxin-like Rossman fold [116], conserved across the ThiJ-PfpI superfamily. It
contains seven parallel β-strands flanked by nine α-helices. The subunit-subunit
interface is stabilized by a large number of hydrophobic interactions, H-bonds
and salt bridges. The dimeric state of the protein has been confirmed by both
in vivo and in vitro investigations. It is believed that DJ-1 carries out its func-
tion exclusively in the dimeric state [117, 118, 119, 120], since the formation of
High Molecular Weight (HMW) oligomers and/or inefficient formation of dimeric
structures may affect the stability of the protein and/or its affinity for molecular
partners in the cell [27, 102, 121].
Structure/function relationships in PD-linked mutations.
Some PD families present missense mutations of DJ-1 in homozygous and/or het-
erozygous forms (M26I, E64D, A104T, D149A and L166P) [28, 115, 50, 114, 122,
123, 124]. The mechanism by which these mutants change or abolish DJ-1 function
is still a matter of debate.
L166P and M26I are the most studied DJ-1 missense mutations [121, 125, 50,
120, 111]. In particular L166P is very unstable and its expression level, both in
transfection studies and in patient lymphoblasts, is lower than in the WT protein.
This suggests that L166P mutation may induce a loss of DJ-1 function [111, 28,
126, 127]. The mutant does not form a dimeric structure; instead, it may assemble
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Figure 2.7: DJ-1 WT structure. X-ray structure in the reduced state (PDB code
1UCF) [116]. The two monomers are colored in light blue and brown respectively.
in HMW oligomers [121, 119, 111]. At the structural level, L166 is located in the
middle of one of the helical regions of the protein (α8 helix in Fig. 2.7), thus its
mutation to Pro breaks the helix [102, 50, 123, 111]. Because the α8 helix forms
hydrophobic interactions with a series of residues located at the subunit-subunit
interface (V181, K182, L187 of α9 helix and the C-term), such a mutation could
affect the stability of the homodimer [102, 123, 28]. However, this hypothesis has
not yet been proven by in silico and/or in vitro analysis of the conformational
changes in the mutant.
M26I does form dimers but it is a matter of debate whether dimer formation occurs
at the same rate as WT or less efficiently. Furthermore, the relevance of these
differences, if any, for neurodegeneration is unclear [121, 125, 120]. This mutation
is located on α1 helix at the subunit-subunit interface (Fig. 2.7), therefore it
may affect subunit-subunit interactions. However, methionine is structurally and
chemically very similar to isoleucine: they are similar in shape and volume and
they are both non-polar residues. Thus, the interactions between M26I subunits
may well be similar to those of the WT, although structural information for this
mutant is lacking.
Chapter 3
Methods
This chapter describes the methodologies used in this thesis. It is divided into
two parts. The first part is related to the bioinformatics and molecular dock-
ing. It includes different cluster algorithm, computational alanine scanning and
molecular screening protocols used in this thesis. The basic concepts of molecular
dynamics simulations are discussed in the second part. The specific features of
each of the studied systems are reported in the Computational Details section of
the corresponding chapters.
3.1 Bioinformatics and docking
3.1.1 Cluster Analysis
There are several different algorithms for the clustering of protein structures [128].
They may be classified as: (i) Exclusive Clustering: a structure belonging to
a cluster cannot be included in another cluster (Fig. 3.1) [128, 129, 130]. (ii)
Hierarchical Clustering: here the algorithm is based on the union between two
nearest clusters (Fig. 3.2) [131]. The initial condition is realized by setting every
structure as a cluster, and after a few iterations the algorithm reaches to the final
set of clusters wanted. (ii) Overlapping Clustering: each structure may belong to
two or more clusters with different degrees of occupation on each cluster [132].
(iv) Probabilistic Clustering: here the algorithm uses a completely probabilistic
approach [133].
Approaches (i)-(ii) were used in the thesis and they are outlined here.
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Figure 3.1: Exclusive Clustering: the separation of points is achieved by a straight
line on a bi–dimensional plane
Exclusive Clustering
This clustering algorithm is based on the intuitive expectation that the best repre-
sentative of each cluster is the one closest to the cluster center. The best way to
identify the center of a cluster, is to find the member with the largest number of
neighbors within a suitably chosen cutoff (the proximity score). In this case, the
proximity score is chosen to be the Root Means Square Distance (RMSD) of atom
positions between all pairs of structures. Indeed, points further from the center
will have fewer neighbors.
The algorithm starts by choosing the first representative of the set as the one with
the highest number of neighbors (highest proximity score). The cluster associated
to this representative is defined as all of the representaitve’s neighbors within a
certain predefined RMSD cut-off. This starting point identifies simultaneously
both the largest cluster and its representative. The next step is the remotion of
the previous representative and its cluster from the set, and the proximity score
of the remaining points is recalculated and, again, the member with the highest
score is selected. The algorithm proceeds in this iterative manner until the set of
surviving points is exhausted. In this way, a series of nonoverlapping clusters of
structures is obtained [129, 130].
Hierarchical clustering
The hierarchical clustering starts from an ensemble of conformations and after
several iterations it finish with the best set of clusters with their representatives.
The algorithm involves 6 steps (Fig. 3.3 ) [131]
(i) “Distance determination”: the clustering requires the calculation of the pair
RMSD matrix among all the conformations in the ensemble. The RMS is calcu-
lated by superposing each member of the ensemble onto each of the other members
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Figure 3.2: Hierarchical clustering
of the ensemble in a pairwise manner. The superposition is carried out on all non-
hydrogen atoms. For N members, this results in a NxN matrix of RMSD values.
(ii) “Clustering”: the RMSD matrix is used with the average linkage algorithm
(based on the average distance between objects)∗ for a hierarchical cluster analysis.
The method of average linkage takes the distance (DIST ) between two cluster n
and m to be:
DISTn,m =
Nn∑
i=1,i∈n
Nm∑
j=1,j∈m
dist(i, j)
NnNm
(3.1)
where cluster n contains Nn members, and cluster m contains Nm members;
dist(i, j) is the RMSD between the two members, i and j, of clusters n and m, res-
pectively, after superposition. At each stage of the clustering algorithm, a search
is performed for the two nearest clusters; these are merged to form a single cluster.
At each stage of clustering, the spread of each cluster and the average spread
(AvSp) for the clustering are calculated. The spread of a cluster m containing N
members is given by:
spreadm =
Nm∑
k=1
Nm∑
l=1,l<k
dist(k, l)
Nm(Nm − 1)/2 (3.2)
where i and k are members of cluster m. The average spread for the clustering is
then given by:
∗Other possible algorithms are: single linkage(based on the shortest distance between
objects); complete linkage (based on the largest distance between objects); the Ward’s
method (based on the sum of squares between the two clusters, summed over all variables
and the centroid method (based on the distance between clusters centroids.)
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Figure 3.3: Hierarchical Clustering algorithm
AvSpi =
cnumi∑
m=1
spreadm
cnumi
(3.3)
where cnumi , is the number of clusters at stage i of the clustering (excluding
outlying points, i.e. clusters that contain only one member).
(iii) “Normalization of the average spread”: Once clustering is complete, the set
of AvSpi values are normalized to lie within the range 1 to N − 1, where N is the
number of structures in the original data set. Normalization is performed to give
equal weight in the penalty function (Step 4) to the number of clusters and the
average spread.
AvSp(norm)i = (N − 2) AvSpi −Min(AvSp)
Max(AvSp)−Min(AvSp) + 1 (3.4)
where Max(AvSp) and Min(AvSp) are the maximum and minimum values res-
pectively of average speed in the set (AvSp1, AvSp2, ...AvSpN−1).
(iv)“Penalty function” : For each stage of clustering i, a penalty value, Pi is
calculated as:
Pi = AvSp(norm)i + nclusi (3.5)
3.1 Bioinformatics and docking 21
where nclusi, is the total number of clusters at step i of the clustering (including
outlying points).
(v) “Cut–off ”determination: The minimum penalty value in the set (P1, P2, ...PN−1)
is chosen as the cut–off level.
Picut = Min(Pi) (3.6)
Thus, the stage icut represents a state where the clusters are as highly populated
as possible, whilst simultaneously maintaining the smallest spread. The smaller
the spread of the clusters, the more similar the conformations of its members; the
greater the population of a cluster, the less likely is the chance of excluding a
member of similar conformation.
(vi) “Representative structures” calculation: Once a cut–off value in the clustering
has been determined in this way, Eigen analysis [134] is performed on each cluster
at stage icut. This allows for the determination of the structure within each cluster
that is closest to the centroid of that cluster.
3.1.2 Computational Alanine Scanning
The alanine scanning methodology was used in order to analyze the interface of
protein–protein complexes. Several studies have shown the existence of a small
set of “hot spot” residues at the interface of protein–protein complexes that con-
tribute significantly to the binding free energy [135, 136]. Many subsequent studies
suggest that the presence of a few –hot spots–may be a general characteristic of
most protein–protein interfaces. The alanine scanning methodology is a fast com-
putational approach for the prediction of these energetically important amino acid
residues or ”hot spots ” in protein–protein interfaces. The input consists of a
three–dimensional structure of a protein–protein complex and the output is a list
of ”hot spots,” or amino acid side chains that are predicted to significantly destabi-
lize the interface when mutated to alanine, analogous to the results of experimental
alanine–scanning mutagenesis.
The computed energies take into account van der Waals and the electrostatic
contributions to the binding free–energy. Hot spots are identified as those residues
at the interface whose mutation to alanine causes a free–energy loss greater than
1 kcal/mol.
∆G = WattrELJattr +WrepELJrep +WHB(sc−bb)EHB(sc−bb)
+WHB(sc−sc)EHB(sc−sc) +WsolGsol +WCoulECoul
+Wφ/ψEφ/ψ(aa) +
20∑
aa=1
naaE
ref
aa
(3.7)
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where, ELJattr is the attractive part of the Leonnard–Jones potential, ELJrep is a
linear distance–dependent repulssive term, EHB(sc−bb) is the orientation dependent
hydrogen bond potential (SC: side chain, BB: backbone), Gsol is the solvation term
and W are the relative weights of the different energy terms. The Eφ/ψ is the amino
acid type (aa) dependent backbone torsion angle propensity and Erefaa is the amino
acid type dependent reference energy.
The effects of alanine replacement are computed both for the protein complex and
for the corresponding uncomplexed partners to yield the change in binding energy
∆∆Gbind:
∆∆Gbind = ∆GMUTbind −∆GWTbind
=
(
∆GMUTcomplex −∆GMUTpartnerA −∆GMUTpartnerB
)
− (∆GWTcomplex −∆GWTpartnerA −∆GWTpartnerB)
(3.8)
where ∆Gcomplex, ∆GpartnerA, and ∆GpartnerB are the stabilities of the complex
and the unbound partners, and WT and MUT describe wild–type and mutant
proteins.
Neutral residues and hot spots are defined as residues showing a change in the
binding free energy by less or more than 1 kcal/mol when replaced by alanine
(∆∆Gbind), respectively (alanine substitutions with experimentally measured sta-
bilizing effects were rare and not larger than -0.9 kcal/mol; these were included in
the neutral category.) A correctly identified hot spot is a residue with a predicted
and observed ∆∆Gbind value larger than or equal to 1 kcal/mol; a correctly iden-
tified neutral residue has both predicted and observed ∆∆Gbind values less than
1 kcal/mol. Interface residues were defined as residues with a side chain having
at least one atom within a sphere with 4 A˚ radius of an atom belonging to the
other partner in the complex or as those that, upon complex formation, become
significantly buried, i.e. if there is a significant increase in the number of Cβ atoms
located within a sphere of radius 8 A˚ centered on the Cβ atom of the residue con-
sidered. These energies are necessary very approximate and are here used only
for qualitative comparisons.
3.1.3 Molecular screening and design protocol
Screening
The molecular screening of a database of molecules against a set of template
molecules performed in this thesis is based on 2 algorithms. The first algorithm is
based on the shape similarity between all molecules in the database and the tem-
plate molecules and the second algorithm is based on the electrostatic similarity.
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Shape similarity The more the volumes of two molecules differ, the more the
shapes will differ. The volumes of two molecules can be defined as:
V1 =
∫
f(x, y, z)dv
V2 =
∫
g(x, y, z)dv
(3.9)
Where f(x, y, z) and g(x, y, z) are the characteristic functions of two different
molecules. They correspond to the common definition of a volume field.
If the function S is defined as:
Sf,g =
√∫
[f(x, y, z)− g(x, y, z)]2 dV (3.10)
Is possible to arrive to the fundamental equation for shape comparison defined as:
S2f,g =
∫
f(x, y, z)2dV +
∫
g(x, y, z)2dV − 2
∫
f(x, y, z)g(x, y, z)dV (3.11)
If
∫
f(x, y, z)2dV = If (the self-volume overlap of f(x, y, z));
∫
g(x, y, z)2dV =
Ig (the self-volume overlap of g(x, y, z)) and
∫
f(x, y, z)g(x, y, z)dV = Of,g (the
overlap between the two functions), then:
S2f,g = If + Ig − 2Of,g (3.12)
The three terms in this function constitute the necessary terms to calculate and
compare the shapes of two molecules. The quantity referred to as a Tanimoto
coefficient may be derived by recombining I’s and O so:
Tanimotof,g =
Of,g
If + Ig −Of,g (3.13)
Thus, knowing the volume of the molecules and their alignment, it is possible
to calculate the Tanimoto coefficient for the shape similarity between the two
molecules. The coefficient is 1 if the two molecules are the same and 0 if they are
completely different.
The programs ROCS (Rapid Overlay of Chemical Structures) [137], was used
to calculate the shape similarity between molecules. It calculate the Tanimoto
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coefficient (eq. 3.13) using a shape-based superposition method. The molecules are
aligned by a solid-body optimization process that maximizes the overlap volume
between them. The volume function is calculated taken each atom as solid sphere
but using a Gaussian approximation [138].
The screening of a database of molecules against a template molecule, using this
algorithm, give an output that consists on a list with all the molecules in the
database ranked according to their shape similarity with the template molecule
Electrostatic similarity The program EON [139] was used to calculated the
electrostatic similarity. It uses a field-based measure of Tanimoto to compare
the electrostatic potential of two small molecules. This electrostatic potential
is calculated solving the Poisson-Boltzman (PB) equation. If A and B are the
functions for the electrostatic potential of two molecules, the basic equation for a
field Tanimoto for the electrostatic is:
TanimotoA,B =
∫
A(~r) ·B(~r)∫
A(~r) ·A(~r) + ∫ B(~r) ·B(~r)− ∫ A(~r) ·B(~r) (3.14)
The two boundary cases for electrostatic Tanimoto occur when B = A:
Tanimoto =
∫
A(~r) ·A(~r)∫
A(~r) ·A(~r) + ∫ A(~r) ·A(~r)− ∫ A(~r) ·A(~r) = 1 (3.15)
and the opposite case, when B = −A:
Tanimoto =
∫
A(~r) · −A(~r)∫
A(~r) ·A(~r) + ∫ −A(~r) · −A(~r)− ∫ A(~r) · −A(~r) = −13 (3.16)
Thus, the Tanimoto coefficient for the electrostatic is between 1 and -1/3.
Atomic charges: The AM1BCC charges were calculated for all the molecules in
order to use them for the calculation of the electrostatic potential. The AM1BCC
method [140] starts with partial charges derived from the AM1 semiempirical wave-
function and in a second stage, bond-charge corrections (BCC) are applied to
the partial charges on each atom to generate the final partial charges. All the
AM1BCC parameters were tuned to reproduce the HF/6-31G* RESP-fit charges
[141, 142]. The MOLCHARGE program from the OpenEye software was used for
the calculation of the atomic charges.
3.1 Bioinformatics and docking 25
Design of new compounds
The process for the generation of new virtual compounds is based on the generation
of new molecules from a ”seed” molecule. The WABE program from the OpenEye
software was used for this purpose. It takes the ”seed” molecule and generates
from it a number of new virtual compounds, changing and adding different sets
of chemical groups. This process is typically used to explore the chemical space
around a lead compound or drug of interest. Once the virtual structures are
enumerated, they are scored using a scoring method based on their electrostatic
complementarities to another template molecule. Basically it is used to generate
new virtual compounds with high electrostatic similarity with a template molecule
starting from a ”seed” molecule (the seed molecule could be another molecule
similar to the template or only a chemical group).
Filter undesirable compounds: The filter program was used to eliminate inap-
propriate or undesirable generated new compounds. It attempts to remove all
of the compounds that are wrong candidates to suggest to a medicinal chemist
as a potential hit. It is based on different molecular properties like: polar surface
area, pKa normalization (pH 7.4), LogP, LogS, aggregators, lipinski and hydrogen-
bonds rules, reagent selection, pharmacokinetics, structural and chemical features
and functional groups. A drug-like filter was used for these purpose in this thesis
(see [143] for details).
3.1.4 Docking
The molecular docking is procedure to obtain the 3D structure of protein-protein or
protein-ligands complexes. It uses a scoring function to assign to each result a score
that it could be related with the binding affinity. In this thesis, the AUTODOCK
program [144, 145] was used for this procedure. Historically, the version 3.0.5 of
the program was used, but the final results were obtained with the version 4 of
the program. In this section, the algorithm and the scoring function implemented
in the program are described.
Genetic Algorithm
In order to perform the docking experiments, the AUTODOCK program with the
Lamarckian Genetic Algorithms (LGA) was used [144, 145]
The LGA uses ideas based on the language of natural genetics and biological
evolution and it involved several step.
The first is the definition of all the variables and evaluations that will be used in
the LGA:
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Gene, genotype and phenotype: the particular arrangement of a ligand and a pro-
tein can be defined by a set of values describing the translation, orientation, and
conformation of the ligand with respect to the protein: these are the ligand’s state
variables and, in the LGA, each state variable corresponds to a gene. The ligand’s
state corresponds to the genotype, whereas its atomic coordinates correspond to
the phenotype. Each genotype is composed by one chromosome. The chromo-
some is composed of a string of real valued genes: three Cartesian coordinates for
the ligand translation; four variables defining a quaternion specifying the ligand
orientation; and one real–value for each ligand torsion, in that order.
Fitness and generation: the fitness is the total interaction energy of the ligand
with the protein, and is evaluated using the energy function. Random pairs of
individuals are mated using a process of crossover, in which new individuals inherit
genes from either parent. In addition, some offspring undergo random mutation,
in which one gene changes by a random amount. Selection of the offspring of the
current generation occurs based on the individual’s fitness: thus, solutions better
suited to their environment reproduce, whereas poorer suited ones die.
The next step is the beginning of the Genetic Algorithm (GA). In AUTODOCK,
the simplest GA is applied, this GA algorithm it is also called the “Canonical GA”.
The GA starts by creating a random population of individuals, where the user
defines the number of individuals. For each random individual in the initial pop-
ulation, each of the three translation genes for x, y, and z is given a uniformly
distributed random value between the minimum and maximum x, y, and z extents
of the grid maps, respectively; the four genes defining the orientation are given
a random quaternion, consisting of a random unit vector and a random rotation
angle between -180◦ and +180◦; and the torsion angle genes, if any, are given
random values between -180◦ and +180◦.
In the LGA, the creation of the random initial population is followed by a loop over
generations and local search on a defined proportion of the population, repeated
until the maximum number of generations or the maximun number of energy
evaluations is reached.
In the following steps of the generation, each individual is mapped to its coordi-
nates (genotype to phenotype) and the individual fitness is calculated. The fitness
is calculated based on a free energy evaluation that will be discussed in more detail
later.
The proportional selection is the following step in the protocol. It is based on
the fitness values of each individual and it helps to decide which individuals will
reproduce.
The number of offspring is calculated as follows
ni =
fw − fi
fw − 〈f〉 fw 6= 〈f〉 (3.17)
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Figure 3.4: Genetic algorithm: selection and recombination.
where ni is the number of offspring to be allocated to the individual i; fi is the
fitness of the individual (the energy of the ligand); fw is the fitness of the worst
individual, or highest energy in the last defined generations and 〈f〉 is the mean
fitness of the actual population. After this stage the worse individuals (ni < 1)
will be replaced by the best individuals (ni > 1) in a proportional way creating an
intermediate population, like a normal evolutionary program.
Crossover and mutation are performed after the selection on random members of
the intermediate population according to a defined rate of crossover and mutation
Fig.3.4.
First, crossover is performed. Two–point crossover is used, with breaks occurring
only between genes, never within a gene. Thus, both parents’ chromosomes would
be broken into three pieces at the same gene positions, each piece containing
one or more genes; for instance, ABC and abc. The chromosomes of the resulting
offspring after two–point crossover would be AbC and aBc. These offspring replace
the parents in the population, keeping the population size constant. Crossover is
followed by mutation; it is performed by adding a random real number that has a
Cauchy distribution to the variable, the distribution being given by:
c(α, β, x) =
β
pi (β2 + (x− α)2) (3.18)
where α and β are parameters that affect the mean and the spread of the distri-
bution.
The last step in the generation is the elitism selection. The elitism is an integer
parameter that determines how many of the top individuals automatically sur-
vive into the next generation. The new population that has resulted from the
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Figure 3.5: This figure illustrates genotypic and phenotypic search, and contrasts
Darwinian and Lamarckian search. The space of the genotypes is represented by the lower
horizontal line, and the space of the phenotypes is represented by the upper horizontal
line. Genotypes are mapped to phenotypes by a developmental mapping function. The
fitness function is f(x). The result of applying the genotypic mutation operator to the
parent’s genotype is shown on the right–hand side of the diagram, and has the corre-
sponding phenotype shown. Local search is shown on the left–hand side. It is normally
performed in phenotypic space and employs information about the fitness landscape. Suf-
ficient iterations of the local search arrive at a local minimum, and an inverse mapping
function is used to convert from its phenotype to its corresponding genotype. In the case
of molecular docking, however, local search is performed by continuously converting from
the genotype to the phenotype, so inverse mapping is not required. The genotype of the
parent is replaced by the resulting genotype, however, in accordance with Lamarckian
principles. Taken from [144].
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proportional selection, crossover, and mutation is sorted according to its fitness;
the fitness of new individuals having resulted from crossover and/or mutation is
calculated as necessary.
In the LGA, each generation is followed by a local search algorithm on a defined
proportion of the population; the indivual in the population is then replaced by
the result of the local search Fig. 3.5. The local search algorithm implemented
in AUTODOCK is the one proposed by Solits and Wets [146]. In particular,
this algorithm searches through the genotypic space rather than the more typical
phenotypic space. This means that there is no need to pass from the genotypic
space to the phenotypic space like any other algorithm and then to come back
again. Nonetheless, this molecular variation of the genetic algorithm still qualifies
as Lamarckian, because any “environmental adaptations” of the ligand acquired
during the local search will be inherited by its offspring.
In the Lamarckian genetic algorithm, genotypic mutation plays a somewhat dif-
ferent role than it does in traditional genetic algorithms. Traditionally, mutation
plays the role of a local search operator, allowing small, refining moves that are not
efficiently made by crossover and selection alone. With the explicit local search
operator, however, this role becomes unnecessary, and is needed only for its role in
replacing alleles that might have disappeared through selection. In LGA, mutation
can take on a more exploratory role.
Scoring function
The approach implemented in AUTODOCK 3.0.5 to calculate the relationship be-
tween molecular structure and binding free energy (structure–based scoring func-
tion), uses the thermodynamic cycle of Wesson and Eisenberg Fig. 3.6 [147].
The form of the free energy function includes five terms:
∆G = Wvdw
∑
i,j
(
Aij
r12ij
− Bij
r6ij
)−Whbound
∑
i,j
E(φ)(
Cij
r12ij
− Dij
r10ij
+ Ehbound)+
+Welec
∑
i,j
qiqj
ε(rij)rij
+WconfNtor +Wsol
∑
i,j
SijVj exp(−r2ij/2σ2)
(3.19)
Where coefficients W were empirically determined using linear regression analysis
[144]. The summations are performed over all pairs of ligand atoms, i, and protein
atoms, j, in addition to all pairs of atoms in the ligand that are separated by three
or more bonds.
The in vacuo contributions include three interaction energy terms, used in pre-
vious versions of AUTODOCK: a Lennard–Jones 12–6 dispersion/repulsion term;
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Figure 3.6: Thermodynamic cycle for the binding of an enzyme, E, and an inhibitor,
I, in both the solvated phase and in vacuo. Note the solvent molecules are indicated by
filled circles: they tend to be ordered around the larger molecules, but when E and I bind,
several solvent molecules are liberated and become disordered. Taken from [148]
a directional 12–10 hydrogen bonding term, where E(φ) is a directional weight
based on the angle φ, between the probe and the target atom and Ehbound is the
estimated average energy of hydrogen bonding of water with a polar atom; and a
screened Coulombic electrostatic potential. A measure of the unfavorable entropy
of ligand binding due to the restriction of conformational degrees of freedom is
added to the in vacuo function. This term is proportional to the number of sp3
bonds in the ligand, Ntor. Note that the internal or intramolecular interaction
energy of the ligand is not included in the calculation of binding free energy.
The desolvation term is calculated using a volume–based approach [149]. For each
atom in the ligand, fragmental volumes of surrounding protein atoms (Vj) are
weighted by an exponential function and then summed, evaluating the percent-
age of volume around the ligand atom that is occupied by protein atoms. This
percentage is then weighted by the atomic solvation parameter of the ligand atom
(Si) to give the desolvation energy.
Improvements
The new version of AUTODOCK (V. 4.0) used an improved version of the semiem-
pirical free energy force field. It was calibrated using a large set of diverse pro-
tein–ligand complexes and includes two major advances [145].
1- An improved thermodynamic model of the binding process, which allows the
inclusion of intramolecular terms in the estimated free energy. This gives also the
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possibility to rotate protein side chains during the docking procedure.
The free energy of binding is estimated to be equal to the difference between (1)
the energy of the ligand and the protein in separated states and (2) the energy of
the ligand–protein complex.
∆G = (V L−Lbound−V L−Lunbound)+(V P−Pbound−V P−Pbound)+(V P−Lbound−V P−Lunbound+∆Sconf ) (3.20)
Where the first two parentheses are intramolecular energies for the bound and
unbound states of the ligand and the protein respectively and the third parenthe-
ses is the intermolecular energy between the bound and unbound state plus the
conformational entropy lost upon binding.
∆Sconf = WconfNtor (3.21)
2- An improve pair-wise evaluation for the force field, that includes a full des-
olvation model that includes terms for more atom types, including the favorable
energetics of desolvating carbon as well as the unfavorable energetics of desolvating
polar charges groups.
V = Wvdw
∑
i,j
(
Aij
r12ij
\
Bij
r6ij
)−Whbound
∑
i,j
E(φ)(
Cij
r12ij
− Dij
r10ij
+ Ehbound)+
+Welec
∑
i,j
qiqj
ε(rij)rij
+Wsol
∑
i,j
(SiVj + SjVi exp(−r2ij/2σ2)
(3.22)
The desolvation term is now calculated using the same approach as before [147]
but now the atomic solvation parameter (Si) is calculated as a function of the
partial atomic charge (qi):
Si = (ASPi +QASP × |qi|) (3.23)
Where ASPi is the atomic solvation parameter of atom i and QASP is the charged-
based atomic solvation parameter (QASP = 0.01097, stderror = 0.0063)
Another approach is implemented in the GOLD program [150, 151] but it has not
been used in thesis. This approach uses a multi-population genetic algorithm and
different types of scoring functions. It is presented in the Appendix B.
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3.2 Molecular Dynamics
Molecular dyanmics (MD) simulations are based on the following assumptions:
1. The nuclei can be treated as classical particles
2. The Born-Oppenheimer approximation holds
3. The electronic degrees of freedom can be integrated out.
Under these greatly simplifying assumptions, the dynamics of the system can be
described by the Newton second law:
~Fi(t) =
d2~ri(t)
dt2
·mi = −dEtot(t)
d~ri
(3.24)
where is ~ri the position of the ith atom and Etot is the total energy of the system
of N particles. So, knowing the initial structure (by experiments or by computer
modeling) and providing a velocity distribution consistent with the temperature
simulated, one can provide the time-evolution of the system. MD average values
of several properties can be evaluated from the resulting trajectory.
The MD run consist on several steps.
1. Defining of the initial conditions, potential interaction as a function of atom
positions; position ~r and velocities ~ν of all atoms in the system
2. Compute the force acting on each atom.
3. Solve the Newton’s equations of motion and update configuration of the system.
4. Write the new positions, velocities, energies,. . . , etc
5. Back to point 2
In the followings, the form of the equations of mations used for proteins and some
details of MD algorithms are given.
3.2.1 Equation of motions
Molecular dynamics simulation consists of the numerical, step-by-step, solution of
the classical equations of motion (eq. 3.24).
Where ~Fi(t) is the total force acting on the i − th atom, mi is its mass, d
2~ri(t)
dt2
is its acceleration, ~ri(t) is its position and Etot is the total energy action on the
atom. The integration time step is set to ∆t, it is chosen at the begging of the
simulation and remain unchanged during the all run.
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The most common used algorithms for the integration of the equations of motion
are the so called Verlet and Leap-Frog algorithm [152]. In both algorithms the
positions of each atom are expressed by Taylor expansions. The lack of explicit
velocities in the Verlet algorithm is remedied by the leap-frog algorithm [153] .
Positions at times t+∆t and t are given by the Taylor expansions around t+∆t/2.
~vi(t+ ∆t/2) = ~vi(t+ ∆t/2) +
~Fi(t)
mi
·∆t
~ri(t+ ∆t) = ~ri(t) + ~vi(t+ ∆t/2) ·∆t
(3.25)
which make use of the positions and forces at time t and velocities at time t+∆t/2,
alternating the update of the position and velocities.
First, the velocities are calculated at half time step, then these are used to calculate
the positions at one time step. In this way, positions and velocities leap each other.
The advantage of this algorithm is that velocities are explicitly calculated, and
the disadvantage is that they are not calculated at the same time as the positions.
As a consequence, kinetic and potential energy cannot directly compute the total
energy at time t, but energy evaluation is possible using the following approximate
value of velocities at time t:
~vi(t) =
~vi(t−∆t/2) + ~vi(t+ ∆t/2)
2
(3.26)
3.2.2 Force field
In order to solve numerically the equations of motion, we need to be able to
calculate the forces acting on the atoms, and these are usually derived from a
potential energy represents the complete set of 3N atomic coordinates.
The potential energy function, also called force field, used in most of the standard
molecular simulation programs for biological systems consist of:
Etot = Ebonds + Eangles + Edihedrals + Evdw + Eelect (3.27)
It takes form of the summation of different additive terms that correspond to bond
distances stretching (Ebonds), bond angles bending (Eangles), bond dihedral or tor-
sion angle (Edihedrals), van der Waals potential (Evdw) and electrostatic potential
(Eelect). The first three terms are considered to be the intramolecular bonding in-
teractions, each term involves a multiplet of atoms connected by chemical bonds.
The other two terms represent the non-bonded interactions between atoms.
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The specific form of each of these terms is shown below:
Ebonds =
∑
bonds
1
2
kr(r − req)2
Eangles =
∑
angles
1
2
kθ(θ − θeq)2
Edihedrals =
∑
dihedrals
1
2
Vr(1 + cos(nϕ)− γ)
Evdw =
atoms∑
i<j
(
Aij
r12ij
− Bij
r6ij
)
Eelec =
atoms∑
i<j
qiqj
4piε0rij
(3.28)
In the bonding interactions, the bond stretching and angle bending terms are rep-
resented as harmonic energy functions where req and θeq refer to equilibrium bond
lengths and angles, kr and kθ are the vibrational constants. The equilibrium values
of the bond and angle parameters are usually derived from structural databases,
while the force constants are derived from infrared spectroscopy. In the third term,
Vn is the torsional barrier corresponding to the nth barrier of a given torsional an-
gle with phase γ: dihedral parameters are calibrated on small model compounds,
comparing the energies with those obtained by quantum chemical calculations.
Improper dihedral angles are added to take into account quantum effects that are
not present in Etot as, for example, to preserve planarity in aromatic rings.
In the non-bonded interactions, the van der Waals potential is described by a
Lennard-Jones potential, containing an attractive and a repulsive term, the pa-
rameters are defined so as to reproduce chemical-physical properties (e.g., den-
sities, enthalpies of vaporization, solvation free-energies) in organic liquids. The
electrostatic energy is evaluated by assuming the dielectric constant ε equal to 1,
and using the restrained electrostatic potential model [141] to define partial atomic
point charges: in this model, charges are assigned to the atom-centered points so
as to fit the electrostatic potential derived from quantum chemistry calculations
for a set of small representative molecules. Van der Waals (vdW) and electro-
static potentials are calculated between atoms belonging to different molecules or
for atoms in the same molecule separated by at least three bonds. In principle,
the non-bonded interaction is suppose to be calculated aver all pairs of atoms in
the system, and they are the most expensive part of a MD calculation. In prac-
tical applications, however, the number of interactions is limited by a predefined
cutoff distance, so the non-bonded interaction is calculated only between atoms
separated by a distance not larger than the cutoff. For the vdW potential, this
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truncation introduce only a small error in the energy but it is not the case for the
electrostatic potential because the Coulomb interaction between charges qi and qj
decays much less rapidly with distance. Hence it can not be truncated, but when
periodic boundary conditions are used, it could be treated with schemes such as
Particle Mesh Edwald, which approximate the exact result to an acceptable error
similar to the error in the vdW potential.
3.2.3 Constrains
The integration time-step ∆t is limited in the integration of the equations of motion
to the fastest motions of the system. Bond stretching, in particular those involving
hydrogen atoms, has the highest frequency and relatively low amplitude, and this
restricts the time-step to 1 fs. Since these motions are of little interest in most
cases, they are constrained to the equilibrium bond length and these allow an
increase of ∆t by a factor of 1.5-2 the time-step, with small affects on the accuracy
of the simulation.
In the NAMD program [154], the algorithm used is called SHAKE algorithm.
In this algorithm, the constrains are introduced through the Lagrangian [155] or
Hamiltonian [156] formalism.
3.2.4 Periodic boundary conditions
MD simulations are usually performed under periodic boundary conditions (PBC),
to minimize boundary effects and to mimic the presence of the “bulk” environment.
In this approach, the system is surrounded with replicas of itself in all directions,
to yield an infinite periodic lattice of identical cells. When a particle moves in the
central cell, its periodic image in every another cell moves accordingly (Fig 3.7).
As one molecule leaves the central cell, its image enters from the opposite side
without “filling” the cell boundary.
The PBCs are taken into account only in the calculating of non-bonded interactions
between atoms belonging to different molecules, and if the potential range is not
too long (cutoff radius used to truncate non-bonded interactions does not exceed
half the shortest box vector), the minimum image convention could be adopted.
This means that each atom interacts only with the nearest atom or image in the
periodic array.
When a macromolecule, such as a protein, is studied in solution, this restriction
does not suffice. In principle a single molecule should not be able to “see” both
sides of the macromolecule. This means that the length of each box vector must
exceed the length of the macromolecule in the direction of that edge plus two time
cutoff radius. But it is common to compromise in this respect, and make the
solvent layer somewhat smaller in order to reduce the computational cost.
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Figure 3.7: Periodic boundary conditions. As a particle moves out of the simulation
box, and image particle moves in to replace it. In calculating particle interactions within
the cutoff range, both real and image neighbors are included.
3.2.5 Neighbors list
Computing the non-bonded contribution to the interatomic forces in an MD simu-
lation involves, in principle, a large number of pairwise calculations. Let us assume
that the interaction potentials are of short range, equal to 0 if rij > rcut. In this
case, the program skips the force calculation, avoiding expensive calculations, and
considers the next candidate j. Nonetheless, the time to examine all pair separa-
tions is proportional to the number of distinct pairs and this still consumes a lot
of time.
Some economies result from the use of lists of nearby pairs of atoms. The potential
cutoff sphere, of radius rcut, around a particular atom is surrounded by a ‘skin’,
to give a larger sphere of radius rlist as shown in Fig. 3.8. At the first step in
a simulation, a list is constructed of all the neighbours of each atom, for which
the pair separation is within rlist. Over the next few MD time steps, only pairs
appearing in the list are checked in the force routine. From time to time the list
is reconstructed: it is important to do this before any unlisted pairs have crossed
the safety zone and come within interaction range.
3.2.6 Long range forces
A long-range force is often defined as one in which the spatial interaction falls off
no faster than r−d where d id the dimensionality of the system. In this category is
the charge-charge interactions between ions (V (r) ≈ r−1). These interactions are
serious problem for the simulations, since their range is greater then half the box
length.
3.2 Molecular Dynamics 37
Figure 3.8: The potential cutoff range (solid circle), and the list range (dashed circle),
are indicated. The list must be reconstructed before particles originally outside the list
range (black) have penetrated the potential cutoff sphere.
Electrostatics
The Edwald sum is a technique for efficiently summing the interactions between
ions and all its periodic images (see Appendix C for details). The potential energy
can be written as
V =
1
2
∑
n
′
 1
4piε0
N∑
i=1
N∑
j=1
qiqj
rij , n
 (3.29)
Where qi and qj are the charges, n is the box index, rij is the distance between
the charges and the prime indicates that we omit i = j fon n = 0. For long-
range potential, this sum is conditionally convergent, and thus extremely slow.
Therefore, a very large number of images is required to achieve a reliable estimate
of V . The idea behind the Ewald method is to surround every point charge by a
charge distribution of equal magnitude and opposite sign %−, which spreads out
radially from the charge. This distribution is conveniently taken to be Gaussian
%Gi (r) = qi
(α
pi
) 3
2 exp
(
−α |ri + nL|2
)
(3.30)
Where α is an arbitrary parameter which does not determine the final result, but
can be adjusted to optimized the convergence rate (it is related to the width of
the gaussian distribution). In this way an efficient screening is realized, so that
interactions rapidly go to 0 and direct summation is possible. This extra distribu-
tion acts like an ionic atmosphere, to screen the interaction between neighboring
charges. The screened interactions are now short-ranged, and the total screened
potential is calculated summing over all molecules. A charge distribution of the
same sign as the original charge, and the same shape as the distribution %Gi (r) is
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also added. This canceling distribution reduces the overall potential to that due to
the original set of charges. In order to exclude self-interactions the contributions
of these three charge densities should not be evaluated in ri. However, it is conve-
nient to keep self-interactions due to the cancelling charge distribution %+, since
%+ is in this way periodic and can be represented as a rapidly converging Fourier
sum. The spurious self-interaction can be easily subtracted separately. The can-
celing distribution is summed in the reciprocal space. In other words, the Fourier
transforms of this distribution are added, and the total transformed back into real
space. Thus, the total charge distribution of the system %(r) may be rewritten as:
ρ(r) =
∑
i
qiδ (r − ri + nL)
ρ(r) =
∑
i
(
qiδ (r − ri + nL)− ρGi (r)
)
+
∑
i
ρGi (r)
(3.31)
Where the first sum (which only produce short ranged potentials) is calculated in
the direct space, while the second is calculated in the reciprocal space:
V = (εdir − εself + εrec)
εdir =
1
2
∑
n
′
N∑
ij
qiqj
|rij + nL|erfc
(√
α |rij + nL|
)
εself =
√
α
pi
N∑
i=1
q21
εrec =
2pi
V
∑
k 6=0
∑
ij
exp
(
k2
4α
)
k2
qiqj exp ( −ik · (r − rj))
(3.32)
Where erfc = pi−
1
2
∫∞
r exp
( −r2) dx is the complementary error function.
εdir is very similar to eq. 3.29, although the long ranged 1r function is here sub-
stituted by the short ranged erfc(r)r : as a result, the interaction vanishes above a
cutoff roughly equal to α−
1
2 , and for every i and j the interaction can be approx-
imated by only one periodic image term. Typically, α is chosen in order to keep
the truncation error in the order of 10−5/10−6 of εdir.
εself is the self interaction of the gaussian charge distributions: it must be sub-
tracted from the total, as the reciprocal space term εrec contains it, albeit it is a
constant number, not depending on the atomic configuration.
εrec is a sum over an infinite number of terms, but the factor k
2
4α ensures a fast
convergence in the reciprocal space, and normally no more than 5/10 wave vectors
in each direction are required. Its calculation is however the most consuming part
in the Ewald scheme.
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3.2.7 Temperature control
In MD simulations it is possible to realize different types of thermodynamics en-
sembles which are characterized by the control of certain thermodynamic quan-
tities, the microcanonical ensemble (NVE) is obtained from the derivation of the
equation of motion. However the microcanonical ensemble does not correspond
to the conditions under which most experiments are carried out. The ensembles
in which most of the experiments are carried out are the canonical (NVT) or the
isothermal-isobaric ensembles. If one is interested in the behavior of the system
in such ensembles, a thermostat is required to control the temperature during the
simulation. Among the several methods to control the temperature usually avail-
able in MD software packages, the weak coupling method [157] and the coupling
to an external bath algorithm [158, 159] are used in this work.
Berendsen thermostat
The instantaneous value of the temperature T (t) of a system with Ndf degrees of
freedom is related to the kinetic energy Ekin via the particles velocities as follows:
Ekin(t) =
N∑
i=1
1
2
miv
2
i (t) =
1
2
NdfkBT (t)
T (t) =
N∑
i=1
miv
2
i (t)
NdfkB
(3.33)
An obvious way to alter the temperature is to scale the velocities by a factor λ .
So:
∆T =
N∑
i=1
mi(λvi)2
NdfkB
− miv
2
i
NdfkB
∆T = (λ2 − 1)T (t)
(3.34)
If T0 is the desired temperature and T (t) is the current temperature and the
variation of the current temperature along the time is defined as:
dT (t)
dt
=
T0 − T (t)
τT
∆T =
∂t
τT
(T0 − T )
(3.35)
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It is easy to demonstrate that:
λ(t) =
√
1 +
∆T
τT
(
T0
T (t)
− 1
)
(3.36)
The factor λ is used to scale the velocities at each time-step, in order to relax
the temperature toward the desired temperature value T0. The relaxation rate
is controlled by the time coupling constant τt, which should be small to achieve
the required temperature but large enough to avoid disturbance of the physical
properties of the system by coupling to the bath. Even though the Berendsen weak
coupling algorithm is efficient for relaxing the system to the reference temperature,
it does not allow for a proper sampling of the canonical ensemble. Canonical
ensemble simulation is enabled by employing the Nose´-Hoover thermostat.
Nose´ -Hoover temperature coupling
The Berendsen thermostat is extremely efficient for relaxing a system to a target
temperature, but once the system has reached the equilibrium, it might be more
important to probe a correct canonical ensemble. The extended system method
was originally introduced by Nose´ and subsequently developed by Hoover. So, in
the Nose´ -Hoover approach [157, 158], the idea is to consider the heat bath as an
integral part of the system by addition of an artificial variable s˜ associated with a
“mass parameter’ Q > 0 as well as velocity .The magnitude of Q determines the
coupling between the bath and the real system an so influences the temperature
fluctuations. The artificial variable s˜ plays the role of a time-scaling parameter.
The Nose Hamiltonian (HN ) for the extended system is chosen to be:
HN = H0(q, p/s) + gkBT ln s+ p2s/2Q (3.37)
Where H0 is the usual Hamiltonian for a classical many body system, except
that everywhere one would normally expect to see a momentum p appearing, it is
replaced by p/s thus:
H0(q, p/s) =
∑
i
(pi/s)2/2mi − U(q) (3.38)
The Nose´ equations of motions are:
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r˙i =
∂HN
∂p
=
pi
ms2
p˙i =
∂HN
∂r
= Fi(r)
s˙ =
∂HN
∂ps
=
ps
Q
p˙s =
∂HN
∂s
=
∑ p2i
ms3
−NdfkBT
s
(3.39)
These coupled first order equations take a simpler form if the time scale is reduced
by s, so that dtold ≡ sdtnew . All of the rates given before can then be expressed
as derivatives with respect to tnew.
r˙i =
∂HN
∂p
=
pi
ms
p˙i =
∂HN
∂r
= Fis
s˙ =
∂HN
∂ps
=
pss
Q
p˙s =
∂HN
∂s
=
∑ p2i
ms2
−NdfkBT
(3.40)
And
r¨i =
dr˙i
dt
=
p˙i
ms
− pi
m
s˙
s2
=
~Fi
mi
− ξr˙i (3.41)
where ξ = psQ is the thermodynamic friction coefficient that evolves in time accord-
ing:
ξ˙ =
∑
mr˙2−NdfkBT
Q
=
T (t)− T0
Q
(3.42)
The time derivative is calculated from the difference between the current tempera-
ture T (t) and the reference temperature T0, and Q determines the strength of the
coupling to the heat bath.
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Langevin
In the Langevin thermostat [160], an additional random force term and a constant
frictional coefficient are introduced to the system.
r¨i(t) =
Fi
mi
− βr˙i(t) + ηi(t) (3.43)
where ni(t) is randomly extracted from a gaussian distribution having the following
properties:
〈ηi(t)〉 = 0
〈ηi(t) · ηi(0)〉 = 2kBT0βiδ(t)
(3.44)
with δ(t) indicating the Dirac delta. In many cases random numbers for ηi(t) are
extracted individually for each atom.
3.2.8 Pressure control
Berendsen barostat
The Berendsen algorithm, to control the pressure of the system, is similar to the
Berendsen thermostat. In this case, the algorithm scales the coordinates and the
box vectors. So the effect is a first-order kinetic relaxation of the instantaneous
pressure P (t) toward a reference pressure P0, with a time constant τP that can
be specified as an input parameter. The equations for the Berendsen algorithm
barostat are:
dP (t)
dt
=
P0 − P (t)
τP
(3.45)
The pressure is given by
P =
2
3V
(
Ek −Θ
)
, (3.46)
where Θ is the internal virial for pair-additive potentials:
Θ = −1
2
∑
i<j
rijFij
rij = ri − rj
(3.47)
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and Fij is the force on particle i due to particle j. Since intramolecular contribu-
tions to the pressure vanish, in molecular systems Eqs(2) and (3) can be evaluated
using only the center of mass coordinates and velocities and forces acting on the
centers of mass. A pressure change can be acomplished by changing the virial
through scaling the interparticle distances. A simple proportional coordinate scal-
ing, concomitant with volume scaling, minimizes local disturbances. So, an extra
term in the equation of x˙ = v is added, proportional to x (x˙ = v + αx), while the
volume changes accordingly:
V˙ = 3αV
α = −P0 − P
τP
β
3
(3.48)
The modified equation of motion is
x˙ = v − P0 − P
τP
β
3
· x (3.49)
This proportional scaling of coordinates and box length l (assuming an isotropic
system in a cubic box) per time step from x to µx and l to µl with the scaling
factor µ:
µ = 1− β∆t
3τP
(
P0 − P
)
(3.50)
Te compressibility, that may not be accurately known, occurs in the same expres-
sion for the scaling factor µ. Since the accuracy in β only influences the accuracy
of the noncritical time constant τP , the imprecision of β is of no consequence for
the dynamics. The equation 3.50 apply to an isotropic system. However, it is
possible to modify the equations for anisotropic systems.
Nose´ -Hoover / Langevin piston
One of the pressure control schemes used in this thesis is Nose`-Hoover / Langevin
piston introduced in NAMD [154]. Such barostat is a hybrid method, combin-
ing two pressure control schemes, the Nose`-Hoover like barostat [161], and the
Langevin–piston barostat [159]. Both barostats consider the unit cell vectors as
virtual particles, and both require that a temperature control method is used in
conjunction for the degrees of freedom of the extended set (atom coordinates plus
unit cells).
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Specifically, the barostat referred as Nose`-Hoover was introduced in order to re-
move the unphysical dependence of the trajectory on unit cell vectors [161], partic-
ularly in markedly anisotropic systems. The degrees of freedom of unit cell vectors
are embedded in the temperature control scheme, using a formalism that leads to
the correct isothermal/isobaric partition function [161].
On the other hand, the Langevin-piston barostat [159], while also explicitly con-
sidering the unit cell vectors as additional degrees of freedom, assigns them to a
Langevin thermostat rather than a Nose`-Hoover one.
The equations of motion of each atom are modified by the introduction of an
additional degree of freedom, the piston σ, which undergoes a Langevin like dy-
namics, in analogy with the motion of each particle (also in this case, the absolute
coordinates are used rather than the scaled ones):
mi
d2~ri(t)
d2t
= ~fi(t)− βid~ri(t)
dt
+ ~ηi(t) +
d2U(t)
d2t
U−1~ri(t)
d2U(t)
d2t
=
V (U)
W
(P − Pref )− βU dU(t)
dt
+ ηU (t)
(3.51)
Where βi and the vector ~ηi(t) are the Langevin friction coefficient and noise term
for the simulated atoms, βU and the matrix ηU (t) are those for the unit cell vectors.
Therefore, this barostat also includes explicitly the Langevin thermostat for the
atomic degrees of freedom.
3.2.9 Analysis of molecular dynamics trajectories
The data obtained from MD trajectories can be used to calculate several structural
and dynamical properties.
Root Mean Square Displacement (RMSD)
The displacement of the atoms or group of atoms along the trajectory could be
estimated calculating the Root Mean Square Displacement (RMSD). The RMSD
of a set of N atoms at time t, with respect to a reference conformation (ex: initial
conformation), reads:
RMSD(t) =
√∑N
i=0
∣∣~ri(t)− ~r0i ∣∣2
N
(3.52)
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Where
∣∣~ri(t)− ~r0i ∣∣ is the displacement of the ith atom at time t from the reference
position r0i . An increase of the RMSD indicates that the protein moves to a
conformation different from the initial structure and thus suggests an incomplete
sampling or a conformational change.
Root mean square fluctuation (RMSF)
Similar to the previous analysis is the calculation of the fluctuations of an atom
or a groups of atoms, this calculated according:
RMSFi =
√〈
(~ri − 〈~ri〉)2
〉
(3.53)
where ~ri is the position vector of the ith atom and the brackets stand for a temporal
average. This analysis give clues about the most mobile regions of the protein.
Electrostatic Calculations
Electrostatic potentials have been calculated with the Poisson-Boltzmann equa-
tion [162]. In this approach, the solvent is represented as continuum and the
electrostatic potential Ψ(r) can be determined by solving the following equation:
~∇ ·
(
ε(~r)~∇Ψ(~r)
)
= −4piρf (~r)− 4pi
∑
i
c∞i ziq exp
( −ziqΨ(~r)
kBT
)
λ(~r) (3.54)
Where ρf (~r) is the fixed charge distribution of the molecule, ε(~r) is the position
dependent dielectric constant, c∞i is the concentration of ion i at an infinite distance
from the molecule, zi is its valency, q is the proton charge, kB is the Boltzmann
constant, T is the temperature and λ(~r) describes the accessibility to ions at point
~r.
An analytical solution of the equation can be obtained only for very simple geome-
tries and charge distributions. For proteins, the equation can be solved numerically
using the finite difference methods on a grid. As a first step, the molecular surface
is generated using a spherical probe of 1.4 A˚ , which is the water radius. A grid
is generated and, according to the surface, a high dielectric constant value is then
assigned to the grid points that lie on the external side of the macromolecule,
which are supposed to belong to the solvent, and a low dielectric constant value is
assigned to the remaining grid points. Each atom charge is split to the nearest grid
points of the mesh and a smoothing algorithms are used to improve the results.
Finally, the electrostatic potential is numerically estimated for each grid point and
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the energy of the charged grid is calculated. Since every atom charge is split to
different grid points, different parts of the charge of the same atom interact each
other. The self-grid energy is removed in the difference between energies obtained
for the same protein conformation with the same grid in different conditions.
Here, the Poisson-Boltzmann equation is numerically solved using the APBS pro-
gram [163].
Chapter 4
Computational approach to the
investigation of
alpha-synuclein/dopamine
interactions
4.1 Introduction
The interplay between dopamine and α-synuclein (AS) plays a central role in
Parkinson’s disease. Unraveling structural determinants of dopamine binding may
shed light on the mechanisms by which this molecule modulates AS fibrilliza-
tion and toxicity,thus providing new clues for therapeutics intervention in PD and
related diseases. In this chapter, to clarify the structural determinants of the
interactions between dopamine and AS, a series of computational studies to iden-
tify the exact residues and the nature of the interactions mediating the dopamine
binding to AS was performed. The molecular modeling results were later corrob-
orated by biochemical experiments performed by a group in collaboration. Our
modeling studies involve dopamine (DOP) and several of its derivatives (Fig. 4.2)
because all of these species could be present under physiological conditions [164]
and interacts with AS [100].
The 125YEMPS129 region was predicted to form non-specific hydrophobic contacts
with the ligands’ aromatic ring. The ligands were also stabilized by significant
long-range electrostatic interactions with E83 in the NAC region. By forming
these interactions with AS, dopamine may affect AS fibrillation properties. The
in vitro the effects of dopamine on the aggregation of mutants designed to alter
the properties of these moieties were later investigated by the Group of Prof.
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Gustincich. They found that point mutations in the 125YEMPS129 region do not
largely affect fibrillization, consistently with the fact that dopamine interacts non-
specifically with that region. In contrast, as suggested by modeling, the E83A
mutation abolishes the ability of dopamine to inhibit AS aggregation.
Together, these findings demonstrate how the use of structural models of even
highly heterogeneous states of proteins determined by NMR spectroscopy in com-
bination with molecular dynamics simulations can provide novel insight into the
structural determinants of ligand binding. This strategy which enables ligands,
that mimic the interactions between dopamine and AS, to be devised, and it will
help to develop therapeutics for PD and related synucleinopathies.
4.2 Methodologies Used
4.2.1 Cluster analysis
The modeling is based on the 4,000 NMR conformations of AS [14]. First, the
938 conformations among them which exhibit 5 or more amino acids (not Gly)
in the forbidden region of the Ramachandran plot were discarted, as defined by
the ”what check” algorithm [165]. Then, we selected a set of 87 representative
conformations out of the remaining 3,062 ones using the cluster analysis method
proposed by Micheletti et al. [130]. This is a method for clustering conformational
ensembles into suitable similarity classes, and it is based on the RMS pair distance
distribution. A RMSD cutoff of 19 A˚ was used for the selection of the representative
conformers. To crosscheck the results, we carried out a second analysis, based on a
smaller number of starting structures (1,000 randomly selected out of the ensemble
of 3,062 NMR structures above ) using a different clustering algorithm [131, 134].
4.2.2 Docking.
The ligands in Fig. 4.2 were docked onto the first 6 representatives conformations
of AS using AUTODOCK 3.0 [144]. The parameters for the molecules were cal-
culated using its standard parameterization procedure (Morris G.M. et al., 1998).
The Lamarckian Genetic Algorithm [144] was applied as a search method for the
different docking results. Therefore, 54 complexes were considered. The potential
grid map for each atom type was calculated using a cubic box of 252 grid points
in each direction, with a distance of 0.5 A˚ between grid points. For each complex,
100 docking runs were performed resulting in a total of 5,400 calculations. The
ligand location was then identified using cutoff distance criterion of 5 A˚ between
the Cα of each amino acid and the center of mass of each ligand. The most prob-
able region of interaction for each complex was identified using a cluster analysis
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Figure 4.1: α-synuclein conformations chosen randomly from the 4,000 NMR confor-
mations
Figure 4.2: Dopamine forms (Adapted from [100]).
based on the RMSD distance between the ligand on each run (RMSD cutoff of 2
A˚).
4.2.3 Molecular dynamics simulations.
Each of the 6 representative conformations, with each of the 7 ligands (Fig. 4.2)
in the most populated positions obtained with AUTODOCK,were inserted into
a box of water of 80 x 100 x 100 A˚3 edges. Periodic boundary conditions were
applied by ensuring that the minimum distance between AS and its images was
larger than 12 A˚. The overall charge of the system studied was neutralized by the
addition of 8 Na+ ions. The AMBER99 [166] and TIP3P [167] force fields were
used for biomolecules with counter ions and water respectively. As for the ligands,
RESP atomic charges [141] were calculated at the HF/6-31G* level of theory,
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using the GAUSSIAN98 suite of programs [168] (Tab. D.1). The atom types and
parameters (i.e.van der Waals, bond lengths, valence angles and dihedral angles)
were assigned according the AMBER99 force field. Electrostatic interactions were
calculated using the particle mesh Ewald method , with 64x64x64 grid points. A
cutoff distance of 10 A˚ for the real part of the electrostatic and van der Waals
interactions was used. The time-step was set to 2 fs. The SHAKE algorithm [169]
was applied to fix all bond lengths. The simulations were performed at T=300K
and P=1.013 bar, by coupling the systems with a Langevin thermostat and Nose-
Hoover Langevin barostat [159]. The coupling coefficient of 5 ps-1 for the Langevin
thermostat was used for all atoms in the complexes studied. For the Nose-Hoover
Langevin barostat, an oscillation period of 200 fs and the damping timescale of 100
fs were used. The stability of the complexes studied on the timescale considered
(6 ns) was estimated based on the RMSD and radius of gyration of the protein
along the trajectory. MD calculations were performed using NAMD program [154]
while the obtained results were analyzed using Gromacs and VMD programs. The
Tanimoto coefficients for the electrostatic potential (Te) and shape (Ts) of the
ligands [170] were calculated using EON code for chemical similarity analysis.
Electrostatic interaction energies between residues of the NAC region and the
ligands was calculated using the Amber force field as in the work by Guidoni et
al [171]. We considered only the residues which form such interactions for at least
80% of the dynamics. This is a very approximate methodology and it was used
here only to provide qualitative results.
4.2.4 Additional experiments
In order to prove the molecular modeling results, several experiments were done
by the group of Prof. Gustincich
Human WT AS cDNA was cloned into the bacterial and the mutants were obtained
using site-directed mutagenesis. Later, fibrillization studies were performed on the
WT protein and all the mutants in absence or presence of an equimolar quantity
of dopamine. Fibril formation was monitored by the ThT assay, circular dichroism
(CD)spectroscopy and gel electrophoresis (SDS-PAGE). The final fibrils were then
observev by Transmission Electron Microscopy (TEM).
4.3 Results
4.3.1 Docking of dopamine and its derivatives on AS.
A set of 6 structures representing about 75% of the total number of conformers were
selected from the NMR ensemble of 4,000 structures using a cluster methodology
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[130]. The adducts with dopamine (DOP) and its derivatives (Fig. 4.2) were
constructed by molecular docking (4,200 complexes). Most ligands bind mostly
to the C-terminal region that includes the residues 125YEMPS129 , (Fig. 4.3) and
Tab. 4.1).
This result is consistent with previous in vitro biochemical and biophysical studies
implicating these residues in dopamine-induced inhibition of AS fibrillation in vitro
[17, 16]. However, a significant number of hits are also found at the N-terminal
region of AS for LEUK, DQ and DCH (Fig. 4.3).
Region DCH DHI DOP DOP-H DQ IQ LEUK
100-140 40.7 % 39.2 % 62.2 % 71.3 % 74.7 % 42.7 % 38.3 %
110-140 32.3 % 27.3 % 43.4 % 51.9 % 55.9 % 30.0 % 27.7 %
120-140 21.1 % 18.3 % 32.3 % 37.0 % 38.2 % 19.1 % 17.6 %
125-129 7.6 % 5.4 % 10.4 % 9.5 % 5.9 % 5.1 % 4.6 %
Table 4.1: Relative contribution for the binding of the C-terminal regions, calculated
as percentages of the total number of ligand-protein contacts.
4.3.2 Molecular dynamics simulations of the docked
structures.
Because of the lack of solvent in the docking procedure, we next investigated
the structural stability of the docked structures in aqueous solution by molecular
dynamics simulations (MD). We considered the most populated complexes between
the first 6 representatives and each ligand as obtained by the docking procedure
(overall 42 starting complexes).
In more than 60% of the cases, the ligands form stable contacts with AS. In as
much as 73% of the ensemble of the stable adducts, the binding region includes
the 125Y EMPS129 residues in the C-terminal region (Fig. 4.4 and Tab. 4.2);
specifically, it involves hydrophobic interactions between the aromatic ring of the
ligand and hydrophobic side chains of AS, (Tab. 4.2 shows the interactions. In
addition, the O and N groups of the ligands form, in some cases, hydrogen bonds
(H-bonds) to polar groups in the same region of the AS protein. The similar
binding mode is paralleled by the remarkable structural and electrostatic similarity
between the ligands, which is pointed out by the calculated Tanimoto coefficients
for the electrostatic potential (Te) and shape (Ts) [170] between each of them
(values ranging between 0.7±0.3 and 0.8±0.1 for Te and Ts, respectively, see Tab.
4.3). We conclude that the ligands share a similar binding mode in which the most
frequent contacts involve the ligands’ aromatic ring moieties.
An analysis of the structural properties of the protein suggests that the C-terminal
binding region assumes a specific conformation accommodating the ligand (Fig.
52
Computational approach to the investigation of
alpha-synuclein/dopamine interactions
Figure 4.3: Number of hits between α-synuclein (AS) and the seven ligands as obtained
by 4,200 docking runs. A hit is defined as a contact within a cutoff of 5 A˚ between the
Cα of each amino acid and the center of mass of each ligand.
Figure 4.4: α-synuclein conformations of the 11 conformations out of 18, from the MD
simulations, where the ligands bind to the 125YEMPS129 region. Here we show the six
structures (among those) which form an additional (water-mediated) contact with E83.
The 125-129 residues and E83 are colored in blue, the ligand is colored in red
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Cluster Ligand Hydrogen Bonds Hydrophobic contacts
1 (39 %)
DCH
Met127(O)-DCH(N1), (D: 3.7±0.8 A˚) Tyr125, (D: 4.7±0.6 A˚)
Ser129(O)-DCH(O1), (D: 4.2±0.5 A˚) Tyr136, (D: 6.4±0.6 A˚)
DHI Glu137(OE2)-DHI(N1), (D: 2.8±0.2 A˚)
Lys80, (D: 4.0±0.3 A˚)
Asp135, (D: 7.0±0.3 A˚)
Tyr136, (D: 9.9±0.5 A˚)
DOP
Lys96, (D: 6.2±0.7 A˚)
Val118, (D: 6.0±09 A˚)
Pro120, (D: 5.4±0.5 A˚)
DOP-H
Glu123(OE2)-DOP-H(O1), (D: 3.5±1.2 A˚)
Glu123(OE2)-DOP-H(O2), (D: 3.0±0.6 A˚)
DQ
Asp135(N)-DQ(O2), (D: 3.3±0.4 A˚) Ile112, (D: 6.6±0.7 A˚)
Gly111(O)-DQ(N1), (D: 3.9±1.0 A˚) Asp135, (D: 5.4±1.0 A˚)
IQ Thr81, (D: 4.0±0.2 A˚)
LEUK
Glu131, (D: 7.4±2.2 A˚)
Gly132, (D: 5.8±2.1 A˚)
2 (15 %) DOP-H
Ser129(O)-DOP-H(N1), (D: 3.7±0.9 A˚)
Ser129, (D: 5.4±0.7 A˚)
Glu131(O)-DOP-H(N1), (D: 2.8±0.2 A˚)
3 (7 %)
DOP Met127, (D: 7.8±2.4 A˚)
DQ Thr81(N)-DQ(O2), (D: 4.6±0.5 A˚) Lys34, (D: 6.9±0.7 A˚)
IQ Lys34, (D: 5.9±0.8 A˚)
4 (6 %)
DCH
Ala90(N)-DCH(O1), (D: 3.3±0.7 A˚) Phe94, (D: 4.5±0.3 A˚)
Lys97(NZ)-DCH(O2), (D: 3.0±0.5 A˚) Val118, (D: 5.7±0.6 A˚)
Tyr136 (D: 6.3±0.5 A˚)
DHI
Ala90, (D: 4.8±0.3 A˚)
Phe94, (D: 6.5±0.5 A˚)
Lys97, (D: 4.9±0.3 A˚)
DOP Gly68(N)-DOP(O1), (D: 3.4±0.4 A˚)
Gly67, (D: 4.8±0.6 A˚)
His50, (D: 5.0±0.5 A˚)
Val66, (D: 6.2±0.5 A˚)
DOP-H Thr92(O)-DOP-H(N1), (D: 3.5±0.8 A˚) Tyr125, (D: 5.5±0.7 A˚)
DQ Gln134(NE2)-DQ(O2), (D: 3.5±0.5 A˚) Tyr39, (D: 4.7±0.3 A˚)
Val49, (D: 6.3±0.5 A˚)
IQ Glu123(OE2)-IQ(N1), (D: 3.2±0.8 A˚) Phe94, (D: 5.4±0.6 A˚)
Met116, (D: 5.5±0.7 A˚)
5 (4 %)
DCH
Glu105(OE2)-DCH(N1), (D: 4.0±0.7 A˚) Asp115, (D: 4.8±0.4 A˚)
Met116(O)-DCH(N1), (D: 3.5±0.4 A˚) Pro117, (D: 6.6±0.5 A˚)
DOP-H Glu105(OE2)-DOP-H(O1), (D: 2.5±0.1 A˚) Val118, (D: 6.0±0.6 A˚)
IQ Tyr125, (D: 6.2±1.9 A˚)
6 (4 %)
DCH
Ser129, (D: 6.3±1.2 A˚)
Tyr133, (D: 5.7±1.4 A˚)
DHI
Gly41, (D: 6.4±0.8 A˚)
Pro128, (D: 4.8±0.6 A˚)
DOP Ala89(O)-DOP(O1), (D: 3.5±0.9 A˚) Leu113, (D: 6.0±0.7 A˚)
Asp135, (D: 6.3±0.4 A˚)
DOP-H Asp98(OD1)-DOP-H(N1), (D: 2.9±0.4 A˚) Asn65, (D: 5.4±0.6 A˚)
Glu61, (D: 5.5±0.2 A˚)
DQ Ala89(O)-DQ(N1), (D: 3.3±0.5 A˚)
Ala90, (D: 5.8±0.5 A˚)
Ser129, (D: 6.3±1.4 A˚)
Tyr133, (D: 6.1±1.3 A˚)
IQ
Ala56, (D: 5.5±1.0 A˚)
Glu57, (D: 5.5±0.9 A˚
Table 4.2: H-bonds and hydrophobic contacts in Dopamine-AS ‘stable’ adducts. Sev-
eral of then shown interactions with the C-terminal region, including the 125Y EMPS129
region. The distance (D) in the hydrogen bond column was measured between the heavy
atoms. The hydrophobic contacts were measured as the distance (D) between the center
of mass of the ligand and the specific amino acid.
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Ts, Te DCH DHI DOP DQ IQ LEUK
DCH 1, 1 0.99, 0.38 0.85, 0.38 0.88, 0.82 0.99, 0.96 0.99, 0.46
DHI 1, 1 0.85, 0.54 0.86, 0.37 0.99, 0.38 0.99, 0.91
DOP 1, 1 0.99, 0.15 0.85, 0.02 0.86, 0.51
DQ 1, 1 0.86, 0.72 0.86, 0.43
IQ 1, 1 0.99, 0.51
LEUK 1, 1
Table 4.3: Similarity between the ligands in Fig. 4.2 The Tanimoto coefficients [170]
for the shape (Ts) and the electrostatic potential (Te) between each ligand and all the
others are shown. DOP-H is not shown due to its +1 charge.
Figure 4.5: Close up on the 125YEMPS129 Cα carbons (YEMPS region) after the
MD simulation. If the ligands bind to this region (Stable Aducts), the angle between Cα
125-126-129 shows a relatively small spread (79◦±11◦). The remaining 7 conformations is
also shown (Non-Stable Aducts) (105◦±20◦).
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Figure 4.6: Average values of angles formed by Cα (n – n+1 – n+4) on stable (left)
and non stable (right) adducts.
Figure 4.7: standard deviation of the angles formed by Cα (n – n+1 – n+4) on stable
(left) and non stable (right) adducts (the average is 30◦ for the stable adducts and 28 for
the non stable adducts).
4.5). To quantify this property, we calculated the standard deviation (SD) of
the n, n+1, n+4 angles among the Cα’s of the protein for the 26 stable and 16
unstable complexes. In the 26 stable complexes the smallest values are those of
the C-terminal binding region (SD of the angle 125-126-129 is 13◦; to be compared
to the value of 28◦ (averaged over all the angles’ SD) (Fig. 4.6 and 4.7). In
addition, these deviations are smaller than any of the correspondent angles in the
16 unstable complexes (average 29◦) (Fig. 4.6 and 4.7).
Taken together, our calculations suggest that almost all the ligands bind mostly
to the C-terminal part of the protein that includes the 125YEMPS129 region, fully
consistent with previous in vitro experiments [17, 16] and in all cases, AS always
assumes a similar, kinked conformation in its binding region (Fig. 4.6).
The discussion of these ‘stable’ adducts so far has been focusing on the C-terminal
region. As for the rest of the protein, we notice that the ligands spend a significant
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Figure 4.8: Electrostatic analysis. Left: Number of times that NAC amino acids are
found within a 12 A˚ from the ligands of Fig. 4.2.The residues selected for the electrostatic
analysis are marked in black. Right. Averaged energies values, for the selected residues
(Res), expressed in units of the total average (Av) electrostatic interaction energy of -2.7
Kcal/mol and total standard deviation (Std) of 2.2 Kcal/mol.
amount of the simulated time in proximity of the NAC residues (Fig. 4.8), although
they never form a direct contact with them. According to a simple and very
approximate electrostatic calculation, E83 is the NAC residue forming the largest
long-range electrostatic stabilization of the ligands (at least 30% larger than any
other residue in the region and with the lowest standard deviation, Fig. 4.8).
Test calculations suggest that nullifying E83 charge results in a large decrease of
such interactions (∼ 60%). Within the limitations of our analysis, we suggest
that additional stabilization of dopamine in its adducts with AS may arise from
electrostatic interactions with E83.
In all the remaining simulations, the ligands do not bind in a stable manner with
the protein. For example, in one case with DOP, the ligand moves from its starting
binding region (residues 92, 93 and 103) towards residues 99, 105 and 106 after 3
ns, and does not form stable interactions with the protein during the time scale of
the MD simulation.
4.3.3 Testing the domain of applicability of our pre-
dictions
We have repeated the entire computational procedure using a different clustering
algorithm [131, 134] on a different number of initial conformers (1000 conformers
randomly chosen among the 3,062 initial ones). The results, summarized in the
Appendix D, are very similar to those of the other analysis, suggesting that our
findings are robust and do not depend significantly on the chosen clustering anal-
ysis and/or the number of conformations chosen (Figs. D.1, D.2 and Tabs. D.2,
D.3, D.4).
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4.3.4 Experimental validation
Our calculations suggest that all the ligands bind mostly to the C-terminal part
of the protein that includes the 125YEMPS129 region, consistently with the exper-
imental observation that dopamine binds in vitro to this region [17, 16]. The
ligands form nonspecific hydrophobic interactions with all of the five residues
in the 125YEMPS129 region (Tab. 4.2) and form H-bond to E126 and S129 in
some cases. In all cases, AS always assumes a similar, kinked conformation in its
binding region (Fig. 4.5). In addition, the ligands are significantly stabilized by
electrostatic interactions with E83. To test the validity of these conclusions, the
aggregation properties of four alanine mutants of AS in vitro, which involve the
125YEMPS129 residues in the C-terminal region were investigated by the group
of Prof. Gustincich. The investigated mutants were E83A, E126A, S129A and
E83A/E126A/S19A in the presence and absence of dopamine. Because our cal-
culations suggest that ligand-AS interactions at the C-terminus are dominated by
nonspecific hydrophobic interactions, we predict that the E126A and S129A mu-
tations would not significantly alter ligand-AS interaction. In addition, in the case
of S129A, the Ser to Ala mutation might not affect H-bonding with the ligand
as it involves the backbone. In contrast, the E83A mutation is expected to affect
dopamine affinity for AS (and therefore it might affect the fibrillation process).
The aggregation properties of the five proteins were determined in the absence
or presence of equimolar dopamine. All the mutants show increased aggregation
relative to the WT (Fig. 4.9.A). Interestingly, the two AS variants containing the
E83A mutation retain the ability to form fibrils in the presence of an equimolar
quantity of dopamine (Fig. 4.9.A), whereas fibril formation by the WT, E126A
and S129A variants is abolished in the presence of dopamine. This result clearly
suggests that the nature of dopamine-AS interactions in the C-terminal region
is distinct from that of the interactions in the NAC region, consistent with our
predictions.
A consistent picture is obtained by monitoring the loss of soluble protein during
the fibrillization reaction by SDS-PAGE. We see a decrease of soluble content that
is proportional to the degree of aggregation by each protein (Fig. 4.9.B). In the
presence of dopamine, the majority of WT, S129A, and E126A protein remain in
solution, whereas very little soluble protein remains in the case of the two E83A-
containing mutants (Fig. 4.9, red rectangles).
CD spectra show in the absence of dopamine and after incubation for 72 hrs, the
majority of WT, E126A, and S129A precipitates out of solution and the CD spectra
of the remaining material exhibits a predominantly random coil structure, except
for S129A which exhibits a spectra consistent with species (soluble aggregates)
rich in β-sheet structure (Fig. 4.9.C). Co-incubation with dopamine prevents the
transition from random coil to β-sheet in the case of WT, S129A, E126A, but not
in the case of E83A or E83A/E126A/S129A, further confirming that dopamine is
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Figure 4.9: In vitro experiments of WT and mutant (E83A, E126A, S129A and Triple)
AS in absence or presence dopamine.(A) Kinetics of fibrillization as monitored by the
enhancement of Thioflavin-T (ThT) fluorescence intensity over time. (B) Amount of
soluble protein remaining after 72 hrs, monitored by means of SDS-PAGE. (C) CD spectra
of WT and mutant AS in absence (blue line) or presence (red line) of DOP. (D) TEM
analysis.
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able to prevent fibrillization of the WT, E126A and S129A mutants but not the
E83A E83A/E126A/S129A mutants (Fig. 4.9.C).
The EM studies of AS in the absence of dopamine, after 48-72 hrs, the mutant
proteins showed abundant fibrils resembling those formed by WT AS (Fig. 4.9.D
left panels). In the presence of dopamine, WT AS, E126A and S129A formed
predominantly soluble aggregates and no mature fibrils could be detected in these
samples, consistent with previously reported data on the WT protein. On the con-
trary, addition of dopamine did not inhibit fibril formation or change the structure
of the fibrils formed by both E83A containing mutants (Fig. 4.9.D right panels).
4.4 Concluding Remarks
In this chapter, the interaction between AS and dopamine was investigated by
docking the latter and six of its derivatives onto selected representatives of a large
ensemble of AS structures and by performing further molecular dynamics sim-
ulations on the most representative structures. Our calculations suggested that
the C-terminal region including residues 125Y EMPS129 bind non-covalently with
dopamine. This may be important for the inhibition of fibrillation and it is there-
fore consistent with in vitro experiments [17, 16]. The dopamine-binding region
assumes a similar structure in all the cases that we investigated (Fig. 4.5). Thus,
although the docking does not cover the entire set of conformers representing the
initial configurations (it covers 75% of it), we expect that the structural deter-
minants of the binding region may be similar for most of the non-covalent com-
plexes. The fingerprint of dopamine-AS non-covalent complexes is the formation
of nonspecific hydrophobic contacts between the ligands’ aromatic ring and the
125Y EMPS129 region in the C-terminal (Tab. 4.2) helped by the particular con-
formation adopted by the binding region, accommodating the ligand (Fig. 4.5).
These interactions are also complemented by nonspecific H-bonding interactions.
In addition, dopamine and its derivatives are stabilized by significant electrostatic
interactions with E83 in the NAC region (Fig. 4.8).
Based on our calculations, we hypothesized that the 125Y EMPS129-DOP, non-
specific hydrophobic interactions may affect the AS-DOP binding and hence DOP
ability to modulate AS fibrillation [65]. In addition, replacement of E83 with ala-
nine in the NAC region, affects the favorable long range electrostatic interactions
with dopamine in its stable adducts. To test this hypothesis, several experiments,
related to dopamine binding [79, 17, 99, 16]) were performed. Together, our find-
ings suggest that hydrophobic interactions with the 125Y EMPS129 C-terminal
region play a critical role in mediating the inhibition of AS fibril formation by
dopamine. Instead, the E83A mutation in the NAC strongly impairs the ability of
dopamine to inhibit AS aggregation. This may be consistent with our conclusion
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that dopamine affinity may be stabilized by E83 long range electrostatic interac-
tions and/or with the fact that such mutation may alter the properties of the NAC
region.
These findings demonstrate how the use of structural models of even highly het-
erogeneous states of proteins determined by NMR spectroscopy in combination
with molecular dynamics simulations can provide novel insight into the structural
determinants of ligand binding.
Chapter 5
Design of dopamine mimics
5.1 Introduction
My previous study has suggested that dopamine and its derivatives form nonspe-
cific hydrophobic contacts with the AS C-terminal as well as long-range electro-
static interactions with NAC region. Among all the residues in the NAC region,
E83 was suggested to be the most important one for the interaction and conse-
quently inhibition of the fibrillation. Here we attempt at identifying other chate-
chols molecules structurally and electrostatically similar to DOP and some of its
derivatives [100], as these molecules might be able to inhibit AS fibrillation with
higher affinity to the protein.
5.2 Methodology and Results
Dopamine mimic screening. Dopamine (DOP) and its derivatives in Fig. 4.2
were used as a template molecule for a virtual screening, based on well-established
shape and electrostatic similarity based scoring functions developed by ”OpenEye
scientific software, Inc” [170, 139, 137].
The 1,159,274 molecules of the ”ligand.info” meta-database [172] (most of them
commercially available), were screened against each of the 7 template molecules
(Fig. 4.2) (See Methodology 3.1.3 for details).
For each template, the top 10 molecules featuring the largest shape scoring-based
scoring function and the largest electrostatic potential-based scoring functions were
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Label Name (IUPAC) CID
1K 1H-indol-5-ol 16054
2K 1H-indole-5,6-dione 440728
3K 4-propylbenzene-1,2-diol 97638
4K 2-amino-4-propan-2-ylphenol 662440
5K 6-methylbenzene-1,2,4-triol 13026
6K 4-(2-methylaminoethyl)phenol 9727
7K 5-(2-aminoethyl)benzene-1,2,4-triol 4624
8K 2-amino-4-tert-butylphenol 70982
9K 2-methyl-3,4-dihydro-1H-isoquinoline-6,7-diol 37764
10K 1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol 54456
11K 1H-indol-6-amine 256096
12K 4-(2-methylaminoethyl)benzene-1,2-diol 4382
13K 4-(2-aminoethyl)phenol 5610
14K 2,3,4-trimethyl-1H-indole-5,6-diol 266595
15K 5,6-dihydroxy-1H-indole-2-carboxylic acid 119405
16K 4-(2-aminoethyl)-2-methoxyphenol 1669
17K 2,4-diaminophenol 7266
18K 5-(2-aminoethyl)benzene-1,2,3-triol 114772
19K 2-(3,4-dihydroxyphenyl)ethyl-trimethylazanium 165581
20K 3-hydroxy-1-methyl-2,3-dihydroindole-5,6-dione 5898
Table 5.1: Names and CIDs of the selected molecules from the ligand.info meta-
database. The CID is the PubChem compound ID.
The resulting 70 molecules were docked onto AS representatives (following exactly
the same procedure as in the chapter 4∗), resulting in 420 ligand/AS adducts. The
molecules were given again a scoring, this time based on the number of contacts
with the C-terminal region (i.e. the YEMPS region, as in Section 4.3.2). The
procedure was identical to that of Chapter 4.
The 20 molecules with the largest score were selected (Tab. 5.1 and Fig. E.1 in
Appendix E), all these molecules are commercially available.
These 20 molecules turn out to dock onto AS in a similar way as dopamine and
its derivatives, as they bind at the C-term (and, at times, also at the N-term) and
they form long range electrostatic interactions with residues in the NAC region
(data not shown). Fig. 5.1 shows models labeled 1K, 4K, 8K and 10K as an
example; all the other molecules bind in a similar way.
Dopamine mimic design. These 20 molecule were used to generate about 100
other molecules by changing or adding substituents E.1). For such procedure, the
drug-like filter [143] was used (see Methodology 3.1.3 for details).
∗Indeed, the representatives conformations of AS were also the same as in the previous
chapter (the 6 representatives from the cluster of 3,062 NMR conformations of AS in
solution).
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Figure 5.1: Average docking results for some of the known small compounds onto
representatives conformations of AS.
By using exactly the same protocol as that used before, the new molecules were
first screened against the 7 template molecules (Fig. 4.2). The two top molecules
for each template were retained. Here only 2 molecules were selected because these
new molecules have to be synthesized (unlike the others, which are commercially
available) and so we prefer to focus only on the best ones according to our proce-
dure. They were named here as the original template plus a digit (for instance, if
a molecule has DOP as a template, its name will be DOP1, then the next DOP2
and so on).
The resulting 14 molecules underwent molecular docking as in the previous section
(Fig. 5.2)
Among the 14 molecules, only the molecules named DCH1, DHI2, DOP1 and
DOP2 were able to interact at the same time and in all the representatives con-
formations of AS with both the C-terminal and the N-terminal or NAC region
(Fig. 5.3, Fig. 5.4 and Tab. 5.3), possibly because of their structural similar-
ity: they are made by two condensed aromatic rings (which interact unspecifically
with residues in the C-terminal region) and a hydrophilic tail (forming unspecific
hydrogen bonds with the C-terminal and/or N-terminal regions) (see Fig. 5.4).
In vitro experiments are now called upon to test or disprove the predicted inhibition
of fibrillation of the screened (20) and designed (4) molecules (Tab. 5.1, Figs. E.1
and E.2).
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Label Name (IUPAC)
DCH1 6-sulfanylidene-2,3-dihydro-1H-inden-5-one
DCH2 2-prop-1-en-2-yl-2,4-dihydro-1-benzofuran-5,6-dione
DHI1 5-bromo-1H-indol-6-amine
DHI2 5-fluoro-1H-indol-6-amine
DOP1 2-(2,3-dihydro-1-benzofuran-6-yl)ethanol
DOP2 N-ethyl-2,3-dihydro-1-benzofuran-6-amine
DOPH1 2-(3-fluoro-4-methylphenyl)ethylazanium
DOPH2 2-(3-chloro-4-methylphenyl)ethylazanium
DQ1 3-(2-aminoethyl)-6-sulfanylidenecyclohexa-2,4-dien-1-one
DQ2 4-(2-aminoethyl)cyclohexa-3,5-diene-1,2-dione
IQ1 5,6-difluoro-1H-indole
IQ2 5-chloro-6-methyl-2,3-dihydro-1H-indene
LEUK1 5-fluoro-6-methyl-2,3-dihydro-1H-indene
LEUK1 6-imino-2-prop-1-en-2-yl-3,7-dihydro-2H-inden-5-one
Table 5.2: IUPAC names of the designed new molecules.
AS Conf. Num. N-terminal NAC C-terminal
1 10-14 85-90 136
2 50-58 125, 134-137
3 125-133
4 88-95 96-116
5 4-6, 14-15
6 4-8 125-131
Table 5.3: Regions on the AS sequence where the 4 selected new molecules bind each
of the 6 analyzed representative conformations of AS.
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Figure 5.2: Average docking results for the first 14 compounds (two for each template)
on AS’s representatives.
Figure 5.3: Docking results for two specific compounds (IQ2 and DOP2 in Tab. 5.2
and Fig. E.2) for each particular representative AS conformation
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Figure 5.4: Superposition of DCH1, DHI2 DOP1 and DOP2 compounds (See Tab.
5.2 and Fig. E.2) after they have been docked onto two representatives of AS
Chapter 6
Insights into DJ-1 mutants by
MD
6.1 Introduction
Mutations in the DJ-1 protein are present in patients suffering from familial forms
of Parkinson’s disease [110, 27].
Here we use computational methods and biological assays to investigate the rela-
tionship between DJ-1 missense mutations and the protein oligomeric state. Molec-
ular dynamics (MD) calculations suggest that: (i) the structure of DJ-1 wild-type
(WT) in aqueous solution, in both oxidized and reduced forms, is similar to the
crystal structure of the reduced form [116, 102]; (ii) the PD-causing M26I variant
is structurally similar to the WT, consistent with the experimental evidence show-
ing this mutant to be a dimer as the WT [121, 115, 125] and in this work [33];
(iii) R98Q is structurally similar to the WT, consistent with the fact that this is
a physiological variant [173]; (iv) the L166P monomer rapidly evolves towards a
conformation significantly different than WT protein, suggesting a change in its
ability to oligomerize [116, 102].
Molecular dynamics (MD) simulations based on the DJ-1 WT x-ray structure are
carried out on homodimeric and monomeric forms of the WT. An extensive MD
study of DJ-1 in the oxidized state has been performed (Fig. 6.1) as well as an
analysis of the PD-causing mutations L166P and M26I.
Comparison is also made with MD simulations of a physiological variant (R98Q),
which is expected to alter neither the DJ-1 fold nor the oligomeric state [173].
Our calculations show that: (i) the reduced and oxidized WT dimers in aqueous
solution are very similar to the reduced dimer in the solid state; (ii) M26I in the
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Figure 6.1: X-ray structure of the DJ-1 protein in the reduced state (PDB code 1UCF)
[116]. The cysteine and methionine Cα atoms are shown as spheres. Labeling of selected
secondary structure elements at the subunit-subunit interface (α1, α8, α9 helices and β3
β-sheet) as in Ref. [116].
monomeric and dimeric states maintains completely the fold of the WT; (iii) R98Q
is also similar to the WT, fully consistent with the fact that this is a physiological
variant; (iv) L166P causes local distortions at α8 helix (Fig. 6.1 and 6.2) and
at the surface-forming contacts in the dimeric structure. We conclude that this
mutation might affect the stability of the dimer by altering the structure of its
local environment. Unfortunately, at present, the stability differences (i.e. the free
energy differences) between the WT and these mutants cannot be firmly estab-
lished by calculations alone. However, our conclusions based on the calculations
are corroborated by previous biological assays in vitro on the WT and its mutants
[125, 122, 111]. Furthermore, experiments carried out in this work confirm that
L166P tends to form multimeric aggregates more than WT does [121, 119, 111].
Finally, our combined computational and experimental methodology is used to
engineer a new mutation that, in contrast to L166P, does destabilize the subunit-
subunit interactions without affecting the secondary structure elements of the
protein. This mutation (R28A) is located at the subunit-subunit interface and
it causes the disruption of salt bridges and hydrophobic contacts at the interface.
6.2 Methodologies Used
6.2.1 Molecular Dynamics simulations
Dimeric and monomeric structural models of reduced and oxidized DJ-1 WT pro-
tein together with M26I, L166P , R98Q and R28A were constructed based on the
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Figure 6.2: Structure of the DJ-1 monomer (PDB code 1P5F ) [102], and location
of PD-causing mutations (M26I, L166P) together with R98, which is mutated to Q in a
physiological variant.
DJ-1 WT homodimer X-ray structure at a resolution of 1.95 A˚ [116].
In the oxidized form Cys and/or Met residues were assumed to be oxidized. We
noticed that the shortest Cys-Cys distance (d[S-Cys53(A) and S-Cys53(B)]=3.2
A˚) is too large for the formation of disulfide bridges. Thus, the three cysteines
present in the protein (C46, C53 and C106) are replaced by cysteine sulphonic
acid [117] (Fig. 6.1). The four methionines (M17, M26, M133 and M134, Fig.
6.1) are oxidized to methionine sulfoxide [29, 109] or methionine sulfone [109].
We further noticed that neither the cysteine residues nor the methiones interact
directly with residues involved in the PD mutations. Several models were consid-
ered, based on the suggestion of Refs. [29, 109, 117]: (i) the protein with all the
Cys residues oxidized and all the Met reduced (WT-OX 1); (ii) the protein with
all the Cys oxidized and all the Met oxidized to methionine sulfoxide (WT-OX 2);
(iii) the protein with all the Cys oxidized, two methionines (M26 and M134) oxi-
dized to methionine sulfoxide and the remaining two (M17 and M133) oxidized to
methionine sulfone (WT-OX 3).
The point mutations were obtained by simple residue substitution, taking care
that the substituted residue would not clash with the rest of the protein and that
the χ1 and χ2 torsion angles would fall in the most energetically favorable regions
[174, 175]. The mutations in the dimeric structures were carried out for both
subunits in order to obtain homodimers.
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The proteins were immersed in a water box of edges ca. 69.0 A˚ x 66.0 A˚ x 69.0 A˚
and 81.0 A˚ x 76.0 A˚ x 94.0 A˚ for the monomeric and dimeric forms respectively.
The solvent molecules were not included if the distance between any solvent atom
and any protein atom was lower than the sum of their respective van der Waals’
radii. Two or three sodium counterions were added to neutralize the systems.
They were located in the regions of minimum electrostatic potential energy as
calculated with the xleap program of the AMBER8 package [176, 177], namely
close to Glu 59 and Asp 189. Periodic boundary conditions (PBC) were applied.
The AMBER99 [178, 166] and TIP3P [167] force fields were used for biomolecules
with counterions and water respectively. The particle mesh Ewald method (PME)
was applied to evaluate the long-range electrostatic interactions [179, 180, 181]. A
cutoff of 8 A˚ was used for both the real part of the electrostatic interaction and the
van der Waals non-bonded interaction evaluation. A timestep of 2 fs was applied to
propagate nuclear degrees of freedom. The SHAKE algorithm [169] was used to fix
all bond lengths. The investigated models first underwent 10,000 steps of energy
minimization. Then, the systems were equilibrated at constant temperature and
pressure for at least 0.5 ns. Subsequently, our models underwent MD simulations
with constant temperature and volume for at least 10.0 ns. Constant temperature
conditions were obtained by using a Langevin thermostat [160] at a target temper-
ature of 300K with a coupling coefficient of 5 ps−1. Constant pressure conditions
were achieved with a Nose´-Hoover Langevin barostat [182, 159]. For the barostat,
an oscillation period of 200 fs was used and the damping timescale used was 100
fs.
All calculations were performed using the NAMD program [154]. The obtained
results have been further analyzed using the Gromacs [183, 184] and VMD [185]
packages.
6.2.2 Computational Alanine Scanning
The mutation causing the largest destabilization of the dimer (R28A) was identified
using the alanine scanning procedure (Methodology 3.1.2). This mutation was
selected for subsequent MD simulations according to the protocol described in the
previous subsection.
6.2.3 Additional experiments
The molecular modeling results were proved by experiments. The experiments were
performed in Prof. Gustincich’s laboratory. The WT DJ-1 protein and its mutants
were analyzed by cross-linking assays and Co-immunoprecipitation experiments.
A densitometric analysis was also performed to quantify ratios between monomeric
and dimeric DJ-1.
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6.3 Results
6.3.1 MD of the DJ-1 WT protein
Molecular dynamics simulations over an 11 ns timescale are used here to investigate
the structure of the reduced and oxidized forms of the DJ-1 protein in aqueous
solution. The simulations are performed for both the dimeric and monomeric forms
of the reduced state and for the dimeric form of the oxidized state. In the latter
state, either the Cys or the Met residues are assumed to be oxidized [109]. The
obtained results are used as a reference for comparison with the corresponding
mutants.
RMSD [A˚]
Dimer Monomer
Average SD Final value Average SD Final value
WT 1.8 0.1 1.9 1.8 0.2 2.1
WT-OX 1 1.6 0.1 1.7 — — —
WT-OX 2 1.4 0.1 1.5 — — —
WT-OX 3 1.6 0.1 1.6 — — —-
L166P — — — 2.0 0.2 1.9
M26I 1.7 0.1 1.7 1.5 0.1 1.8
R98Q 1.4 0.1 1.5 1.9 0.2 1.7
R28A – — 2.5 1.8 0.1 1.9
Table 6.1: Selected MD-averaged RMSD values of the DJ-1 WT and its mutants
investigated in this study. For R28A, the RMSD increases during the dynamics and
therefore only the final value is given.
In the reduced state, the Root Mean Square Deviation (RMSD) values fluctuate
for the last 5 ns of the MD run around a value of 1.8 ± 0.1 A˚ and 1.8 ± 0.2 A˚ for
the dimer and the monomer, respectively (Fig. 6.3 and Tab. 6.1. The standard
deviation (SD) value suggests that the monomer undergoes larger structural fluc-
tuations than the dimer, pointing to a key stabilizing role of the subunit-subunit
association. In particular, the association stabilizes the flexible N- and C-terminal
fragments. The distance values between Cα of the residues 1 and 189 fluctuate
between 23 A˚ and 32 A˚ for the dimer while for the monomeric form they are be-
tween 20 A˚ and 34 A˚ (Fig. 6.3.ii). The average distance is 27.5 A˚ (Fig. 6.3.ii)
for both forms. The secondary structure found in the X-ray experiments is con-
served in both cases. Most of the subunit-subunit hydrogen bonds, along with
the hydrophobic interactions and salt bridges are conserved during the entire MD
run (Tabs. 6.2 and 6.3). However, a salt bridge between Asp 24 and Arg 48, not
detected in the X-ray structure, is formed after a few hundred ps of dynamics. The
average distance between the centers of mass of the DJ-1 subunits in the model
structure is 28.1 ± 0.3 A˚ while it is 27.9 A˚ in the X-ray structure of the DJ-1
protein (Fig. 6.3.iii).
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Figure 6.3: Molecular dynamics of the DJ-1 protein in aqueous solution. i. Root mean
square deviation (RMSD) from the corresponding initial structure of backbone atoms of
the dimeric (black) and monomeric (red) forms plotted as a function of simulation time.
ii. Distance between the N-terminal and the C-terminal C-α of the dimer (black) and of
the monomer (red). iii. Distances between the centers of mass (COM) of subunits in the
reduced (black) and oxidized states (green (WT-OX 1), yellow (WT-OX 2) and magenta
(WT-OX 3)).
Several oxidized forms of the dimeric protein are considered, following previous
work [29, 109, 117]: (i) a form in which the cysteines are oxidized to cysteine
sulphonic acid (WT-OX 1), (ii) one in which the cysteines are oxidized to cysteine
sulphonic acid and the methionines oxidized to methionine sulfoxide (WT-OX 2)
and (iii) one in which the cysteines are oxidized to cysteine sulphonic acid, two
methionines (M26 and M134) oxidized to methionine sulfoxide and the remaining
two (M17 and M133) oxidized to methionine sulfone (WT-OX 3) [109].
Our MD simulations show that such forms are fairly similar to the reduced form:
(i) the RMSD ranges between 1.4 A˚ and 1.7 A˚ (Tab. 6.1), to be compared with 1.8
± 0.1 A˚ of the WT in the reduced state; (ii) the contacts at the subunit-subunit
interface are rather similar to those of the DJ-1 reduced form in aqueous solution
(Tabs. 6.3 and 6.3); (iii) the MD-averaged distance between the centers of mass
range between 28.0 A˚ and 29.1 A˚ (Fig. 6.3 similar to the value of the reduced state
(28.1 ± 0.3 A˚); (iv) the solvent accessible surface area (SASA) [186, 187] for each
subunit is similar to that of the reduced form (MD-averaged values ranging from
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Hydrophobic Contacts
Distance [A˚]
X-Ray WT WT-OX 1 WT-OX 2 WT-OX 3
Residues Dist. Av. SD Av. SD Av. SD Av. SD
(MET17)’ – (VAL20, ILE21)” 6.0 6.2 0.3 6.0 0.5 5.1 0.2 6.1 0.3
(VAL20, ILE21)’ – (MET17)” 6.0 6.2 0.4 6.0 0.3 5.6 0.3 6.2 0.5
(VAL51, ILE52)’ – (VAL51, ILE52)” 5.7 5.9 0.3 6.1 0.2 5.9 0.2 6.0 0.2
(HIS126)’ – (PRO184, LEU185, VAL186)” 8.5 8.5 0.4 8.5 0.5 9.2 0.3 9.1 0.6
(PHE162)’ – (PHE162)” 11.1 11.9 0.4 12.0 0.4 11.2 1.2 10.5 0.6
(PRO184, LEU185, VAL186)’ – (HIS126)” 8.5 8.2 0.4 8.3 0.4 10.2 0.8 9.0 0.8
Table 6.3: Hydrophobic contacts in the WT DJ-1 in the reduced and oxidized states
as obtained by MD simulations and in the X-ray structure. The distances between the
centers of mass of groups of residues involved in the interactions are presented. The chain
A and B are identified by the ’ and ” respectively.
9,854 A˚2 to 10,150 A˚2, to be compared with 10,160 A˚2 for the reduced state).
We conclude that the oxidized and reduced forms of the DJ-1 protein in aqueous
solution are very similar to the reduced form in the solid state.
6.3.2 MD of PD-causing DJ-1 mutations
Here we focus on the most studied PD-linked mutations: M26I and L166P [121,
115, 125, 50, 122, 111, 28]. Because the estimation of the free energy difference
between the WT and these mutants in the dimeric and oligomeric states by MD is
not possible at the present stage, we adopt here a simple approach which can pro-
vide some indirect hints: first, we compare MD results on the mutant monomers
to the monomeric WT in the reduced state in aqueous solution. Within the lim-
itation of the timescale investigated (∼10 ns), we make the plausible assumption
that the way the monomers assemble in the dimeric structure may be similar to
the WT if the structural determinants of mutant monomers are similar to those
of the WT in the monomeric state.
In that case, we use the WT dimeric X-ray structure to construct the structure of
the dimer mutants and investigate the stability of the dimer by MD simulations.
The RMSD of the M26I monomer turns out to be fairly similar to that of the WT
in the monomeric state: it fluctuates around 1.9 A˚ over the last 5 ns, and the value
at the end of the dynamics ranges between 1.6 A˚ - 2.5 A˚ (Tab. 6.1 and Fig. 6.4.A).
The secondary structure elements are fully maintained during the dynamics and
the overall fold is similar to the WT (Fig. 6.3).
Next, we compare structural determinants of the protein surface involved in the
dimerization with those of the WT: (i) the distance (D) between the centers of
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Figure 6.4: Selected properties of mutants in the monomeric state plotted as a function
of time. (A) RMSD with respect to the initial structure. (B) Distance between the
secondary structure elements at the subunit-subunit interface (defined in the text). Color
coding is as follows: WT: black, M26I: green, L166P: red, R98Q: blue, and R28A violet.
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Monomers Dimer
Distance from Cα WT M26I WT M26I
of residue 26 Dist. SD Dist. SD Dist. SD Dist. SD
CE2, ILE31 4.5 0.2 4.8 0.3 4.7 0.3 5.2 0.2
CE2, ASP68 6.7 0.4 6.3 0.3 6.4 0.3 6.6 0.4
VAL, VAL169 6.1 0.4 5.9 0.3 6.1 0.4 5.9 0.3
Distance from Cα WT L166P
of residue 166 Dist. SD Dist. SD
CE2, PHE162 7.5 2.1 10.4 0.9
CG2, VAL169 5.8 0.3 4.5 0.6
CG2, VAL181 5.9 0.6 4.7 0.7
CD2, LEU185 8.0 1.2 9.0 1.7
Table 6.4: Local interactions of residues in 26 and 166 positions in WT, M26I and
L166P. The MD-averaged distances between the centers of mass of these residues and
those of other residues in contact with them are given in A˚.
mass of the secondary structure elements located at the interface (α1 helix and β3
β-sheet in Fig. 6.1) is similar to that of the WT (D = 15.0 ± 0.6 A˚ vs 14.8 ± 0.5
A˚ respectively, see Fig. 6.4.B); (ii) the Root Mean Square Fluctuation (RMSF)
per residue for M26I is very similar to that of the WT (Fig. 6.6). The similarity
between the WT and M26I can be rationalized observing that the mutation does
not affect the intramolecular interactions (Tab. 6.4). The interactions formed by
M26 in the WT are the same as those formed by I26 in the mutant, since the
methionine and isoleucine have similar volume and shape [187, 188] (Tab. 6.5).
We conclude that the interface of the M26I mutant has a similar conformation to
the WT and subsequently, has a similar tendency to form dimers.
We then proceed to investigate the dimeric structure of M26I. The RMSD value of
M26I in the dimeric state is similar to that of the WT (Tab. 6.1 and Fig. 6.5.A)
oscillating around 1.7 A˚. The secondary structural elements are fully conserved
during the molecular dynamics simulations. The non-bonded interactions at the
subunit-subunit interface are also conserved during the MD run, analogously to the
WT (Tab. 6.5). In addition, the centers of mass distance analysis showed that the
distance between subunits in the mutant is similar to the distance between subunits
obtained for the dimeric form of the WT (Fig. 6.5.B). The local interactions around
residue 26 are also fully conserved (Tab. 6.4). Finally, the SASA for each subunit
is similar to the WT (average value: 10,203 A˚2 and 10,160 A˚2 respectively).
Thus, both the monomeric and dimeric forms of M26I are similar to the WT.
L166P monomer shows a different behaviour than the M26I monomer. Its RMSD
exhibits larger fluctuations than in other mutants (Fig. 6.4.A and Tab. 6.1). In
addition, properties (i)-(ii) are different from that obtained for the WT: (i) the
distance (D) between α1 helix and β3 β-sheet is smaller (D =12.5 ± 0.4 A˚ and
14.8 ± 0.5 A˚, Fig. 6.4.B); (ii) the RMSF of Asp 49 (located on the subunit surface
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78 Insights into DJ-1 mutants by MD
Figure 6.5: MD simulations of DJ-1 WT and its mutants in the dimeric state. (A)
Root mean square deviation (RMSD) of the WT (black), M26I (green), R98Q (blue) from
the initial structure. (B) Distance between the centers of mass (COM) of each subunit.
Same color coding as (A).
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Figure 6.6: Fluctuations of mutant monomers. (A) RMSF of WT, M26I, R98Q,
and L166P. (B) Close up of the region (residues 40 to 55) exhibiting the most significant
residues fluctuations. Color coding as in Fig. 6.4
involved in the dimerization process) is larger (Fig. 6.6). The discrepancies may
be caused, as already suggested [102, 28], by the fact that the replacement of Leu
with Pro disrupts α8 helix and therefore the local interactions of residue 166 are
different (Tab. 6.4).
Thus, our results suggest the lowered dimerization efficiency of the L166P mutant
may be due to structural differences in the monomer. These results are valid within
the limits of the computational power of our analysis.
6.3.3 MD of R98Q physiological variant
Since it is a physiological variant of the DJ-1, R98Q is expected to alter none of DJ-
1’s biochemical functions [173]. From a structural point of view, the replacement of
R98, which is indeed exposed to the solvent, with a polar residue such as Q should
not dramatically affect the thermodynamic stability of the protein. To investigate
the effect of such a mutation, we follow the same computational protocol as for
the PD-causing mutations.
The mutant monomer shows a similar behaviour to the WT form. Its RMSD does
not show any large fluctuation compared to the WT (Fig. 6.4.A and Tab. 6.1).
In addition, properties (i)-(ii) are similar to those of the WT: (i) the distance
(D) between α1 helix and β3 β-sheet is comparable to that of the WT (14.9 ±
0.5 A˚ and 14.8 ± 0.5 A˚ respectively, Fig. 6.4.B); (ii) the RMSF shows a similar
behaviour to those of the WT and M26I mutation (Fig. 6.6). Furthermore, the
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RMSD value of the dimeric form is comparable to that of the WT dimer (Tab.
6.1 and Fig. 6.5.A) oscillating around 1.4 A˚ with small fluctuations after 5 ns.
The behaviour of this physiological variant is similar to that of the dimeric forms
of the DJ-1 WT and of the M26I mutant (Tab. 6.5). The analysis of centers of
mass distance shows that the DJ-1 variant behaves similarly to the DJ-1 WT (Fig.
6.5.B). Finally, the SASA for each subunit is similar to that of the WT (average
value: 10,040 A˚2 and 10,160 A˚2, respectively).
Within the limitations of our approach, we conclude that R98Q variation, like the
M26I, affects neither the dimeric nor the monomeric structures of the WT.
6.3.4 Engineered mutant
Our calculations suggest that L166P is the only mutation among those considered
that may alter dimer stability by modifying the fold of the single subunits. These
in turn might assemble differently than the WT to form HMW structures.
Here we attempt to identify a mutation that does affect stability by disrupting
none of the secondary structure elements. We perform Baker’s Computational
Alanine Scanning procedure [136, 135], which may quickly (albeit approximately)
estimate changes in the interaction free energy (∆∆G) between the two subunits
upon mutation of each interface residue with Ala. The largest ∆∆G value turns
out to be associated with the R28A mutation (Tab. 6.6). This value is indeed
twice as large than any other Ala substitutions presented in Tab. 6.6.
Residue ∆∆G (bind) kcal/mol
M17 1.3
V20 1.3
R27 1.6
R28 2.9
V50 1.4
I52 1.1
G159 1.5
Table 6.6: Computational Alanine Scanning - based [135, 136] free energies obtained
for the DJ-1 dimeric structure taken from X-ray experiments [116].
Following the MD protocol adopted for the other mutations, we have investigated
by MD simulation the structural properties of the R28A monomeric form and we
compared them to those of the WT monomer MD structure. The R28A monomer
turns out to be similar to the WT: the RMSD value oscillates around 1.8 A˚ after 5
ns (Tab. 6.1 and Fig. 6.7A). In addition, properties (i)-(ii) are similar to those of
the WT: (i) the distance (D) between the α1 helix and the β3 β-sheet is comparable
to that of the WT (14.9 ± 0.5 A˚ and 14.8 ± 0.5 A˚ for the R28A mutant and the
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Figure 6.7: Comparison between selected properties of WT and R28A, plotted as a
function of time. RMSD of backbone atoms of the WT (black) and R28A mutant (red)
for: (A) monomers and (B) dimers. (C) Distance between the centers of mass of subunits
of the WT and R28A dimers. (D) Solvent accessible surface area for monomers (lower
values) and dimers (larger values) of WT and R28A.
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Figure 6.8: Structures obtained after 11 ns of MD simulations of M26I and L166P
monomers (red line) superimposed on the corresponding structure of the WT monomer
(blue line).
WT DJ-1, see Fig. 6.4.B); (ii) the RMSF is similar to those of the WT and the
M26I proteins (Fig. 6.6). The proteins fully maintain the secondary structure
elements (Fig. 6.8). This is expected as the mutation is on the surface of the
monomer.
We proceed then to investigate the dimeric form of R28A by MD simulation (Fig.
6.7.B). The mutation deeply destabilizes the subunit-subunit interactions and the
mutant shows a completely different behaviour compared to that of the WT pro-
tein: (i) The distance between the subunit centers of mass along with the SASA
increases during the dynamics: at the end of the simulation it is much larger than
those of the WT (Fig. 6.7). This suggests that the structure is evolving towards
another minimum, in which the subunit-subunit interaction is less strong than in
the WT. Unfortunately, observing an eventual complete detachment of the two
subunits is well beyond the present domain of applications of MD simulations; (ii)
consistently, the RMSD value increases during the dynamics up to 3.0 A˚ (Fig.
6.7.B), which is significantly larger than the final value found for the WT (1.9 A˚,
Tab. 6.1 and Fig. 6.7.B). Thus, it is not correct to take the average values of the
RMSD (the structure is still evolving). We then calculate for this mutant the av-
erage value of the RMSD and the standard deviation (SD) of each subunit during
the MD run. The values are 2.0 ± 0.5 A˚ for both subunits in the mutant, to be
compared with 1.6 ± 0.1 A˚ and 1.7 ± 0.1 A˚ for each subunit of the WT dimer in
the reduced form. This suggests that the R28A DJ-1 mutant is more flexible than
the WT.
6.3.5 Experimental validation
To compare quantitatively the ability of PD-causing mutations to form dimers
in vitro, chemical cross-linking experiments were performed. Human HEK 293
cells were transfected with FLAG-tagged DJ-1 WT, M26I, L166P, and R28A (Fig.
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Figure 6.9: In vitro analysis of DJ-1 dimer formation. (A) HEK 293 cells were tran-
siently transfected with FLAG-tagged DJ-1 contructs. Equal amount of total protein (5
micrograms) was loaded on gel and immunoblotted with anti-FLAG antibody. (B) Den-
sitometric analysis of protein bands on two independent experiments. Relative expression
was normalized to DJ-1wt protein. (C) HEK 293 cells were transfected as in A. Protein
lysates were treated with chemical cross-linker DSS or with DMSO as indicated. Normal-
ized quantities of transfected proteins were loaded on gel. Monomer, dimer and HMW
forms of DJ-1 were visualized with anti-FLAG antibody. (D) Densitometric analysis of
monomer and dimer bands on two independent experiments. Dimer to monomer ratio was
calculated and normalized to DJ-1wt protein. The experiments were performed in Prof.
Gusticich’s laboratory.
6.9). The amount of L166P mutant was 20-40% of the DJ-1 WT, and the levels
of R28A were higher than those of WT (Fig. 6.9 A and B). To obtain a measure
of the dimerization efficiency, densitometry analysis were performed and the ratio
between dimer to monomer was calculated and compared with the various mutants
and the WT Fig. 6.9. It was confirmed that the L166P mutant has an impaired
capacity to form a homodimer, while displaying a tendency to exist as HMW
complexes. The efficacy in L166P dimer formation was calculated to be 20% of
the WT DJ-1 or even less. The M26I mutant behaved as shown by Moore et al.
[28], since dimer formation capability is equivalent to that of the WT DJ-1. Under
these conditions, we observed that in the R28A (computationally selected mutant)
the ability to form dimers is impaired and reduced to 50% of DJ-1 WT.
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6.4 Concluding Remarks
Several mutations of the DJ-1 gene have been associated with familiar cases of PD
[27, 115, 50]. Some of them clearly result in a loss of function since no DJ-1 protein
is synthesized due to large deletions and/or splicing errors. The molecular basis
of neurodegeneration induced by a group of DJ-1 missense mutations is less clear.
A working hypothesis in the field is that DJ-1 carries out its function as a dimer
and that missense mutations impair the quantity of the dimeric DJ-1 in the cell
[27, 116, 120, 111, 189]. In addition, since oxidized DJ-1 has been found in post
mortem brains of PD patients [109], it is of interest to determine the structural
determinants of such modifications.
Here we have used MD simulations to assess the effects on DJ-1 protein structure
of oxidative stress and of two missense mutations causing familiar PD (L166P,
M26I) [53] along with a physiological variant (R98Q) [173].
Our MD simulations suggest that:
(i) WT in solution is very similar to the X-ray structure in both reduced and
oxidized states and in both monomeric and dimeric forms.
(ii) The M26I monomer is structurally similar to the WT monomer, because the
mutation does not disrupt intra-protein interactions of the WT (Tab. 6.4). Thus,
this monomeric structure may assemble similarly to the WT to form dimers.
(iii) The local conformation around P166 in the L166P monomer evolved towards
a conformation significantly different from that of the WT. This might be due
to the disruption of α8 helix, which in turn affects the conformations of the sec-
ondary structure elements at the subunit-subunit interface (α1, α9 helices and β3
β-sheet). Thus, although P166 is not located at the subunit surface involved in
the dimerization, it changes its shape by modifying some of the intra-protein inter-
actions. This is shown by a comparison of structural determinants of the protein
surface of the mutant with the WT (Tab. 6.4). The different conformation of
L166P monomeric units might affect the mutant’s ability to assemble in dimeric
and multimeric structures. Indeed, by gel filtration and other assays, L166P has
been previously shown to be present mostly as an HMW complex that may contain
either DJ-1 oligomers and/or aggregates with other proteins [121, 119, 111]. This
led to the hypothesis that L166P may have additional, unidentified, dominant-
negative effects. Parkin, CHIP and hsp70 were all able to interact with L166P as
part of a large complex [120]. Furthermore, Parkin interaction provoked the se-
questration of DJ-1 mutants into insoluble fractions [120]. By in vitro experiments
we confirmed previous data that the ectopic expression of L166P is very low and
that dimer formation is very negligible. Interestingly, we detected the previously
identified HMW complex that may be involved in abnormal oligomerization and
protein/protein interactions [121, 119, 111].
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(iv) MD simulations show that the dimeric structures of M26I and R98Q DJ-1s are
similar to that of the WT and they keep the subunit-subunit interactions intact.
The dimeric structures turn out to be less flexible than the monomer, especially
in the flexible N- and C-terminal fragments. This fact points to a stabilizing role
of the subunit-subunit association.
These results for M26I are consistent with our in vitro assays, which show that
M26I has the same ability as WT to form dimers. Therefore, our combined com-
putational and experimental approach, along with previous experimental work
[125, 121], provides a coherent picture in which M26I assumes mostly a dimeric
structure. The results for R98Q are consistent with the fact that this mutant is a
physiological variant.
We conclude that the PD-causing M26I mutation does not largely affect the stabil-
ity of the dimer and does not destabilize it by changing the shape of the subunit-
subunit contact surface.
To identify a mutation that decreases the affinity for the dimeric structure without
changing the fold of the monomer, we next perform Baker’s Computational Alanine
Scanning procedure [136, 135] and MD calculations. We find that R28A is indeed
able to cause destabilization at the interface. Furthermore, the MD structure
of the R28A monomer turns out to be similar to that of the WT monomer, as
shown by the comparison of selected structural determinants (Fig. 6.4.B and Fig.
6.6.AB). This may be caused by the fact that A28 faces the solvent. However, the
MD simulations point to the destabilization of the dimer as already observed in
the timescale investigated (∼10 ns).
The SASA for water and the distances between the centers of mass increase on
passing from the WT to R28A (Fig. 6.7.D). This is caused by the disruption of
subunit-subunit interactions, rather than a change of shape of the subunit surface.
The computational results are consistent with in vitro experiments that showed
R28A has a reduced, although not abolished, capacity to form homodimers as
compared to DJ-1 WT. This effect is not caused by a reduced stability of the
R28A mutant since the protein is expressed at even higher levels than the DJ-1
WT (Fig. 6.9 A and B).

Chapter 7
Concluding remarks
I have presented a computational study on two important proteins involved in the
derangement of familial Parkinson’s Disease.
I have focused first on interactions with dopamine to alpha-synuclein. Dopamine is
known to inhibit fribillation experimentally [16, 17, 79, 100, 99], although the pro-
tein is unstructured in aqueous solution. Thus, modeling dopamine/interactions is
really challenging. Here we have used a rather elaborated computational protocol,
involving structural clustering, docking and molecular dynamics techniques along
with the experimental validation of the results. Our calculations suggest that the
C-terminal region of the protein, including the 125YEMPS129 region bind non-
covalently with dopamine and several of its derivatives. Moreover, the C-terminal
region binding region adopts a specific kinked conformation upon binding (Fig.
4.5). The ligands are stabilized into the binding region by unspecific hydrogen
bond and hydrophobic interactions (Tab. 4.2). Furthermore, there are long range
electrostatic interaction between the ligands and specific amino acids in the NAC
region, which stabilize the ligand. The most important residue in the NAC region
involved in such interactions is GLU83 (Fig. 4.8). The experimental work carried
out in SISSA and in EPFL corroborates this result.
As next step I have attempted to design molecules structurally and electrostati-
cally similar to dopamine and its derivatives studied here. In vitro experiments
- carried out exactly as in the previous study, may be performed to test whether
the molecules identified by study (reported in Fig. E.1) do affect AS fibrillation.
Our findings demonstrate how the use of structural models of even highly het-
erogeneous states of proteins determined by NMR spectroscopy in combination
with molecular dynamics simulations can provide novel insight into the structural
determinants of ligand binding as well as it can be used to design new ligands.
In my thesis work, I have then moved my attention to the role of PD-linked
mutations for the oligomeric state of the DJ-1 protein. Whilst the WT protein is
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a dimer [116], the mutant L166P - found in patients from familial cases of PD - is
a monomer and may form high molecular weight complexes [28, 121, 111, 119]. In
addition, M26I - found also in familial cases of PD - is still a dimer [121, 102] but
it is a matter of debate whether dimer formation occurs at the same rate as WT or
less efficiently. Our calculations suggest that the M26I mutation, which is known
experimentally to reduce the thermal stability of DJ-1 in solution [190], affects
neither the monomeric structure nor the dimeric one [33, 125], and it has a similar
tendency to form dimers as that of the WT. This suggests that the pathological role
of this mutant for PD may arise from factors other than structural determinants.
Our calculations provide also a possible rationale on why L166P mutation favors
the formation of multimers, as shown experimentally [121, 111, 119]. Indeed,
this is is probably due to the structural changes of the monomeric subunit upon
mutation [116]: although the mutated residue is located on a inner helix (the α8
helix), it produces changes in the interactions among secondary structure elements
(α1 helix and β3 beta sheet, Fig. 6.4), which in turn may affect subunit-subunit
interactions in a sort of ’domino’ effect [191]. Thus, this mutation may allow
the protein to form in vivo oligo or monomeric structures. This proposal is
supported experimentally here and in the previous work [28]. Our methodology is
subsequently used to search for mutations that decrease the affinity for the dimer
without affecting DJ-1 fold (as it occurs in L166P). This leads to identify a key
residue on the subunit-subunit interface and to develop a new engineered mutant
R28A. This mutant experimentally shows a reduce ability to form dimers but due
to a different mechanism than the L166P mutant. This is consistent with with
the fact that this mutant does not affect the structural properties of the monomer.
Instead, it affects the subunit-subunit interactions (indeed, the mutation is located
in subunit-subunit interface of the dimer).
In conclusion, my combined computational and experimental work may be a valu-
able strategy to address key issues related to the molecular medicine of PD. In
particular, different computational methodologies along with experimental studies
have helped addressing a difficult and medically relevant problem such as ligand
binding to a completely unstructured protein. In spite of its important pharmaco-
logical implications, this issue has never been addressed before, to the best of my
knowledge.
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Appendix A
The neurotransmitter
dopamine
A.1 Dopaminergic neurons: synthesis of DOP
In the dopaminergic (DA) neurons, dopamine (DOP) is synthesized by tyrosine
hydroxylase (TH) in the cytosol. Like all catecholamines, DOP is unstable and
prone to autoxidation, with production of ROS and reactive DOP derivatives such
as quinones (Q) and dopaminochrome (DCH) which are cytotoxic species able to
cause oxidative damage to cellular proteins and DNA. This toxicity is avoided by
rapid sequestration of DOP in synaptic vesicles by vesicular monoamine trans-
porter 2 (VMAT2). Interestingly, mice that express low levels of VMAT2 display
age-associated nigrostriatal dopamine dysfunction that ultimately results in neu-
rodegeneration [192]. After release in the synaptic cleft, DOP is re-uptaken in the
cytosol by the dopamine transporter (DAT) (Fig. A.1).
A.2 AS/Dopamine: covalent and non-covalent
adducts
Covalent adducts: Conway et al., in 2001 performed an screening of a commer-
cially available library of 169 compounds to identify drug-like molecules able to
block AS fibrillization in vitro, 14 of the 15 inhibitors found were found to be cate-
cholamines related to dopamine. The inhibitory activity of dopamine depended on
its oxidative ligation to AS and was selective for the protofibril-to-fibril conversion,
causing accumulation of the AS protofibril [98].
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Figure A.1: Synthesis of dopamine in the presynaptic terminal of dopaminergic neu-
rons. The potential function of AS in intracellular dopamine storage is also presented
(adapted from [11]).
DOP modulates differently the stability of protofibrils and fibrils composed of wild-
type or variants of AS (A30P and A53T) as shown by a high hydrostatic pressure
(HHP) study. Although fibrillization of AS was inhibited by DOP, long incubation
times (18 days) eventually led to the formation of fibrils with a decreased stability.
As for the protofibrils, in the absence of DOP they all exhibited identical stability,
while in its presence, the mutant ones acquired a greater stability, which can shed
light onto why these mutations are so aggressive. Indeed the A30P protofibrils,
when added to mesencephalic and cortical neurons in culture, decreased the num-
ber and length of neurites and increased the number of apoptotic cells. The toxic
effects were abolished by HHP treatment, which is able to break the protofibrils
into smaller aggregates, as seen by atomic force microscopy. This suggests that
strategies aimed at breaking and/or clearing these aggregates are promising in
alleviating the symptoms of PD. The exact mechanism of DOP/AS interaction
has not been fully elucidated yet, and given its potential pharmacological and
therapeutical relevance, is the object of many ongoing research efforts.
In another work, Li et al., tested the inhibitory abilities of DOP and several analogs
including chemically synthetic and natural polyphenols in vitro. The MS and NMR
characterizations demonstrated that DOP and its analogs inhibit AS fibrillization
by a mechanism where the oxidation products (quinones) of DOP analogs react
with the amino groups of AS chain, generating AS/quinone adducts. NMR ex-
periments suggest that at least three amino groups of lysine residues in a AS
molecule are modified by DOP to generate imino groups that link to the aromatic
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ring of quinone and the side chains of the protein. The covalently cross-linked
AS adducts by DOP are primarily large molecular mass oligomers, while those
by catechol and benzoquinone (or hydroquinone) are largely monomers or dimers,
probably because DAQ reacts with the amino group of DOP molecule to form
melanin that further covalently cross-links DOP/AS adducts to form more com-
plicated DOP/AS oligomers. The DOP quinoprotein retains the same cytotoxicity
as the intact AS, suggesting that the oligomeric intermediates are the major ele-
ments that are toxic to the neuronal cells [99].
Non-covalent adducts: There is strong debate about the covalent [79, 100, 99]
or non-covalent [16, 17] nature of the DOP/AS complexes.
Norris et al. proved that dopamine inhibition of AS fibrillization generated ex-
clusively spherical oligomers that depended on dopamine autoxidation but not AS
oxidation, because mutagenesis of Met, His, and Tyr residues in AS did not abro-
gate this inhibition. However, truncation of AS at residue 125 restored the ability
of AS to fibrillize in the presence of dopamine. Mutagenesis and competition stud-
ies with specific synthetic peptides identified AS residues 125 to 129 (i.e. YEMPS)
as an important region in the dopamine- induced inhibition of AS fibrillization.
They also show that the inhibition of the interaction is reversible if the system
is treated with urea and renaturated by dialysis in PBS, demostrating that the
DOP/AS interactions is non covalent. Thus, their data indicate that dopamine
and also dopaminochrome (an autooxidation product of DOP) inhibits AS fibri-
llization, probably inducing structural changes in AS that can occur through the
interaction of dopaminochrome with the 125YEMPS129 motif of AS forming non
covalent adducts [16].
On the other hand, Mazzulli et al., using molecular and biochemical approaches
were able to demostrated the important role of the C-terminal region of AS for the
inhibition of its fibrillization. Interestingly, they have shown that the intracellular
inhibition of AS aggregation requires the oxidation of catechols and the specific
non-covalent interaction of the oxidized catechols with residues 125YEMPS129 in
the C-terminal region of the protein [17].
In addition, Bisaglia et al. carried out a kinetic and structural analysis of the
early oxidation products of dopamine. Specifically, considering the potential high
toxicity of dopaminochrome for both cells and mitochondria, they focused on its
rearrangement to 5,6-dihydroxyindole. After the spectroscopic characterization of
the products derived from the oxidation of dopamine, the structural information
obtained was used to analyze the reactivity of quinones toward AS. The results
suggest that all these molecules should be able to interacts with AS forming co-
valent or non-covalent adducts, but indole-5,6- quinone (IQ), is the most reactive
species [100] (Fig. A.2).
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Figure A.2: Characterization of dopamine forms (Adapted from [100]).
A.3 Oxidation pathways of DOP
A summarizing scheme of the oxidative pathway DOP and of the proposed inter-
actions with AS is shown in Fig. A.2. The initial reaction involves the oxidation of
dopamine (DOP) to yield the corresponding dopamine-oquinone (DAQ). The two
following steps are the cyclization of the quinone to give leukoaminochrome and
its subsequent oxidation to dopaminochrome (DCH). Then, dopaminochrome rear-
ranges to 5,6-dihydroxyindole (DHI) which can be oxidized to indole- 5,6-quinone
(IQ) and polymerize to form neuromelanin [100].
Appendix B
Other docking algorithms
B.1 Multi-population GA
In the section 3.1.4 we have explained the structure of a single population genetic
algorithm as it is implemented in the programs AUTODOCK 3 and 4 (Fig B.1)
In other programs, like the GOLD program [150, 151], it is applied instead a
multi-population genetic algorithm. This program was not used in this thesis,
but it will be used in the future work. With this program, better results are
obtained by introducing multiple subpopulations. Every subpopulation evolves
over a few generations isolated (like the single population genetic algorithm) before
one or more individuals are exchanged between the subpopulation (migration).
The multi-population evolutionary algorithm models the evolution of a species in
a way more similar to nature than the single population genetic algorithm. Fig.
B.2 shows the structure of such an extended multi-population genetic algorithm.
Goldscore and Chemscore scoring functions: The GOLD program is able to use
different scoring functions, GoldScore, ChemScore and a User Defined Score.
The Goldscore fitness function is evaluated in six stages as follows. (1) A confor-
mation of the ligand and protein active site is generated. (2) The ligand is placed
within the active site using a least-squares fitting procedure. (3) A hydrogen bond-
ing energy H-Bond-Energy, is obtained for the complex. (4) A pairwise energy,
Complex-Energy, is obtained for the steric energy of interaction between the pro-
tein and the ligand. (5) Molecular mechanics expressions are used to generate the
term Internal-Energy which is a measure of the internal energy of the ligand. (6)
The energy terms are summed together to give a final fitness score [151].
The ChemScore fitness function [193, 194] was derived empirically from a set of
82 protein-ligand complexes for which measured binding affinities were available.
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Figure B.1: Scheme of the genetic algorithm used in the AUTODOCK program
Figure B.2: Scheme of the genetic algorithm used in GOLD program
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Unlike GoldScore, the ChemScore function was trained by regression against mea-
sured affinity data, although there is no clear indication that it is superior to
GoldScore in predicting affinities. It estimates the total free energy change that
occurs on ligand binding as:
∆Gbinding = ∆G0 + ∆Ghbond + ∆Gmetal + ∆Glipo + ∆Grot (B.1)
Each component of this equation is the product of a term dependent on the mag-
nitude of a particular physical contribution to free energy (e.g. hydrogen bonding)
and a scale factor determined by regression.
The final ChemScore value is obtained by adding in a clash penalty and internal
torsion terms, which militate against close contacts in docking and poor internal
conformations. Covalent and constraint scores may also be included.
ChemScore = ∆Gbinding+Pclash+cinternalPinternal+(ccovalentPcovalent+Pconstrains)
(B.2)

Appendix C
Ewald Sum
The Ewald sum is a technique for efficiently summing the interaction between an
ion and all its periodic images. It was originally developed in the study of ionic
crystals [195, 196]. The electrostatic potential energy UCoul for a neutral system
composed of N positively and negatively particles of charge qi, placed at ri and
enclosed in a volume V = L3, takes the form:
UCoul =
1
2
N∑
i=1
qiφ(ri) =
1
2
∑
n=0
N∑
ij
qiqj
|rij + nL| (C.1)
where n are the direct lattice vectors and each particle interacts with all the other
N − 1 particles into the simulation box and with all the N particle images in an
infinite 3D array of periodic cells. The prime on the summation indicates that the
sum is over all the images n, and i 6= j if n = 0. The convergence of this series
is conditional and requires a very large number of images to achieve a reliable
estimate of UCoul. The idea behind the Ewald method is to surround every charge
qi with a density cloud %− of opposite sign and total charge −qi. In this way
an efficient screening is realized, so that interactions rapidly go to 0 and direct
summation is possible. Then, a cancellation charge density %+ of total charge
qi centered at ri is also added to recover the original distribution. In order to
exclude self-interactions the contributions of these three charge densities should
be not evaluated in ri. However, it is convenient to keep self-interactions due to
the canceling charge distribution %+, since %+ is in this way periodic and can be
represented as a rapidly converging Fourier sum. The spurious self-interaction
can be easily subtracted separately. In the original formulation Ewald choose two
Gaussian charge distributions, %G−(r) and %G+(r) of width
√
2/α and total charge
−qi and qi, respectively. Thus, the total charge distribution of the system %(r)
may be rewritten as:
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%(r) = %(r) + %G−(r) + %
G
+(r
=
∑
n
[(
N∑
i=1
qiδ(r− (ri + nL)) +
N∑
i=1
(−qi)
(α
pi
) 3
2
e−α|r−(ri+nL)|
2
)
+
N∑
i=1
qi
(α
pi
) 3
2
e−α|r−(ri+nL)|
2
] (C.2)
At this point, %+ %G− and %G+ contributions to the total charge distribution can be
considered separately. From the first term one gets a potential energy Udir rapidly
going to 0 at large r, due only to the fraction of qi unscreened by %G−. From %G+ the
long-range interaction energy U rec comes, that can be evaluated in the reciprocal
space. To this aim, we derive the electrostatic potential in this space through
Poisson’s equation ∇2φ(r) = −4pi%(r). Fourier transforming the members of this
equation gives:
∇2rφ(r) =
1
V
∑
k
φ˜(k)∇2reik·r = −
1
V
∑
k
k2φ˜(k)eik·r (C.3)
%(r) =
1
V
∑
k
%˜(k)eik·r (C.4)
where
f˜(k) =
∫
V
drf(r)e−ik·r (C.5)
and k = (2pi/L)l, l being reciprocal lattice vectors. The Poisson’s equation takes
the particularly simple form:
k2φ˜(k) = 4pi%˜(k) (C.6)
Substituting the expression for %G+(r) in eq. C.5 we have:
%˜G+(k) =
∫
V
dre−ik·r
∑
n
∑
j
(α
pi
)3/2
qje
−α|r−(rj+nL)|2
=
∑
j
(α
pi
)3/2
qj
∫
V
dre−ik·r
∑
n
e−α|r−(rj+nL)|
2
=
∫
allspace
dr
∑
j
(α
pi
)3/2
qje
−ik·re−α|r−rj |
2
(C.7)
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where the relation
∑
n
∫ a
−a f(x + na) =
∫∞
−∞ f(x) for periodic functions has been
used. With the change of variables r→ r′ = r−rj we obtain finally the expression
for %˜G+ in the reciprocal space:
%˜G+(k) =
∑
j
qje
−ik·rj
[(α
pi
)3/2 ∫
allspace
dr′e−ik·r
′
e−αr
′2
]
=
∑
j
qje
−ik·rje−k
2/4α = %˜P (k)γ˜(k)
(C.8)
where %˜P (k) =
∑
j qje
−ik·rj and γ˜(k) = e−k2/4α are the Fourier transform of a
point charges set and of the smearing Gaussian, respectively.
Inserting in Poisson’s equation the potential takes the form:
φ˜G+(k) = g˜(k)%˜P (k)γ˜(k) (C.9)
where g˜(k) = 4pi
k2
is the Green’s function.
Antitrasforming the potential gives the electrostatic energy:
U rec =
1
2
∑
i
qiφ
G
+(ri) =
1
2
∑
i
qi
 1
V
∑
k 6=0
φ˜G+(k)

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2pi
V
∑
k 6=0
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ij
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k2
qiqje
−ik·(ri−rj) =
1
2V
∑
k 6=0
g˜(k)
∣∣%˜G+(k)∣∣2 e−k2/4α
(C.10)
s mentioned above, this term contains the self-interaction of each charge qi with a
Gaussian distribution %self+ = qi(α/pi)
2e−α|r−ri|
2
. The potential due to this cloud
is obtained solving the Poisson’s equation in spherical coordinates (x ≡ |r− ri|):
1
x
=
∂xφself+
∂x2
= 4pi%self+ → φself+ =
qi
x
(
2√
pi
)∫ √αx
0
e−x
′2
dx′ =
qi
x
erf(
√
αx)
(C.11)
where erf(x) = (2/
√
(pi))
∫ x
0 exp(−u2)du. Finally, we get:
U self =
(α
pi
) 1
2
N∑
i=1
q2i (C.12)
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The advantage of this scheme is now clear: the self-contribution energy is simply a
constant, independent on system configuration, and does not enter in the calcula-
tion of the forces. Using the result for φself it is easy to calculate the short-range
interaction energy Udir. Indeed, this energy arises from a potential generated by
charge densities qi − %G−(r) centered at ri, which thus is given at any point r by:
φdir(r) =
∑
n
∑
j
qj
|r− (rj + nL)|erfc
(√
α |r− (rj + nL)|
)
(C.13)
The total electrostatic interaction energy can be finally expressed as:
UCoulE w =
1
2
∑
i
qiφ
tot(ri)
= Udir − U self + U rec = 1
2
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qi
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φdir(ri) + φrec(ri)− φself (ri)
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(C.14)
The accuracy of the method, defined as the difference  = UCoulEw −UCoul, is related
to the optimal choice of the parameters α, width of the Gaussian distribution,
and of the two cutoffs rc and kc in real and reciprocal space, respectively. It
can be shown that  for both the real and reciprocal space terms is proportional
to exp(−s2)/s2 [197], where s ≡ rcα and s ≡ pinc/αL, respectively. Here nc
is a positive integer used to define the cutoff in the reciprocal space vectors as
kc = 2pi/Lnc, so that the number of Fourier components within this cutoff is
(4pi/3)n3c . If one requires the same accuracy on the evaluation of U
dir and U rec
the value of s is fixed, and the choice of α determines both the number of Fourier
components required to calculate U rec and the cutoff rc. The optimal choice of α
is obtained minimizing the total computational time
τ = τdirNdir + τ recN rec (C.15)
where τdir is the time needed to evaluate the interaction between a couple of
particles, τ rec that needed to evaluate the interaction per k vector and per particle,
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Ndir and N rec are the number of cycles per MD step needed for the evaluation of
Udir and U rec, respectively. For a homogeneous system of density D = N/L3 we
have
Ndir =
4
3
pi
(rc
L
)3
N2 =
4
3
pi
( s
αL
)3
N2
N rec =
4
3
pin3cN =
4
3
pi
(
sαL
pi
)3
N
(C.16)
which gives for α and τ the values:
α =
(
τdirpi3N
τ recL6
)1/6
∼ N−1/6
τ =
8
√
τdirτ recN3/2s3
3
√
pi
= O(N3/2)
(C.17)
C.1 Particle-Mesh Approaches
The computational cost for solving eq. C.14 thus scales as O(N3/2). In general,
rc can be safely set to a value < L/2, restricting the calculation of Udir to the
original box only (|n| = 0). However, for convenience rc is sometimes set equal to
the cut-off for short-range interactions, and in this case α does not need to have its
optimum value. This implies that, although the real part of the Ewald sum goes
as O(N), the Fourier part goes as O(N2). To see this, simply substitute s = αrc
in eq. C.16, and recall that N = DL−3 and Nc ∼ Dr−3c , where Nc is the number
of particles within the sphere of radius rc. Either or noth α takes its optimum
value, the computational cost of the Ewald sum becomes prohibitive for large (N >
104). To cope with this problem the so-called Particle-Mesh Approaches have been
developed [197], in which the point charges are spread on a space grid. This leads
to a Poisson equation expressed through Discrete Fourier Transform (DFT), which
is solved using the Fast Fourier Transforms (FFT) [198], scaling as O(M log2M),
where M is the number of grid points or Discrete Fourier Components (in practice
∼ N?). Since the FFT is a grid transformation, there are obvious discretization
problems to be solved (in primis those of charge assignment and calculation of
forces from grid points back to atoms) and corresponding discretization errors to
be minimized. In this sense an improvement in the accuracy has been made by
further splitting interactions in the reciprocal space into a short and long range
term, and evaluating the first directly as particle-particle and the second through
the use of a mesh (Particle-Particle Particle-Mesh, PPPM or P3M). What should
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be kept in mind is that Particle-Mesh approaches have been introduced as the
allow to implement Ewald summation using the FFT, not for reasons of accuracy.
Without their advent, however, computer simulations would have never found
spread use in biological problems.
Appendix D
Computational approach to the
investigation of
alpha-synuclein/dopamine
interactions
D.1 Resp charges on ligands
DCH DHI DOP DOP-H DQ IQ LEUK
C1 0.185 0.070 -0.072 -0.033 -0.029 0.228 0.093
H1 0.186 0.179 0.469 0.477 0.158 0.194 0.177
C2 -0.446 -0.328 -0.327 -0.293 -0.281 -0.397 -0.378
H2 0.212 0.186 0.461 0.471 0.189 0.202 0.220
C3 0.627 0.226 0.329 0.300 0.512 0.534 0.197
O1 -0.498 -0.566 -0.626 -0.594 -0.485 -0.482 -0.663
H4 0.028 0.208 0.178 0.196 0.071 0.191 0.018
C4 0.494 0.284 0.268 0.281 0.588 0.550 0.314
O2 -0.515 -0.557 -0.658 -0.625 -0.493 -0.501 -0.610
H5 0.034 0.318 0.162 0.179 0.071 0.322 0.027
C5 -0.496 -0.385 -0.331 -0.301 -0.291 -0.449 -0.353
H3 0.028 0.162 0.217 0.205 0.169 0.197 0.018
C6 0.040 0.037 -0.175 -0.207 -0.180 0.083 -0.020
C7 0.054 -0.221 -0.031 -0.064 -0.046 -0.350 0.031
H6 0.034 0.426 0.059 0.073 -0.008 0.027
H7 0.302 0.424 0.059 0.073 -0.008 0.294
C8 0.058 -0.252 0.296 0.034 0.342 -0.053 0.050
H8 0.004 0.098 0.395 0.470
H9 0.004 0.098 0.395 0.467
N1 -0.325 -0.209 -1.047 -0.278 -1.070 -0.269 -0.378
H10 0.381 0.303
H11 0.381 0.303
H12 0.303
Net
Charge
0.0 0.0 0.0 1.0 0.0 0.0 0.0
Table D.1: RESP atomic charges of the ligands in Fig. 4.2.
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D.2 Tables of distances
The table D.2 shown the results obtained from the MD simulations of the first six
representatives conformation of AS with all the analyzed ligands.
D.3 Clustering of 1,000 conformations of AS
in solution
The following figures and tables are related to the clustering of 1,000 conformations
of AS in solution.
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Representative from cluster 1 (distances in [A˚] between the ligands and the C-terminal residues)
Res. DCH DHI DOP DOP-H DQ IQ LEUK
Num. Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD
83 18.9 0.9 11.6 1.0 19.8 2.2 21.5 2.3 7.8 1.1 8.3 1.6 33.7 2.5
110 11.2 1.0 9.4 0.7 13.6 1.3 16.0 2.3 7.1 0.9 6.9 0.5 23.1 2.3
111 11.0 0.9 7.6 1.2 14.9 1.6 16.5 2.2 4.4 0.5 11.1 0.7 20.0 2.1
112 12.3 0.8 10.2 0.8 12.3 2.9 19.4 2.2 6.6 0.7 12.3 1.3 22.1 2.1
113 7.0 0.9 12.6 0.9 11.3 1.5 16.2 2.5 8.2 0.8 12.8 0.7 18.3 2.4
114 10.4 0.8 16.6 0.8 14.3 1.6 18.1 1.9 12.5 0.8 16.6 1.1 20.1 2.6
115 11.2 0.7 19.8 1.2 14.1 1.3 15.7 2.0 14.9 0.7 18.3 1.1 23.1 3.1
116 9.0 1.3 20.6 1.1 10.5 1.1 11.9 1.9 15.3 0.8 16.4 1.4 25.0 3.5
117 6.6 0.7 18.4 1.3 10.4 1.0 11.5 2.0 14.4 2.4 12.6 1.2 22.6 3.2
118 8.3 0.7 18.7 1.2 6.0 0.9 11.7 3.8 18.1 2.5 12.0 0.8 25.4 2.7
119 8.5 0.8 15.4 0.9 6.7 1.0 10.3 3.5 17.8 4.2 8.7 0.8 24.4 2.5
120 12.4 0.8 16.2 1.5 5.4 0.5 9.3 3.3 21.0 4.5 9.9 0.6 28.1 2.6
121 13.2 0.8 16.8 0.8 9.6 1.0 9.3 2.6 20.8 4.5 9.6 1.4 26.0 2.8
122 9.3 0.8 16.3 0.6 9.4 1.1 8.7 1.7 17.2 3.3 11.1 2.1 21.5 2.9
123 12.7 0.8 21.2 0.7 11.8 1.8 6.2 1.4 20.0 2.3 15.0 2.1 22.3 3.5
124 8.9 0.9 19.3 1.0 11.9 2.1 9.9 1.4 18.9 2.3 15.7 2.7 18.3 3.4
125 4.7 0.6 14.5 1.3 13.1 1.6 13.5 2.5 16.0 4.0 15.0 2.0 13.3 3.2
126 8.0 1.1 18.6 1.2 16.3 2.4 13.6 1.7 20.2 2.9 18.4 2.1 13.6 3.2
127 8.0 1.0 14.6 1.3 18.4 1.7 16.3 2.1 18.8 3.0 20.4 1.7 12.6 2.5
128 7.4 0.8 16.9 1.7 18.7 1.7 19.9 1.7 18.0 2.9 20.7 1.1 8.4 2.6
129 5.3 0.8 14.4 1.9 18.0 1.0 20.5 1.8 14.4 2.7 18.4 1.0 8.9 1.8
130 9.6 0.8 17.3 2.8 21.6 0.8 25.1 1.8 15.9 2.6 22.2 1.1 10.4 2.0
131 9.8 0.6 19.2 1.8 22.3 1.0 26.8 1.8 14.7 1.2 24.0 0.9 7.4 2.2
132 6.8 0.7 16.6 0.8 18.9 1.1 23.2 1.8 12.3 0.8 20.7 0.9 5.8 2.1
133 6.6 1.3 14.3 1.4 13.8 1.4 18.1 2.0 12.3 0.8 16.3 1.2 8.1 3.1
134 7.8 0.4 11.5 0.7 16.3 0.9 21.0 2.3 7.2 0.4 15.0 0.8 10.0 1.9
135 7.2 0.8 7.0 0.3 13.6 0.8 19.0 2.2 5.4 1.0 10.2 0.8 13.4 2.1
136 6.4 0.6 9.9 0.5 11.9 0.8 17.6 1.8 7.1 1.3 12.1 1.6 16.5 2.1
137 11.6 1.3 5.8 0.3 17.7 0.9 22.5 1.8 6.2 0.9 13.6 1.0 16.4 1.5
138 13.3 0.9 8.4 0.6 20.1 0.9 26.1 2.1 9.2 0.6 18.1 1.0 14.8 1.3
139 15.3 1.4 8.3 1.0 21.5 1.7 27.4 2.7 10.0 0.7 19.9 1.0 14.1 1.5
140 18.2 1.1 7.9 1.9 25.2 1.4 30.6 2.3 9.3 1.2 20.8 1.6 16.7 1.7
Representative from cluster 2 (distances in [A˚] between the ligands and the C-terminal residues)
Res. DCH DHI DOP DOP-H DQ IQ LEUK
Num. Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD
83 34.1 4.8 18.2 1.7 28.7 6.9 37.4 3.8 29.2 5.2 18.3 2.1 11.2 1.7
110 56.9 21.7 27.6 5.0 39.2 7.2 29.0 6.2 36.6 7.1 33.2 2.0 31.0 2.7
111 57.8 21.9 27.2 5.4 37.3 7.3 26.3 7.0 34.6 7.9 35.0 2.7 32.0 2.5
112 55.0 22.3 23.4 5.9 33.2 7.3 26.1 6.6 31.3 7.4 32.6 3.8 29.1 2.9
113 55.2 24.4 21.2 4.8 33.5 7.2 22.7 5.4 30.6 8.8 31.3 3.6 25.6 2.2
114 58.9 23.7 25.7 4.4 37.0 7.3 22.9 5.6 33.9 10.6 36.1 3.7 28.9 2.0
115 59.8 25.5 25.1 3.8 33.2 7.4 18.6 5.5 32.2 11.2 34.7 3.2 27.6 1.5
116 58.0 27.8 21.2 3.6 30.0 7.1 20.3 4.3 31.2 9.7 31.4 3.9 22.9 1.5
117 60.2 28.5 21.7 3.4 28.9 7.1 17.7 3.6 30.3 10.6 30.0 2.9 24.2 1.7
118 61.2 29.3 24.0 2.6 32.1 7.1 20.2 3.4 34.0 10.1 31.6 2.6 23.2 1.7
119 61.6 31.9 21.1 3.5 30.2 6.8 20.7 2.8 35.0 9.3 28.1 3.0 24.1 2.3
120 63.9 31.1 24.1 3.9 30.7 5.4 24.1 2.8 38.2 9.1 28.4 2.8 23.6 2.8
121 63.1 32.9 23.1 3.1 29.1 4.8 23.9 2.9 36.8 8.5 29.1 2.8 23.0 2.1
122 63.9 34.3 20.6 3.8 28.8 4.6 21.6 2.8 36.0 7.7 25.9 3.5 23.1 2.6
123 60.8 35.1 20.9 2.0 24.6 4.6 17.4 2.9 33.0 8.7 24.2 2.3 20.7 2.4
124 59.0 34.6 18.0 1.7 22.3 4.6 18.1 2.7 30.0 8.6 22.3 3.7 17.3 2.5
125 56.7 33.9 20.0 1.9 20.4 5.8 13.9 2.6 29.8 10.1 18.9 2.4 19.1 2.1
126 54.3 35.5 18.1 3.5 17.5 4.9 18.0 2.5 26.8 10.4 18.0 4.8 15.0 2.8
127 52.8 36.1 19.8 3.3 16.8 5.5 15.1 2.8 27.6 12.7 17.6 4.2 15.7 3.0
128 50.5 34.6 17.4 2.9 14.2 6.5 13.0 2.7 25.9 13.5 17.1 2.2 16.6 2.6
129 51.9 33.2 17.9 2.3 17.4 7.1 5.4 0.7 25.4 13.4 19.3 2.1 20.2 2.8
130 50.8 34.7 19.4 2.4 16.1 6.4 10.9 3.0 24.6 14.3 21.7 3.0 22.8 3.2
131 50.7 33.1 23.3 2.4 17.8 6.4 10.3 4.4 22.4 13.6 20.4 3.4 21.1 3.2
132 50.9 30.8 23.0 2.9 19.6 7.3 9.4 3.6 22.7 12.5 16.9 2.9 18.3 3.1
133 50.8 30.7 20.4 2.4 22.0 7.9 12.3 2.9 22.3 10.4 14.3 2.3 17.8 3.3
134 52.2 27.1 23.5 2.3 23.9 7.3 8.6 1.9 23.2 10.2 18.4 2.3 23.6 2.9
135 50.9 25.5 26.2 3.3 27.7 7.8 6.8 1.8 23.1 8.5 16.6 2.6 25.9 3.4
136 52.1 23.5 27.4 3.6 28.6 7.3 8.8 1.5 26.1 6.4 21.5 2.4 26.7 4.0
137 50.4 22.3 30.2 3.7 33.8 7.8 5.8 1.2 26.1 7.5 21.6 3.1 30.8 4.8
138 51.6 20.0 32.7 3.7 36.4 7.7 7.7 1.8 28.4 8.8 24.3 2.8 32.5 5.7
139 51.8 20.9 33.3 3.6 39.7 7.1 11.5 2.5 27.0 10.0 27.6 3.4 35.6 5.1
140 51.2 18.9 34.6 3.9 41.8 7.8 12.8 2.7 29.2 10.4 25.8 3.4 38.3 5.7
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Representative from cluster 3 (distances in [A˚] between the ligands and the C-terminal residues)
Res. DCH DHI DOP DOP-H DQ IQ LEUK
Num. Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD
83 21.8 3.1 24.8 4.2 25.4 6.0 17.6 2.6 11.6 2.8 21.3 4.1 26.3 6.7
110 37.5 2.8 34.0 5.2 26.5 2.4 24.7 6.2 31.9 2.8 42.6 4.2 12.6 6.9
111 39.1 3.9 30.9 5.2 25.3 2.4 25.7 5.7 34.0 3.0 44.8 3.8 12.2 4.8
112 38.4 4.2 27.9 5.5 21.6 2.6 23.6 5.9 36.3 3.1 46.6 3.9 11.7 3.2
113 35.5 5.6 25.2 4.8 23.0 2.5 23.0 6.1 33.1 3.2 41.9 3.8 13.8 2.9
114 33.3 5.1 22.5 5.7 18.1 3.1 18.0 6.1 35.8 3.1 43.8 4.9 12.4 4.2
115 31.5 6.2 20.8 4.6 21.3 3.0 17.9 7.5 35.5 4.6 44.0 4.6 14.6 3.8
116 35.2 6.6 22.4 4.2 21.9 2.5 14.9 7.2 37.1 4.4 44.5 3.5 16.1 6.3
117 35.1 7.2 20.2 4.2 19.7 2.7 12.6 6.4 35.4 4.8 41.6 3.4 14.3 7.0
118 38.3 5.9 22.0 4.8 16.4 2.8 14.4 4.5 36.4 3.3 41.4 2.2 16.5 8.4
119 38.2 4.2 22.4 5.0 16.4 2.1 12.4 3.2 36.7 4.2 40.3 2.0 16.2 8.9
120 39.0 4.5 21.3 4.8 13.3 2.7 13.2 2.9 36.2 4.2 41.0 3.2 17.5 9.2
121 41.1 3.8 24.6 5.4 12.8 2.7 12.0 2.6 35.7 3.8 42.0 3.3 16.2 8.5
122 43.4 4.0 26.0 5.4 16.1 2.6 11.5 4.0 37.2 4.5 44.8 3.1 19.2 8.3
123 42.0 3.7 27.0 6.4 14.4 2.5 9.8 2.5 34.6 4.9 41.9 3.0 19.9 7.5
124 38.3 3.8 23.3 6.3 13.6 2.8 8.2 2.9 32.3 6.2 44.1 3.3 20.2 8.6
125 34.1 3.3 23.1 6.6 12.5 3.1 8.1 2.3 28.9 5.8 40.0 3.3 25.4 9.2
126 37.5 3.4 19.4 5.3 11.0 2.5 10.1 2.7 34.0 6.4 44.7 4.0 25.8 9.2
127 37.1 2.9 20.2 6.5 7.8 2.4 12.9 2.5 34.9 5.4 41.8 4.3 25.8 9.1
128 34.0 2.8 18.7 6.9 7.5 2.2 14.0 3.5 33.6 4.7 38.7 4.6 28.9 9.0
129 36.3 3.7 17.9 6.0 10.5 1.7 14.8 3.8 31.2 4.9 35.5 3.7 27.1 9.4
130 35.5 4.7 18.4 6.1 9.3 2.4 18.1 4.6 29.7 4.4 33.0 4.9 29.6 8.9
131 37.5 5.1 21.4 5.9 10.3 2.3 19.5 3.8 31.2 4.8 35.1 6.0 27.6 8.9
132 40.2 4.4 22.2 5.5 11.5 2.2 17.4 3.6 32.8 4.1 38.0 5.0 24.7 9.3
133 39.9 3.3 22.7 5.6 10.6 2.4 15.4 3.6 35.4 4.6 39.3 3.8 20.8 9.6
134 42.2 4.1 23.5 6.7 14.8 2.6 20.2 4.0 37.1 3.8 34.9 4.7 23.1 8.4
135 44.6 4.0 26.9 5.5 14.7 3.2 21.0 3.5 39.1 4.1 36.6 3.8 20.0 8.2
136 45.7 3.7 26.6 6.1 15.2 2.5 19.4 3.0 38.1 4.4 34.2 3.5 17.1 8.8
137 48.4 3.4 29.8 6.6 18.2 2.7 24.0 3.2 38.2 4.9 38.4 3.2 18.9 7.5
138 50.8 3.8 32.0 6.4 21.3 2.7 24.8 3.2 40.5 5.0 40.7 2.7 17.6 5.6
139 50.8 4.1 32.6 7.8 22.2 3.7 26.7 3.6 42.2 4.5 44.3 3.2 21.0 5.7
140 53.1 4.5 35.2 7.9 25.3 3.4 30.3 3.6 43.9 5.4 46.4 2.2 22.8 4.5
Representative from cluster 4 (distances in [A˚] between the ligands and the C-terminal residues)
Res. DCH DHI DOP DOP-H DQ IQ LEUK
Num. Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD
83 15.4 0.9 11.8 1.5 24.0 1.6 29.3 1.6 23.3 1.2 17.5 1.0 12.1 1.2
110 17.8 1.6 15.3 1.4 22.2 1.0 30.4 1.3 18.5 0.7 19.4 1.1 12.2 3.1
111 15.5 0.8 15.3 0.9 19.2 0.8 27.5 1.4 14.5 0.8 18.6 1.3 14.6 3.7
112 12.9 1.3 13.3 0.8 14.7 0.8 24.6 1.3 10.3 0.7 15.5 1.4 15.7 3.8
113 11.0 0.7 10.2 1.0 14.4 1.1 21.8 1.3 14.3 0.8 12.7 1.2 10.7 4.7
114 6.3 0.9 6.6 0.9 10.0 0.9 17.4 1.3 12.4 0.6 8.5 1.5 12.9 4.1
115 9.4 0.9 7.7 0.8 9.7 2.1 18.5 1.2 15.4 0.9 8.4 1.1 12.0 5.1
116 5.8 0.8 5.3 1.3 9.1 1.3 15.5 1.3 16.8 0.7 5.5 0.7 13.2 3.1
117 8.4 0.8 8.8 1.5 10.1 2.0 17.5 1.2 19.3 1.0 8.8 1.3 11.8 2.2
118 5.7 0.6 8.6 2.3 14.4 1.9 12.9 1.2 23.8 0.9 9.4 2.0 9.4 1.2
119 9.9 0.9 11.1 1.2 16.9 1.4 14.1 0.9 26.1 0.9 9.3 3.0 12.6 1.7
120 10.0 1.9 13.7 1.5 19.6 1.8 13.9 1.6 28.9 1.0 12.6 2.8 14.3 2.4
121 13.6 1.1 14.4 0.8 21.3 1.8 13.0 1.2 31.5 0.9 11.8 2.8 17.3 2.0
122 13.2 1.3 12.4 0.7 18.0 2.6 10.7 1.1 29.7 1.1 11.7 2.6 16.1 1.9
123 9.9 1.2 7.9 0.2 15.4 1.9 6.7 0.7 26.0 1.0 7.4 2.2 19.2 1.0
124 10.8 0.7 11.3 0.8 16.0 1.3 8.2 1.0 25.0 1.2 10.5 1.4 19.2 1.8
125 6.4 0.7 8.0 0.6 14.1 1.7 5.5 0.7 22.2 1.1 8.1 1.7 22.4 1.9
126 11.0 0.9 13.5 1.1 12.5 1.1 8.7 1.3 19.5 1.2 11.4 0.9 22.7 2.8
127 10.0 1.5 14.2 1.2 13.1 0.9 11.1 1.7 18.8 1.6 13.5 1.4 26.3 2.7
128 9.5 0.8 12.6 1.4 8.6 0.8 13.1 1.6 14.5 1.2 10.1 1.6 23.7 3.0
129 14.1 0.7 13.8 1.3 8.3 1.0 16.5 1.5 11.7 1.1 12.1 1.7 24.8 3.8
130 15.1 0.9 17.4 1.4 11.0 0.6 20.4 1.9 9.4 1.2 16.0 1.8 26.3 4.4
131 16.4 0.9 16.7 1.1 9.0 0.5 20.9 1.6 5.6 1.0 13.9 1.7 23.1 4.7
132 13.1 0.9 12.9 1.0 6.2 0.4 19.1 1.4 7.5 0.8 10.6 1.6 20.4 4.3
133 10.0 0.7 9.5 1.4 6.3 0.4 15.9 1.3 10.9 0.9 7.5 1.6 18.7 3.1
134 9.6 1.1 11.3 1.3 11.9 0.6 20.5 1.4 8.4 0.7 12.4 1.6 18.6 3.6
135 11.1 0.7 10.9 1.5 13.3 0.5 17.1 1.4 13.6 0.8 11.0 1.6 18.5 3.0
136 6.3 0.5 9.6 1.5 13.4 1.3 11.6 1.3 15.5 1.0 7.2 1.5 19.6 3.0
137 11.2 0.8 12.3 1.1 16.4 1.0 11.6 1.1 15.8 1.3 9.8 1.6 23.7 3.1
138 12.7 1.5 12.6 1.6 17.2 1.7 7.5 1.1 17.0 1.5 10.3 1.9 25.2 3.4
139 16.3 0.9 16.9 1.5 21.3 1.5 8.4 1.4 13.6 1.8 14.8 1.9 28.0 2.9
140 18.4 1.8 18.8 1.8 22.9 1.5 6.7 1.3 17.4 2.3 16.9 1.8 30.3 3.9
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Representative from cluster 5 (distances in [A˚] between the ligands and the C-terminal residues)
Res. DCH DHI DOP DOP-H DQ IQ LEUK
Num. Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD
83 16.5 2.7 35.0 8.6 12.0 2.3 26.6 2.6 50.6 7.0 23.2 3.4 21.7 3.4
110 14.9 0.7 22.6 11.2 29.8 1.9 11.6 0.7 24.7 12.7 11.7 2.1 13.2 1.5
111 11.9 0.6 19.7 10.9 29.2 1.9 10.3 0.6 24.8 13.3 12.3 2.3 14.0 2.0
112 8.8 0.7 16.7 10.9 25.3 1.9 6.6 0.6 23.8 15.0 9.9 2.4 11.2 2.1
113 8.3 0.6 20.2 11.8 26.8 2.7 9.2 0.9 24.3 14.2 13.0 3.9 14.3 3.5
114 6.4 0.5 17.5 11.8 22.9 3.5 7.1 1.2 21.3 13.7 11.3 5.1 12.0 4.5
115 4.8 0.4 20.1 10.9 23.6 3.6 9.1 1.9 23.4 15.3 15.1 4.7 14.1 4.4
116 7.5 0.4 21.7 12.0 24.0 2.6 8.3 1.2 24.8 15.6 13.3 3.4 12.7 3.4
117 6.6 0.5 24.6 12.8 20.4 2.4 8.2 1.5 25.2 15.7 15.0 3.7 11.0 3.5
118 8.6 0.5 25.4 13.0 19.0 2.1 6.0 0.6 22.6 15.6 12.1 2.7 7.5 2.5
119 12.8 0.5 29.2 13.2 18.3 2.6 10.2 1.1 26.0 14.9 14.4 2.0 8.8 2.0
120 14.3 0.8 31.8 12.7 15.7 2.7 11.9 1.1 26.7 15.0 16.4 2.2 7.3 3.0
121 17.1 0.6 33.3 13.2 18.9 4.0 13.9 1.2 27.9 14.3 16.6 2.6 10.9 2.7
122 13.8 0.6 29.2 13.3 16.7 4.1 9.9 1.5 24.0 14.0 12.6 2.7 11.2 2.1
123 18.1 0.9 32.5 12.5 15.9 6.2 13.4 1.8 25.1 12.8 13.7 4.8 12.8 2.1
124 17.1 1.8 30.9 13.2 13.2 4.4 9.9 2.2 22.4 12.6 6.3 3.0 12.0 2.4
125 15.8 1.0 29.0 12.8 15.3 4.2 10.5 0.9 22.6 12.5 6.2 1.9 15.7 2.1
126 17.4 0.7 30.3 13.3 18.2 5.2 12.5 1.2 25.7 13.2 7.6 2.5 14.7 1.5
127 19.1 1.4 28.0 13.1 20.3 3.9 12.5 0.9 28.6 13.6 12.6 2.6 16.1 2.4
128 16.4 1.4 30.3 14.6 21.6 4.7 13.8 0.8 29.6 12.9 14.3 2.6 13.2 2.8
129 20.4 1.5 32.3 13.3 24.8 5.6 18.5 0.7 32.4 12.8 17.2 2.4 15.2 2.9
130 21.3 2.2 34.3 14.0 28.5 5.4 20.1 2.6 34.7 12.6 19.8 2.7 15.1 4.1
131 24.0 1.9 35.7 12.4 30.1 6.4 22.9 2.4 38.0 12.2 23.1 2.5 18.1 4.4
132 21.1 1.4 34.2 11.1 26.4 6.3 21.8 1.7 38.8 12.8 22.5 2.3 19.6 3.8
133 25.1 1.7 32.9 8.9 30.0 6.5 25.6 2.5 41.3 11.8 25.2 3.1 23.3 2.7
134 25.3 1.1 32.5 10.3 26.7 6.5 23.5 2.1 37.8 11.7 25.9 3.1 23.7 4.1
135 29.0 0.9 31.5 8.6 30.3 6.1 27.6 2.0 37.7 11.5 28.4 3.7 26.7 4.1
136 27.5 1.7 31.2 9.3 26.5 6.1 23.3 2.3 33.8 11.5 29.8 4.0 27.2 5.5
137 23.3 1.1 31.8 8.0 25.2 5.9 21.6 2.3 34.2 11.8 31.6 3.3 29.4 4.7
138 23.5 2.1 33.1 6.0 27.4 6.2 24.4 2.6 34.8 11.0 31.9 4.2 30.7 4.2
139 20.5 2.7 34.1 6.4 28.0 6.1 22.2 3.5 39.3 11.2 35.7 4.2 33.3 5.4
140 20.3 2.2 33.8 8.3 28.6 5.0 21.2 2.6 39.7 11.4 36.6 5.6 35.0 5.3
Representative from cluster 6 (distances in [A˚] between the ligands and the C-terminal residues)
Res. DCH DHI DOP DOP-H DQ IQ LEUK
Num. Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD Av. SD
83 30.3 5.8 11.9 1.4 19.0 1.5 13.1 0.6 21.3 3.4 28.5 1.8 20.1 10.2
110 27.6 5.3 20.9 2.4 15.3 0.7 20.4 2.9 18.7 2.4 16.3 1.1 26.3 13.8
111 23.8 5.6 17.2 2.3 12.4 0.7 20.7 1.3 14.8 2.2 19.5 1.0 25.1 13.0
112 23.0 4.9 14.8 3.3 11.6 0.5 18.3 1.3 13.8 2.1 15.8 1.0 23.0 12.9
113 18.0 4.3 12.2 1.1 6.0 0.7 20.8 1.4 11.7 2.9 19.7 1.3 19.8 13.4
114 19.2 3.5 14.0 1.4 10.2 0.5 14.9 1.5 11.5 2.1 17.8 1.6 18.2 13.0
115 15.9 2.3 10.4 0.7 7.2 0.8 19.4 1.5 8.6 2.4 21.4 1.9 19.3 11.5
116 18.3 1.3 14.2 1.1 11.7 0.9 20.7 1.6 12.9 2.2 19.2 2.5 17.8 12.9
117 14.7 1.4 12.7 1.1 10.6 1.3 21.3 1.4 11.8 2.0 23.9 2.4 19.0 10.5
118 16.1 2.9 16.8 1.5 13.9 2.0 26.0 1.3 13.2 2.1 25.2 3.1 18.7 10.8
119 19.8 1.8 18.2 1.1 16.0 1.7 25.6 2.2 15.7 2.5 22.5 3.0 17.9 12.8
120 21.7 1.1 18.1 1.8 16.4 1.4 23.6 2.9 16.8 2.5 19.3 2.5 17.4 14.3
121 22.8 1.2 19.5 1.6 19.3 1.0 25.6 3.2 20.5 2.3 23.3 2.1 19.9 13.2
122 18.1 1.8 15.9 1.0 15.7 1.1 24.3 1.9 18.8 3.0 25.4 2.3 20.0 10.8
123 18.8 1.7 16.1 1.4 18.1 1.1 22.5 2.4 19.6 2.1 27.3 1.5 22.7 10.0
124 15.0 1.5 12.5 1.0 14.5 1.2 23.6 1.9 15.8 2.1 25.6 1.3 22.0 9.5
125 15.0 2.1 11.1 1.0 12.8 1.1 19.7 2.3 15.6 1.7 29.8 1.3 24.1 7.8
126 11.4 1.8 6.2 0.8 8.0 1.5 23.5 1.5 10.0 1.7 28.7 1.8 24.0 8.2
127 11.2 1.3 6.7 0.4 11.4 2.5 25.4 2.5 11.5 1.5 27.9 1.4 26.5 8.7
128 7.3 1.3 4.8 0.6 9.4 3.1 25.1 1.8 8.5 1.1 30.3 1.2 27.9 8.6
129 6.3 1.2 8.2 0.4 10.1 1.9 29.2 1.8 6.3 1.4 33.1 1.2 30.8 7.4
130 6.7 1.1 11.5 1.0 12.7 1.8 29.7 1.7 9.0 1.4 36.9 1.2 34.3 6.8
131 10.4 1.0 13.7 0.8 13.1 0.8 34.3 1.6 10.9 1.6 40.4 1.2 35.4 6.4
132 8.9 1.4 10.8 0.5 9.6 1.0 32.7 2.2 8.4 2.0 40.1 1.6 33.1 7.1
133 5.7 1.4 6.6 0.5 5.6 1.0 27.2 2.4 6.1 1.3 35.1 1.8 29.1 7.9
134 7.6 0.7 6.9 0.5 7.0 0.8 30.2 2.5 10.4 1.3 37.5 1.4 31.7 8.0
135 6.0 0.6 5.5 0.4 6.3 0.4 26.1 2.4 8.4 1.4 34.5 2.1 29.8 8.4
136 11.1 0.7 10.5 0.5 11.9 0.8 30.1 2.5 6.9 2.3 37.1 2.0 31.4 9.4
137 10.3 2.0 7.1 1.0 7.5 0.7 25.8 2.1 9.2 1.7 31.0 1.8 32.8 9.4
138 12.5 1.8 10.6 0.8 11.7 0.7 27.9 2.2 12.6 1.5 30.8 1.4 32.5 9.0
139 14.0 2.7 9.8 1.6 12.6 0.6 24.6 2.5 13.4 1.8 29.0 1.5 32.4 10.1
140 12.8 3.7 11.6 2.4 12.7 1.0 22.2 4.1 16.6 1.7 32.7 1.6 34.3 9.9
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Region DOP DOP-H DCH
125-129 9.1 % 12.5 % 7.4 %
130-135 14.8 % 16.7 % 9.5 %
125-135 23.9 % 29.2 % 16.9 %
Table D.2: Docking: Relative contribution of the binding to selected regions in the
C-terminal region, calculated as percentage of the total number of ligand-protein contacts.
Cluster Hydrogen Bonds Hydrophobic contacts
1 (5 %)
2 (5 %)
DOPH Glu130(OE2)-DOP-H(O1), (D: 2.9±0.5 A˚) Met127 (D: 4.4±0.4 A˚)
DCH
Ile112 (D: 6.7±1.1 A˚)
Glu126 (D: 7.7±0.5 A˚)
Tyr136 (D: 4.3±0.5 A˚)
3 (4 %)
DOP Ser129(O)-DOP(O1), (D: 2.7±0.1 A˚) Gln134 (D: 4.4±0.4 A˚)
Lys43 (D: 5.2±0.5 A˚)
DCH
Glu126 (D: 5.9±1.5 A˚)
Gln134 (D: 6.6±1.3 A˚)
4 (4 %)
DOP Glu123(OE2)-DOP(O1), (D: 2.6±0.3 A˚) Gln134 (D: 4.7±0.7 A˚)
DOPH Pro128(O)-DOP-H(O2), (D: 2.8±0.2 A˚)
DCH Glu123 (D: 4.3±0.4 A˚)
5 (4 %)
DOP Glu131(OE2)-DOP(O2), (D: 3.0±0.9 A˚) Tyr125 (D: 7.3±1.8 A˚)
DCH
Thr81 (D: 5.7±0.6 A˚)
Pro128 (D: 4.4±0.6 A˚)
6 (3 %)
DOP-H
Glu126(O)-DOP-H(N1), (D: 2.8±0.1 A˚)
Glu126(OE2)-DOP-H(O2), (D: 2.7±0.4 A˚)
DCH
Val66 (D: 5.2±1.1 A˚)
Glu126 (D: 4.0±0. 5 A˚)
Table D.3: Hydrogen bonds and hydrophobic contacts for 11 out of the 18 analyzed
complexes forming interactions with the protein. Several of then shown interactions with
the C-terminal region, including the 125YEMPS129 region. The distance (D) in the hydro-
gen bond column was measured between the heavy atoms. The hydrophobic contacts were
measured as the distance (D) between the center of mass of the ligand and the specific
amino acid.
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Representative from cluster 1 Representative from cluster 2
(Ligs. - C-term residues distances [A˚]) (Ligs. - C-term residues distances [A˚])
Res. DCH DOP DOP-H Res. DCH DOP DOP-H
Num. Av. SD Av. SD Av. SD Num Av. SD Av. SD Av. SD
83 39.9 2.6 27.0 1.9 37.0 4.3 83 34.1 1.8 29.4 2.5 23.4 1.8
110 12.6 2.2 10.0 2.6 14.1 3.2 110 12.6 0.9 6.5 1.1 13.4 0.9
111 13.3 2.3 13.8 2.6 11.7 3.6 111 8.3 1.0 9.7 0.8 14.2 0.6
112 11.2 2.6 15.4 2.3 8.2 4.1 112 6.7 1.1 10.2 0.8 17.8 0.7
113 11.8 2.7 10.7 2.1 9.9 4.6 113 10.1 1.5 6.3 1.1 18.0 0.9
114 14.7 2.6 12.6 1.1 13.2 2.8 114 13.1 1.1 7.0 0.9 16.3 0.5
115 18.5 2.7 12.0 1.1 15.9 3.8 115 16.9 1.0 5.9 1.0 16.3 0.6
116 19.0 3.1 11.9 0.9 16.9 3.1 116 19.3 1.0 9.8 1.1 15.7 0.7
117 22.5 3.0 10.8 1.3 17.8 3.5 117 19.5 1.4 11.6 1.1 16.7 0.7
118 20.6 3.3 6.9 1.6 16.0 3.4 118 17.4 0.9 11.9 1.7 12.2 0.7
119 24.6 3.2 6.9 2.6 17.5 3.8 119 17.8 0.9 14.9 2.2 13.5 0.7
120 27.9 3.2 10.6 2.6 20.8 4.1 120 14.0 1.1 13.4 2.8 13.9 0.8
121 28.5 2.9 9.0 2.6 18.1 4.4 121 12.9 0.8 15.7 3.7 8.9 0.8
122 26.9 2.6 7.8 2.2 18.3 4.7 122 13.8 1.2 19.4 3.7 9.5 0.9
123 27.0 3.6 6.9 1.8 17.5 4.7 123 12.6 0.7 18.8 4.4 6.2 0.7
124 28.4 2.5 10.1 1.6 21.5 4.7 124 10.8 0.5 13.7 4.5 6.4 0.5
125 32.7 2.4 15.1 1.7 23.1 4.9 125 7.2 0.6 12.4 4.3 10.8 0.5
126 32.0 2.9 14.0 1.8 25.3 5.3 126 7.7 0.5 18.5 4.6 9.8 0.5
127 36.3 2.9 17.6 1.9 25.7 5.4 127 12.8 0.6 20.4 4.9 4.4 0.4
128 37.5 3.4 21.1 1.8 28.1 4.7 128 11.6 1.1 15.7 5.3 7.8 0.4
129 35.2 3.9 22.1 1.5 31.3 5.3 129 15.9 0.8 16.8 5.3 7.1 0.6
130 37.6 3.6 24.3 1.6 33.5 4.9 130 17.1 1.7 17.0 6.2 4.2 0.4
131 39.7 2.8 28.2 1.5 37.5 5.0 131 17.8 1.1 20.8 6.3 10.4 0.6
132 37.9 3.1 26.8 1.6 37.0 5.9 132 14.6 0.8 20.3 5.7 9.1 0.5
133 35.0 3.4 24.2 1.7 34.8 6.6 133 12.7 1.0 21.9 5.6 8.6 0.5
134 33.6 3.4 20.9 1.5 32.8 5.2 134 8.7 0.8 16.7 5.4 11.6 0.4
135 35.9 2.8 23.7 1.6 37.2 5.1 135 8.6 0.6 21.2 4.9 14.8 1.0
136 35.2 3.3 19.9 1.7 34.1 4.9 136 4.3 0.5 20.6 5.6 15.6 0.8
137 40.4 3.5 26.4 1.7 39.4 4.8 137 8.2 0.7 23.6 4.8 19.5 0.6
138 42.9 3.0 28.3 1.8 41.7 4.7 138 6.6 1.0 21.6 4.7 18.1 1.1
139 44.9 3.4 31.4 1.7 44.9 4.7 139 10.7 1.3 23.6 4.2 22.1 1.2
140 43.8 3.8 32.6 1.7 44.1 4.6 140 11.7 1.7 23.0 3.7 24.4 0.9
Representative from cluster 3 Representative from cluster 4
(Ligs. - C-term residues distances [A˚]) (Ligs. - C-term residues distances [A˚])
Res. DCH DOP DOP-H Res. DCH DOP DOP-H
Num. Av. SD Av. SD Av. SD Num Av. SD Av. SD Av. SD
83 28.2 3.1 31.7 3.4 32.9 3.4 83 8.2 0.8 6.0 1.2 9.2 0.9
110 14.0 1.7 20.2 2.7 13.7 1.6 110 30.6 1.0 30.2 2.0 26.9 4.0
111 15.1 1.6 18.3 2.2 17.7 1.6 111 27.8 1.3 27.0 1.9 26.0 2.5
112 16.4 1.4 17.6 2.1 18.5 1.7 112 28.4 1.1 25.7 2.1 24.3 3.1
113 12.8 1.5 14.6 1.3 14.0 1.5 113 24.2 1.4 21.1 2.2 21.0 2.2
114 17.3 1.2 16.2 1.2 18.5 1.6 114 20.9 1.1 21.4 1.3 24.3 1.1
115 13.5 1.4 12.7 1.2 14.6 1.7 115 17.6 0.9 18.2 1.5 19.9 1.1
116 17.6 2.0 16.6 1.6 14.4 1.5 116 16.0 0.8 15.0 1.4 17.5 1.9
117 14.8 2.7 13.2 1.3 10.3 1.6 117 11.5 0.8 11.4 1.4 14.4 0.9
118 18.4 2.1 16.8 1.8 14.4 1.5 118 11.1 1.0 11.1 0.8 12.7 0.6
119 16.8 2.0 15.3 1.5 13.7 1.3 119 6.9 1.0 7.1 0.6 7.7 0.6
120 16.7 2.5 15.4 2.0 12.4 1.6 120 8.9 1.1 9.5 0.6 10.5 0.6
121 14.2 1.7 12.7 1.3 14.3 1.5 121 6.3 0.8 7.0 1.5 6.6 0.9
122 10.7 1.3 11.6 1.3 12.0 1.5 122 9.5 0.5 9.3 0.5 9.4 1.0
123 11.8 1.1 11.5 1.6 8.9 1.1 123 4.3 0.4 4.6 0.6 6.2 1.4
124 7.1 1.2 7.2 1.6 8.9 2.0 124 5.6 0.7 5.4 1.2 4.6 0.6
125 9.3 0.9 9.8 1.6 8.6 1.6 125 9.6 0.7 9.1 0.9 9.7 1.6
126 5.9 1.5 10.2 1.5 5.4 1.7 126 8..6 0.8 10.6 1.0 10.0 0.9
127 6.8 0.9 8.7 1.2 6.6 0.6 127 6.2 0.7 9.3 1.7 4.2 1.6
128 6.4 1.0 6.4 1.3 9.2 1.4 128 4.4 0.6 10.2 1.7 2.9 0.7
129 5.8 0.9 4.9 0.8 9.7 1.6 129 7.8 0.6 8.7 2.0 4.9 0.9
130 8.4 1.9 5.9 0.7 9.3 1.8 130 10.4 0.7 12.4 1.1 9.2 0.6
131 9.7 2.2 8.2 0.8 9.7 1.8 131 14.9 0.7 13.2 1.3 13.8 0.7
132 9.0 1.1 9.1 0.8 9.1 1.2 132 11.3 0.8 9.1 1.5 9.6 0.8
133 6.3 1.4 7.1 0.8 6.3 1.2 133 7.6 0.6 5.8 0.9 5.9 0.6
134 6.6 1.3 4.3 0.4 5.4 1.1 134 6.9 0.6 4.7 0.7 6.1 0.6
135 7.0 1.8 5.5 1.0 6.9 1.3 135 12.5 0.7 10.2 0.9 11.0 0.7
136 10.4 1.3 7.8 1.5 9.2 1.5 136 10.7 0.7 9.7 0.9 10.9 0.8
137 10.8 2.8 9.9 1.1 11.0 1.6 137 16.3 0.9 14.3 1.4 15.8 0.6
138 12.4 4.2 9.4 2.8 12.0 2.0 138 19.1 0.8 17.2 0.9 18.8 0.8
139 11.7 5.6 12.5 3.3 9.9 3.1 139 21.4 0.8 19.9 1.4 19.5 1.3
140 12.3 4.3 12.4 2.6 14.0 2.7 140 25.4 0.8 18.9 2.0 17.0 1.9
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Representative from cluster 5 Representative from cluster 6
(Ligs. - C-term residues distances [A˚]) (Ligs. - C-term residues distances [A˚])
Res. DCH DOP DOP-H Res. DCH DOP DOP-H
Num. Av. SD Av. SD Av. SD Num Av. SD Av. SD Av. SD
83 8.3 0.9 10.1 1.9 21.6 2.7 83 23.5 0.8 16.8 2.9 19.5 1.9
110 20.8 2.9 23.3 3.9 10.0 2.8 110 34.8 0.7 19.8 5.4 32.8 1.2
111 22.1 2.4 21.3 3.1 9.4 3.9 111 29.7 0.6 15.8 4.8 28.0 1.3
112 19.7 2.0 24.7 2.7 13.1 3.3 112 28.3 0.9 15.2 4.4 26.8 1.1
113 24.0 2.5 24.0 3.0 11.2 2.4 113 24.2 0.6 11.4 4.6 24.0 2.4
114 23.3 2.5 21.7 3.5 9.7 2.4 114 26.9 0.8 12.8 4.8 25.3 1.8
115 19.6 2.1 17.6 3.3 8.2 1.7 115 27.8 0.6 15.9 3.9 25.4 1.2
116 14.9 2.2 18.2 3.0 6.0 0.9 116 26.5 0.7 16.7 3.4 24.4 0.7
117 15.5 1.6 14.3 2.9 5.9 0.9 117 24.5 0.6 18.4 2.7 23.1 0.8
118 13.1 2.0 16.1 2.7 9.5 1.7 118 22.7 0.7 16.8 3.2 21.1 0.9
119 12.8 2.2 13.6 2.6 12.9 1.3 119 18.7 0.5 13.0 3.0 17.8 0.6
120 13.4 1.8 14.2 2.4 15.2 1.7 120 19.3 0.7 12.0 4.2 17.6 0.8
121 11.5 2.3 10.7 2.3 18.2 1.8 121 15.3 0.5 12.4 4.7 13.1 0.7
122 15.0 2.6 12.8 2.4 22.9 1.9 122 14.6 0.4 15.1 3.8 12.5 1.3
123 12.6 2.1 10.0 1.5 23.9 1.8 123 10.5 0.4 15.7 4.1 8.8 2.0
124 11.6 2.0 9.2 1.5 22.0 2.1 124 11.3 0.5 12.0 4.0 9.3 0.4
125 6.3 1.5 7.3 1.8 23.1 2.7 125 10.8 0.6 13.0 2.5 9.8 0.4
126 10.3 1.5 11.7 1.6 24.1 3.0 126 4.0 0.5 16.5 3.4 3.9 0.2
127 10.1 0.7 12.4 1.7 27.6 3.3 127 6.5 0.5 16.5 4.6 4.9 0.3
128 4.4 0.6 11.4 1.8 28.3 4.1 128 7.9 0.4 15.4 3.9 6.8 0.2
129 8.8 1.3 9.6 1.1 29.4 3.0 129 7.1 0.3 19.8 4.1 7.1 0.3
130 9.9 1.8 7.3 0.9 32.2 2.7 130 11.3 0.4 19.1 4.2 11.2 0.5
131 13.0 1.6 5.0 0.4 31.3 2.2 131 11.7 0.5 17.2 4.0 11.7 0.4
132 11.6 1.3 8.0 0.8 28.2 2.2 132 11.3 0.4 21.6 4.1 11.3 0.6
133 8.9 1.2 5.6 1.0 25.8 2.2 133 11.4 0.5 24.5 4.3 11.5 1.0
134 13.4 1.6 6.4 1.3 24.5 1.6 134 16.2 0.5 22.3 3.2 15.7 1.0
135 11.8 1.4 9.2 2.4 20.2 1.4 135 17.0 0.4 23.8 4.1 16.2 0.8
136 17.4 1.5 12.7 1.7 24.3 2.2 136 14.1 0.4 24.2 4.6 14.0 0.8
137 17.7 1.8 13.9 2.2 20.7 1.8 137 11.6 0.6 26.0 4.1 11.1 1.0
138 21.3 1.7 17.0 1.9 22.4 3.4 138 16.0 0.6 27.6 4.0 15.5 1.1
139 23.1 2.2 16.5 2.7 22.8 2.0 139 17.2 0.5 31.5 4.0 17.1 1.0
140 26.6 2.0 19.7 2.3 25.1 1.8 140 18.9 0.8 32.4 4.1 17.9 1.1
Table D.4: Molecular dynamics simulations of the all dopamine forms/AS adducts
studied with the conformations from the second clustering algorithm (18 complexes). The
average values (Av.) with their standard deviations (SD) of the distance between the center
of mass of E83 along with the C-Terminal residues (from 110 to 140) and dopamine, along
the trajectory, are reported here
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Figure D.1: Molecular docking and MD simulations of dopamine and its derivatives
onto α-synuclein (AS): A) Number of hits between AS and dopamine (DOP), protonated
dopamine (DOP-H) and dopaminochrome (DCH) as obtained in the 5,400 docking. B)
Close up on the 125YEMPS129 Cα carbons (B.1) after the MD simulation. If the ligands
bind to this region (B.2), the angle between Cα 125-126-129 shows a relatively small spread
(79◦ ± 11◦). The remaining 7 conformations is also shown (B.3) (105◦ ± 20◦). C) In 11
simulations out of 18, the ligands bind to the 125YEMPS129 region. Here we show the six
structures (among those) which the ligand close to E83. The 125-129 residues and E83
are colored in blue, the ligand is colored in red.
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Figure D.2: TElectrostatic analysis. Left:Number of times that NAC amino acids are
found within a 12 A˚from the analyzed ligands.The residues selected for the electrostatic
analysis are marked in black. Right. Averaged energies values, for the selected residues
(Res), expressed in units of the total average (AV) electrostatic interaction energy of -1.4
Kcal/mol and total standard deviation (Std) of 1.3 Kcal/mol.
Appendix E
Design of dopamine mimics
E.1 Database screening
The results from the screening of the database of known small compounds is shown
in the Fig. E.1
Figure E.1: Known molecules after the screening protocol, the 20 candidates from the
set of 70 molecules are shown.
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E.2 New compounds
The designed new molecules are shown in the Fig. E.2.
Figure E.2: Design of new molecules: the 14 molecules from the design protocol
selected for the docking analysis are shown.
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